<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">479871</PMID><DateCompleted><Year>1979</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>167</Volume><Issue>9</Issue><PubDate><Year>1979</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Postpartum mania in bipolar manic-depressive patients withdrawn from lithium carbonate.</ArticleTitle><Pagination><MedlinePgn>572-4</MedlinePgn></Pagination><Abstract><AbstractText>Three women, previously diagnosed as bipolar I manic-depressive, were withdrawn from lithium carbonate prophylaxis immediately prior to their pregnancies. The patients had been euthymic while on lithium carbonate for at least 3 1/2 years prior to their pregnancies. Two of the three patients developed a manic syndrome within 2 weeks postpartum. The use of lithium carbonate during pregnancy, and particularly in the postpartum period, requires reassessment. We advocate an ongoing clinical relationship and the reinstitution of lithium in the third trimester in most cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Targum</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Y B</ForeName><Initials>YB</Initials></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">479871</ArticleId><ArticleId IdType="doi">10.1097/00005053-197909000-00009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20559146</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2011</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4112</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>Complicated management of mania in the setting of undiagnosed obstructive sleep apnea.</ArticleTitle><Pagination><MedlinePgn>e15-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCT.0b013e3181dd7c82</ELocationID><Abstract><AbstractText>In this article, we describe the treatment of a patient with bipolar affective disorder, which was complicated by an underlying obstructive sleep apnea (OSA). The patient's underlying OSA made pharmacological intervention complicated and actually led to respiratory failure. Moreover, her manic psychosis proved to be resistant to treatment. Eventually, electroconvulsive therapy (ECT) was effectively used to control her manic psychosis. This case highlights the importance of screening for OSA due to the complications of psychotropic medications in this context. The pre- and post-electroconvulsive therapy management in the setting of the comorbidity of bipolar affective disorder and OSA is also described as part of this case report.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bastiampillai</LastName><ForeName>Tarun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Queen Elizabeth Hospital, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khor</LastName><ForeName>Lynn Ju</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Dhillon</LastName><ForeName>Rohan</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020181" MajorTopicYN="N">Sleep Apnea, Obstructive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20559146</ArticleId><ArticleId IdType="doi">10.1097/YCT.0b013e3181dd7c82</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24286629</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Could comorbid bipolar disorder account for a significant share of executive function deficits in adults with attention-deficit hyperactivity disorder?</ArticleTitle><Pagination><MedlinePgn>270-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12158</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The frequent comorbidity between attention-deficit hyperactivity disorder (ADHD) and bipolar disorder (BD) represents a challenge for disentangling specific impairments of each disorder in adulthood. Their functional impairments seem to be mediated by executive function deficits. However, little is known about the extent to which each executive function deficit might be disorder specific or explained by the comorbidity. The aim of the present study was to determine if comorbid BD could account for a significant share of executive function deficits when measured by the Wisconsin Card Sorting Test (WCST) in adults with ADHD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adult patients with ADHD and healthy subjects were evaluated in the ADHD outpatient Program at the Hospital de Clínicas de Porto Alegre. Psychiatric diagnoses were based on DSM-IV criteria. WCST scores were compared by multivariate analysis of covariance among three groups: ADHD with BD (n = 51), ADHD without BD (n = 278), and healthy subjects (n = 91).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When compared to patients without BD and healthy subjects, patients with ADHD and comorbid BD showed lower scores in total correct answers (p = 0.003); higher scores in total errors (p = 0.004) and non-perseverative errors (p = 0.002); and completed fewer categories (p = 0.009). Patients with ADHD without BD did not differ from healthy subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">WCST impairments among patients with ADHD seem to be to a large extent attributable to comorbid BD. Although other executive function deficits (e.g., in the inhibitory control domain) have been demonstrated to accompany ADHD, the present findings suggest that set-shifting deficits are strongly related to comorbid BD.</AbstractText><CopyrightInformation>© 2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Katiane L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>ADHD Outpatient Program-Adult Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovaris</LastName><ForeName>Diego L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Guimarães-da-Silva</LastName><ForeName>Paula O</ForeName><Initials>PO</Initials></Author><Author ValidYN="Y"><LastName>Victor</LastName><ForeName>Marcelo M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Salgado</LastName><ForeName>Carlos A I</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Vitola</LastName><ForeName>Eduardo S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Contini</LastName><ForeName>Verônica</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bertuzzi</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Picon</LastName><ForeName>Felipe A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>Rafael G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Belmonte-de-Abreu</LastName><ForeName>Paulo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rohde</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Grevet</LastName><ForeName>Eugenio H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Bau</LastName><ForeName>Claiton H D</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADHD</Keyword><Keyword MajorTopicYN="N">Wisconsin Card Sorting Test</Keyword><Keyword MajorTopicYN="N">attention-deficit hyperactivity disorder</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">executive function</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24286629</ArticleId><ArticleId IdType="doi">10.1111/bdi.12158</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1101046</PMID><DateCompleted><Year>1975</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0077-0094</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>1975</Year></PubDate></JournalIssue><Title>Modern problems of pharmacopsychiatry</Title><ISOAbbreviation>Mod Probl Pharmacopsychiatry</ISOAbbreviation></Journal><ArticleTitle>Genetic factors and lithium response in manic-depressive illness.</ArticleTitle><Pagination><MedlinePgn>23-9</MedlinePgn></Pagination><Abstract><AbstractText>The relationship between success in lithium treatment and the presence of affective illness in the families of manic-depressive patients was investigated in a double-blind study of lithium prophylaxis. Of a total of 89 outpatients who were followed for periods of up to 48 months, 43 were randomly assigned to lithium and 46 to placebo. 56% of the lithium-treated patients remained asymptomatic, as compared to 28% of the placebo patients. Of the 24 successfully treated lithium cases, 16 (66%) had at least one first-degree relative with bipolar illness, while only 4 of the 19 lithium failures (21%) had a first-degree relative with bipolar illness. No relationship was found between response to lithium and the presence of unipolar illness in the patients' families.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stallone</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Mod Probl Pharmacopsychiatry</MedlineTA><NlmUniqueID>0425142</NlmUniqueID><ISSNLinking>0077-0094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1975</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1101046</ArticleId><ArticleId IdType="doi">10.1159/000397916</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28641149</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>221</Volume><PubDate><Year>2017</Year><Month>10</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Thyroid autoimmunity in bipolar disorder: A systematic review.</ArticleTitle><Pagination><MedlinePgn>97-106</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(17)30421-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2017.06.019</ELocationID><Abstract><AbstractText Label="BACKGROUND">Accumulating evidence points to the pathophysiological relevance between immune dysfunction and mood disorders. High rates of thyroid dysfunction have been found in patients with bipolar disorder (BD), compared to the general population. A systematic review of the relationship between BD and thyroid autoimmunity was performed.</AbstractText><AbstractText Label="METHODS">Pubmed, EMBASE and PsycINFO databases were searched up till January 28th, 2017. This review has been conducted according to the PRISMA statements. Observational studies clearly reporting data among BD patients and the frequency of autoimmune thyroid pathologies were included.</AbstractText><AbstractText Label="RESULTS">11 original studies met inclusion criteria out of 340 titles first returned from the global search. There is evidence of increased prevalence of circulating thyroid autoantibodies in depressed and mixed BD patients, while there is no evidence showing a positive relationship between BD and specific autoimmune thyroid diseases. There is a controversy about the influence of lithium exposure on circulating thyroid autoantibodies, even if most of studies seem not to support this association. A study conducted on bipolar twins suggests that autoimmune thyroiditis is related to the genetic vulnerability to develop BD rather than to the disease process itself. Females are more likely to develop thyroid autoimmunity.</AbstractText><AbstractText Label="LIMITATIONS">The samples, study design and outcomes were heterogeneous.</AbstractText><AbstractText Label="CONCLUSION">Thyroid autoimmunity has been suggested to be an independent risk factor for bipolar disorder with no clear association with lithium exposure and it might serve as an endophenotype for BD.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbuti</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERSAM, Barcelona, Catalonia, Spain; University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>André F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Köhler</LastName><ForeName>Cristiano A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdolini</LastName><ForeName>Norma</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERSAM, Barcelona, Catalonia, Spain; Division of Psychiatry, Clinical Psychology and Rehabilitation, Department of Medicine, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guiso</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samalin</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Department of Psychiatry, EA 7280, University of Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; IMPACT Strategic Research Center, School of Medicine, Barwon Health, Deakin University, Geelong, Australia; Health Sciences Postgraduate Program, Health Sciences Center, State University of Londrina, Londrina, Brazil; Revitalis, Waalre, The Netherlands; Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>Brendon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom; Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, Box SE5 8AF, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERSAM, Barcelona, Catalonia, Spain. Electronic address: EVIETA@clinic.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="N">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013967" MajorTopicYN="N">Thyroiditis, Autoimmune</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Lithium treatment</Keyword><Keyword MajorTopicYN="Y">Thyroid autoantibodies</Keyword><Keyword MajorTopicYN="Y">Thyroid autoimmunity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28641149</ArticleId><ArticleId IdType="pii">S0165-0327(17)30421-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2017.06.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16612219</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0951-7367</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers.</ArticleTitle><Pagination><MedlinePgn>313-23</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">There exists a growing appreciation that, though not classical neurodegenerative disorders, severe mood disorders are associated with regional impairments of structural plasticity and cellular resilience. Exciting recent data suggest that synaptic plasticity probably is involved in mechanisms of actions of mood stabilizers and antidepressants. Notably, the extracellular signal-regulated kinase pathway is a critical 'plasticity pathway' in the brain. The present review summarizes neurobiological, pharmacological, and behavioral data on the role of the extracellular signal-regulated kinase pathway in regulating some of the symptoms of bipolar disorder and as a therapeutically relevant target for mood stabilizers.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">The extracellular signal-regulated kinase pathway is known to mediate neurotrophic actions and synaptic plasticity. Treatment with lithium and valproate activates the extracellular signal-regulated kinase pathway in cultured cells and in prefrontal cortex and hippocampus. In addition, lithium or valproate treatment promotes neurogenesis, neurite growth, and cell survival. The extracellular signal-regulated kinase pathway is also targeted by antipsychotics. Modulation of the central nervous system extracellular signal-regulated kinase pathway induces animal behavioral alterations reminiscent of manic symptoms; these complex behaviors probably depend on the effects of extracellular signal-regulated kinase on discrete brain regions and the presence of other interacting molecules.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">The extracellular signal-regulated kinase pathway may represent a novel target for the development of improved therapeutics for bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institute of Health, Bethesda, Maryland 20892-3711, USA. guangchen@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manji</LastName><ForeName>Husseini K</ForeName><Initials>HK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>83</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16612219</ArticleId><ArticleId IdType="doi">10.1097/01.yco.0000218604.63463.cd</ArticleId><ArticleId IdType="pii">00001504-200605000-00014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23948785</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression.</ArticleTitle><Pagination><MedlinePgn>627-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0b013e31829a83f5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder may be associated with mitochondrial dysfunction. Therefore, agents that enhance mitochondrial functioning may be efficacious in bipolar disorder. We performed a randomized placebo-controlled trial of the mitochondrial enhancers acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA) in patients with bipolar depression, and assessed markers of cerebral energy metabolism using phosphorus magnetic resonance spectroscopy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We administered ALCAR (1000-3000 mg daily) plus ALA (600-1800 mg daily) or placebo for 12 weeks to 40 patients with bipolar depression and obtained imaging data at baseline, week 1, and week 12 of treatment in 20 patients using phosphorus 3-dimensional chemical-shift imaging at 4 T. Statistical analysis used random effects mixed models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found no significant difference between ALCAR/ALA and placebo on change from baseline in the Montgomery-Asberg Depression Rating Scale in both the longitudinal (mean difference [95% confidence interval], -1.4 [-6.2 to 3.4], P = 0.58) and last-observation-carried-forward (-3.2 [-7.2 to 0.9], P = 0.12) analyses. ALCAR/ALA treatment significantly reduced phosphocreatine levels in the parieto-occipital cortex at week 12 (P = 0.002). Reduction in whole brain total nucleoside triphosphate levels from baseline to week 1 was associated with reduction in Montgomery-Asberg Depression Rating Scale scores (P = 0.02) in patients treated with ALCAR/ALA. However, this was likely a chance finding attributable to multiple statistical comparisons.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment with ALCAR and ALA at the dose and duration used in this study does not have antidepressant effects in depressed bipolar patients and does not significantly enhance mitochondrial functioning in this patient group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Brian P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Biological Psychiatry Laboratory, McLean Hospital, Belmont, MA 02478, USA. bbrennan@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>John Eric</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>James I</ForeName><Initials>JI</Initials></Author><Author ValidYN="Y"><LastName>Coit</LastName><ForeName>Caitlin E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Beaulieu</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pope</LastName><ForeName>Harrison G</ForeName><Initials>HG</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Renshaw</LastName><ForeName>Perry F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K05 DA031247</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH058681</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA007252</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-DA07252</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>020IUV4N33</RegistryNumber><NameOfSubstance UI="D010725">Phosphocreatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6DH1W9VH8Q</RegistryNumber><NameOfSubstance UI="D000108">Acetylcarnitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>73Y7P0K73Y</RegistryNumber><NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000108" MajorTopicYN="N">Acetylcarnitine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010725" MajorTopicYN="N">Phosphocreatine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008063" MajorTopicYN="N">Thioctic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23948785</ArticleId><ArticleId IdType="doi">10.1097/JCP.0b013e31829a83f5</ArticleId><ArticleId IdType="pmc">PMC4699308</ArticleId><ArticleId IdType="mid">NIHMS746383</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biol Psychiatry. 2008 Sep 15;64(6):468-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18534556</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 May 1;69(9):822-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21288506</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1561-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18647623</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1992;42(1):89-93</Citation><ArticleIdList><ArticleId IdType="pubmed">1541322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1995 Sep;274(3):1122-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7562478</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1998 Jun 15;796(1-2):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9689456</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2010 Feb;35(3):834-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19956089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Dec;135(1-3):389-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21719110</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Apr;65(4):386-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18391127</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Exp Clin Res. 1990;16(2):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2205455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Feb;4(1):61-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12047496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11256685</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 1999 Aug;22(8):1296-301</Citation><ArticleIdList><ArticleId IdType="pubmed">10480774</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1992 Sep;23(9):1312-7; discussion 1317-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1519288</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1997 Mar 14;224(2):83-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9086462</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2006 May;16(4):281-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16316746</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2004 Apr;28(2):143-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15172762</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Mar;61(3):300-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14993118</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1990 Aug 27;526(1):108-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2078811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Apr;5(2):85-97</Citation><ArticleIdList><ArticleId IdType="pubmed">12680897</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Pharmacol Physiol. 2006 Aug;33(8):725-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16895547</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2012 Mar;25(1):43-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22467846</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Mar 15;65(6):489-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19103439</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1988;35(5):555-62</Citation><ArticleIdList><ArticleId IdType="pubmed">3234464</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 2003 Apr;41(4 Suppl 4):S4-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12751049</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Oct 15;64(8):718-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18602089</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2356-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11854529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2004 Nov;1033:30-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15591001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Oct;10(10):900-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16027739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005;66 Suppl 5:5-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16038596</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pharmacol Res. 1990;10(6):355-60</Citation><ArticleIdList><ArticleId IdType="pubmed">2099360</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Apr 15;53(8):671-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12706953</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11854488</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Exp Clin Res. 1987;13(7):417-23</Citation><ArticleIdList><ArticleId IdType="pubmed">3308388</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2005;19 Suppl 1:1-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15998156</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 1995 Aug;19(2):227-50</Citation><ArticleIdList><ArticleId IdType="pubmed">7649494</ArticleId></ArticleIdList></Reference><Reference><Citation>NMR Biomed. 2002 Aug;15(5):338-47</Citation><ArticleIdList><ArticleId IdType="pubmed">12203225</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1996;50(6):513-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8858282</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Sep;47(3):705-11</Citation><ArticleIdList><ArticleId IdType="pubmed">8797468</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1985 Jun;35(6):781-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4000479</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1870-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11854487</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):953-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21256179</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2010 Aug;177(2):575-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20566748</ArticleId></ArticleIdList></Reference><Reference><Citation>Reprod Nutr Dev. 1988;28(5):1317-27</Citation><ArticleIdList><ArticleId IdType="pubmed">3253902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 1995 May;84(5):627-33</Citation><ArticleIdList><ArticleId IdType="pubmed">7658356</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasc Med. 1997;2(2):77-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9546959</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):555-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17485607</ArticleId></ArticleIdList></Reference><Reference><Citation>NMR Biomed. 2010 Apr;23(3):242-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19908224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24140225</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>152-154</Volume><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Increased energy/activity, not mood changes, is the core feature of mania.</ArticleTitle><Pagination><MedlinePgn>256-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.09.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00707-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, the occurrence of increased energy/activity and elation of mood or irritability became necessary symptoms for the diagnosis of an episode of mania or hypomania.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate whether increases in energy/activity or mood changes represent the core feature of the manic syndrome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The symptomatology of 117 hospitalized patients with bipolar mania was evaluated using the Schedule for Affective Disorders and Schizophrenia-Changed version (SADS-C). Based on six items of the SADS-S related to mania, a Confirmatory Factor Analysis (CFA) was performed. An Item Response Theory (IRT) analysis was used to identify how much each symptom informs about the different levels of severity of the syndrome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">According to the CFA, the item "increased energy" was the symptom with the highest factorial loadings, which was confirmed by the IRT analysis. Thus, increased energy was the alteration most correlated with the total severity of manic symptoms. Additionally, the analysis of the Item Information Function revealed that increased energy was correlated with the larger amplitude of severity levels compared with the other symptoms of mania.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Only six manic symptoms were considered. The sample might not be representative because the patients were evaluated while presenting peak symptom severity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased energy/activity is a more important symptom for a diagnosis of mania than mood changes and represents the core feature of this syndrome.</AbstractText><CopyrightInformation>© 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheniaux</LastName><ForeName>Elie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro (IPUB-UFRJ), Universidade do Estado do Rio de Janeiro (UERJ), Brazil. Electronic address: echeniaux@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filgueiras</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Rafael de Assis da</ForeName><Initials>Rde A</Initials></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>Luciana Angélica Silva</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Ana Letícia Santos</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Landeira-Fernandez</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="Y">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Factor analysis</Keyword><Keyword MajorTopicYN="N">Hyperactivity</Keyword><Keyword MajorTopicYN="N">Item Response Theory</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Mood change</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24140225</ArticleId><ArticleId IdType="pii">S0165-0327(13)00707-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.09.021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30605424</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1105-2333</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2018 Jul-Sep</MedlineDate></PubDate></JournalIssue><Title>Psychiatrike = Psychiatriki</Title><ISOAbbreviation>Psychiatriki</ISOAbbreviation></Journal><ArticleTitle>Hypothalamus-pituitary-adrenal (HPA) axis parameters and neurocognitive evaluation in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>199-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22365/jpsych.2018.293.199</ELocationID><Abstract><AbstractText>Bipolar disorder is associated with neurocognitive impairment but the etiology of such impairment remains largely unknown. The present study aimed at investigating the performance of bipolar patients in various neuropsychological tasks within the framework of HPA axis hyperactivity model and also the impact of disease characteristics on neuropsychological functioning. Cognitive performance of 60 bipolar-I patients and 30 healthy controls was evaluated by using tasks from the CANTAB battery targeting visual memory, executive function and inhibitory control. Current symptoms were evaluated via administration of the Hamilton Depression Rating Scale (HAMD) and Young Mania Rating Scale (YMRS) whereas assessment of functioning was performed with the Global Assessment of Functioning (GAF). Basal cortisol levels were determined and all patients were administered the Dexamethasone Suppression Test (DST). Statistically significant differences between patients and controls were found in visuo-spatial associative learning and memory, planning, attentional set shifting and inhibitory control. Worse performance in visuospatial associative memory correlated with longer duration of illness and higher levels of basal cortisol. Poorer attentional set shifting was related to higher number of manic episodes. We found no relationship of neurocognitive measures with DST suppression status, current symptom severity or history of psychosis. The results of our study confirm the presence of cognitive deficits in bipolar disorder and provide evidence on the relation of cortisol with neuropsychological functioning, especially visuo-spatial associative memory. Moreover, we have found that number of previous manic episodes and duration of illness is associated with worse cognitive performance. It is known that neurocognitive deficits are evident in many patients with bipolar disorder. These deficits are often a cause of considerable distress and can lead to impairment of psychosocial and occupational functioning. The role of HPA axis needs to be further examined in bipolar disorder. Nevertheless, the identification of factors affecting neurocognitive functioning, like basal cortisol and number of manic episodes, may contribute to the implementation of more appropriate prevention strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tournikioti</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Second Department of Psychiatry, Attikon General Hospital, University of Athens, Medical School, Athens.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dikeos</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>First Department of Psychiatry, Eginition Hospital, University of Athens, Medical School, Athens.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alevizaki</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Endocrine Unit, Department of Medical Therapeutics, Alexandra Hospital, University of Athens, Medical School, Athens.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michopoulos</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Second Department of Psychiatry, Attikon General Hospital, University of Athens, Medical School, Athens.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferentinos</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Second Department of Psychiatry, Attikon General Hospital, University of Athens, Medical School, Athens.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porichi</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Second Department of Psychiatry, Attikon General Hospital, University of Athens, Medical School, Athens.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soldatos</LastName><ForeName>C R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Mental Health Care Unit, Evgenidion Hospital, University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douzenis</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Second Department of Psychiatry, Attikon General Hospital, University of Athens, Medical School, Athens.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Psychiatriki</MedlineTA><NlmUniqueID>101534363</NlmUniqueID><ISSNLinking>1105-2333</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007030" MajorTopicYN="N">Hypothalamo-Hypophyseal System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010913" MajorTopicYN="N">Pituitary-Adrenal System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30605424</ArticleId><ArticleId IdType="doi">10.22365/jpsych.2018.293.199</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17963846</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>108</Volume><Issue>1-2</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Patterns of response to repetitive transcranial magnetic stimulation (rTMS) in major depression: replication study in drug-free patients.</ArticleTitle><Pagination><MedlinePgn>59-70</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Repetitive transcranial magnetic stimulation (rTMS) has been found to exert modest to moderate therapeutic effects in major depression, but mechanism of action and its clinical relevance have not been clarified yet. Previous trials have reported patterns of symptomatology predicting response to rTMS. As most patients also received concomitant antidepressant medication these response patterns may rather refer to combined treatment than rTMS alone. Thus, this study aims to replicate previous findings and explore patterns of response in drug-free patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the Munich-Berlin Predictor Study data of 79 patients from two open clinical trials evaluating effects of high-frequency rTMS of the left dorsolateral prefrontal cortex were pooled. Previous models predicting the response to rTMS [Fregni, F., Marcolin, M.A., Myczkowski, M., Amiaz, R., Hasey, G., Rumi, D.O., Rosa, M., Rigonatti, S.P., Camprodon, J., Walpoth, M., Heaslip, J., Grunhaus, L., Hausmann, A., Pascual-Leone, A., 2006. Predictors of antidepressant response in clinical trials of transcranial magnetic stimulation. Int. J. Neuropsychopharmacol. 9, 641-654; Brakemeier, E.L., Luborzewski, A., Danker-Hopfe, H., Kathmann, N., Bajbouj, M., 2007. Positive predictors for antidepressive response to prefrontal repetitive transcranial magnetic stimulation (rTMS). J. Psychiatr. Res. 41, 395-403.] were systematically tested and new explorative regression analyses were conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 79 patients, 34.2% showed an antidepressant response. Previous models could not be validated. Explorative regression analysis revealed a significant model with therapy resistance, HAMD items 1 (depressed mood), and 2 (feelings of guilt) as negative and retardation as positive predictors.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">No controlled study; specific statistical issues; sample size; differences concerning patient population and stimulation parameters between study sites.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In sum, this study does not confirm clinical valid and robust patterns being predictive for a response to rTMS in depression. The only exception is a high level of therapy resistance being associated with poor outcome. Future predictor studies should focus on large and homogenous samples of rTMS multicenter trials and include neurobiological variables.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brakemeier</LastName><ForeName>Eva-Lotta</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilbertz</LastName><ForeName>Gregor</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rodax</LastName><ForeName>Silke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Danker-Hopfe</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zinka</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zwanzger</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Grossheinrich</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Várkuti</LastName><ForeName>Bálint</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rupprecht</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bajbouj</LastName><ForeName>Malek</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Padberg</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="Y">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>06</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17963846</ArticleId><ArticleId IdType="pii">S0165-0327(07)00335-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2007.09.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1561285</PMID><DateCompleted><Year>1992</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>1</Issue><PubDate><Year>1992</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Prodromal symptoms and signs of bipolar relapse: a report based on prospectively collected data.</ArticleTitle><Pagination><MedlinePgn>1-8</MedlinePgn></Pagination><Abstract><AbstractText>Prospectively collected data on 19 recently hospitalized patients with bipolar disorder were examined for prodromal changes preceding relapse. The 4-month periods before six manic and six depressive relapses were compared with each other and with a comparable period for seven patients who did not relapse. The Brief Psychiatric Rating Scale was used to assess symptoms. Significant elevations in unusual thought content were found 1 month before manic relapse. Depressive relapsers evidenced higher levels of conceptual disorganization throughout the prerelapse period. Nonrelapsers showed very stable symptom profiles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altman</LastName><ForeName>E S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California, Los Angeles 90024-1563.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rea</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>MH-08744</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-14584</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-33758</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1561285</ArticleId><ArticleId IdType="pii">0165-1781(92)90012-R</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(92)90012-r</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3074349</PMID><DateCompleted><Year>1989</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0039-9450</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>10</Issue><PubDate><Year>1988</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme</Title><ISOAbbreviation>Tanpakushitsu Kakusan Koso</ISOAbbreviation></Journal><ArticleTitle>[Biochemistry of manic-depressive disorders (III)--Action mechanisms of therapeutic drugs].</ArticleTitle><Pagination><MedlinePgn>1702-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Semba</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Tanpakushitsu Kakusan Koso</MedlineTA><NlmUniqueID>0413762</NlmUniqueID><ISSNLinking>0039-9450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>46</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3074349</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9133761</PMID><DateCompleted><Year>1997</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>1997</Year></PubDate></JournalIssue><Title>Psychopharmacology bulletin</Title><ISOAbbreviation>Psychopharmacol Bull</ISOAbbreviation></Journal><ArticleTitle>Treatment of elderly institutionalized bipolar patients with clozapine.</ArticleTitle><Pagination><MedlinePgn>113-8</MedlinePgn></Pagination><Abstract><AbstractText>In an open trial, clozapine was used to treat 3 elderly (mean age 72 +/- 2.5 years) institutionalized male patients with bipolar I disorder, most recent episode manic, severe with psychotic features. All patients were refractory or intolerant of treatment with lithium, valproate, benzodiazepines, and traditional neuroleptics both alone and in combination. Response to clozapine was determined using the Severity of Illness score on the Clinical Global Impression (CGI) scale (1 = normal, not at all ill, 7 = among the most extremely ill). Pre-clozapine severity of illness scores on the CGI averaged 6.33 +/- 0.6; post-clozapine CGI scores averaged 2.0 +/- 1.0 (t = 13.00, df = 2, p &lt; .01). The therapeutic dosage of clozapine varied (range = 25-112.5 mg/day). There were no significant drops in granulocyte counts. Followup revealed sustained improvement over an average of 11 months. These dramatic results suggest that clozapine may be an effective alternative treatment for similar patients and that prospective trials are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>R W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>K I</ForeName><Initials>KI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychopharmacol Bull</MedlineTA><NlmUniqueID>0101123</NlmUniqueID><ISSNLinking>0048-5764</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9133761</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12149680</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0720-4299</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie-Psychiatrie</Title><ISOAbbreviation>Fortschr Neurol Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Differences between unipolar and bipolar affective disorders. Review and results from a clinical population].</ArticleTitle><Pagination><MedlinePgn>403-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">On account of the different therapeutic options in mood disorders, differences between unipolar and bipolar disorders are described by reviewing the literature and evaluating data of a psychiatric basic documentation system (DGPPN-BADO).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Based upon a sample of 18 846 psychiatric in-patients of the Bezirksklinikum Regensburg between 1989 and 1999, data of 2644 patients with unipolar depression (UD) and bipolar affective disorders (BAS) were analysed and compared with findings from previous studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">77,8 % suffer from unipolar depression, 22,2 % from bipolar affective disorders. Patients with BAS fall ill 10 years earlier than patients with UD, they have a 50 percent higher number of hospital stays and longer cumulative length of stay, and they are significantly more ill at admission. In both patient groups we found a mean duration of hospital stay of about 45 days and a clinical improvement of nearly 25 points in GAF. Patients with BAS attempt suicide more often and have comorbid alcoholism more frequently. At discharge they show greater deficits in their psychosocial capability (measured with GAF) than patients with UD do.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with BAS, which had to be hospitalised, have a more severe course of illness, but they can be treated equally as effective and efficient as patients with UD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spiessl</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität am Bezirksklinikum Regensburg, Germany. hermann.spiessl@bkr-regensburg.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hübner-Liebermann</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Cording</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Unterschiede zwischen unipolaren und bipolaren affektiven Störungen - Ubersicht und eigene Ergebnisse bei einer klinischen Klientel.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr</MedlineTA><NlmUniqueID>8103137</NlmUniqueID><ISSNLinking>0720-4299</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>8</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>8</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12149680</ArticleId><ArticleId IdType="doi">10.1055/s-2002-33055</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19552485</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1172-7047</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>7</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>569-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2165/00023210-200923070-00003</ELocationID><Abstract><AbstractText>Bipolar disorder is one of the most severely debilitating of all medical illnesses. For a large number of patients, outcomes are quite poor. The illness results in tremendous suffering for patients and their families and commonly impairs functioning and workplace productivity. Risks of increased morbidity and mortality, unfortunately, are frequent occurrences as well. Until recently, little has been known about the specific molecular and cellular underpinnings of bipolar disorder. Such knowledge is crucial for the prospect of developing specific targeted therapies that are more effective and that have a more rapid onset of action than currently available treatments. Exciting recent data suggest that regulation of certain signalling pathways may be involved in the aetiology of bipolar disorder and that these pathways may be profitably targeted to treat the disorder. In particular, mania is associated with overactive protein kinase C (PKC) intracellular signalling, and recent genome-wide association studies of bipolar disorder have implicated an enzyme that reduces the activation of PKC. Importantly, the current mainstays in the treatment of mania, lithium (a monovalent cation) and valproate (a small fatty acid) indirectly inhibit PKC. In addition, recent clinical studies with the relatively selective PKC inhibitor tamoxifen add support to the relevance of the PKC target in bipolar disorder. Overall, a growing body of work both on a preclinical and clinical level indicates that PKC signalling may play an important role in the pathophysiology and treatment of bipolar disorder. The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zarate</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Bethesda, Maryland, USA. zaratec@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manji</LastName><ForeName>Husseini K</ForeName><Initials>HK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 MH002830-05</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 MH002830-06</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>81</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19552485</ArticleId><ArticleId IdType="pii">3</ArticleId><ArticleId IdType="doi">10.2165/00023210-200923070-00003</ArticleId><ArticleId IdType="pmc">PMC2802274</ArticleId><ArticleId IdType="mid">NIHMS162876</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annu Rev Pharmacol Toxicol. 2008;48:569-99</Citation><ArticleIdList><ArticleId IdType="pubmed">17919087</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1997 Nov 14;775(1-2):30-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9439825</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jan;57(1):95-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10632242</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1992 Jan 20;570(1-2):333-40</Citation><ArticleIdList><ArticleId IdType="pubmed">1617424</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1993 Apr 1;33(7):520-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8513036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2004 Feb;36(2):183-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14643884</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1994 Dec;63(6):2361-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7964759</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2003 Dec 17;147(1-2):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14659568</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2007 Dec 17;97(12):1625-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18000503</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2008 Apr;13(7-8):295-302</Citation><ArticleIdList><ArticleId IdType="pubmed">18405841</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Sep 1;50(5):364-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11543740</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2007 Jun;55(6):498-510</Citation><ArticleIdList><ArticleId IdType="pubmed">17574431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Aug;9(8):734-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15136794</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 1997 Apr;21(3):407-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9153066</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2007;55(3-4):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17641532</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 1986 Dec 15;35(24):4463-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3790165</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2008 Feb 19;151(4):1184-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18222042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1999 Mar;4(2):117-28</Citation><ArticleIdList><ArticleId IdType="pubmed">10208444</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1995 Feb;64(3):619-28</Citation><ArticleIdList><ArticleId IdType="pubmed">7715775</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Feb;13(2):197-207</Citation><ArticleIdList><ArticleId IdType="pubmed">17486107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2007 Jun;55(6):545-59</Citation><ArticleIdList><ArticleId IdType="pubmed">17582782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cancer. 2007 Jul;7(7):554-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17585335</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1992 Dec;31(12):1211-22</Citation><ArticleIdList><ArticleId IdType="pubmed">1361666</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosurgery. 1993 Mar;32(3):485-9; discussion 489-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8384328</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Nov;83(22):8535-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3464969</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurooncol. 2006 Jul;78(3):311-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16710748</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 1;59(11):1006-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16487491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 1999 Dec;1(2):81-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11252663</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1998 Feb;284(2):592-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9454802</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1993 Dec;32(12):1289-97</Citation><ArticleIdList><ArticleId IdType="pubmed">8152520</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Oct 1;40(7):568-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8886289</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2008 Jan;42(2):106-16</Citation><ArticleIdList><ArticleId IdType="pubmed">17208254</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Oct 29;306(5697):882-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15514161</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1994 Dec 30;6(1):69-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7703432</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Mar;65(3):252-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18316671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7 Suppl 1:S1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11986989</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):600-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17258372</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Mar;65(3):255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18316672</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Investig Drugs. 2007 Oct;16(10):1693-707</Citation><ArticleIdList><ArticleId IdType="pubmed">17922632</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2001 Oct;158(1):80-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11685387</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 1993 Sep;27(3):277-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8312586</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1992 Dec;31(12):1201-10</Citation><ArticleIdList><ArticleId IdType="pubmed">1361665</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2006 May;55(5):1327-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16644689</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1989;99(2):213-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2508156</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 1994;17:551-67</Citation><ArticleIdList><ArticleId IdType="pubmed">8210187</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19571-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18073185</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1997 Dec;283(3):1445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9400020</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1990 Apr 25;188(4-5):193-202</Citation><ArticleIdList><ArticleId IdType="pubmed">2163872</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Oncol. 2006 Aug;33(4):466-78</Citation><ArticleIdList><ArticleId IdType="pubmed">16890801</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Apr 24;38(2):157-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12718851</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1978 Jan 31;56(1):111-2</Citation><ArticleIdList><ArticleId IdType="pubmed">415319</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 1993 Dec;20(4):289-98</Citation><ArticleIdList><ArticleId IdType="pubmed">8114616</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2005 Sep 26;170(7):1147-58</Citation><ArticleIdList><ArticleId IdType="pubmed">16186260</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Nov 15;46(10):1328-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10578449</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1996 Oct;15(4):370-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8887991</ArticleId></ArticleIdList></Reference><Reference><Citation>Learn Mem. 2005 Mar-Apr;12(2):103-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15805309</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1991;104(2):255-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1876670</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 Oct 6;48(1):77-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16202710</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1996;57 Suppl 13:23-31; discussion 32-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8970502</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1998 Dec 14;814(1-2):112-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9838071</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1996 Aug;67(2):767-77</Citation><ArticleIdList><ArticleId IdType="pubmed">8764606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Mar;11(3):227-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16432528</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jun 7;447(7145):661-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1999 Mar-Apr;33(2):171-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10221749</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1986 Mar;47(3):153-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3949729</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 1994;31(1):41-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7981455</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2006 May;31(4):543-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16356651</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Biosci. 1998 Nov 01;3:D1134-47</Citation><ArticleIdList><ArticleId IdType="pubmed">9792904</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1993 Dec;61(6):2303-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8245981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Sep;9(6):561-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17845270</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1998 Jun 1;332 ( Pt 2):281-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9601053</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2000 Aug 21;95(2):109-18</Citation><ArticleIdList><ArticleId IdType="pubmed">10963797</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 1997 Jul;26(3):281-91</Citation><ArticleIdList><ArticleId IdType="pubmed">9183817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1988 Aug 1;109(3):219-28</Citation><ArticleIdList><ArticleId IdType="pubmed">3291659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1977 Nov 10;252(21):7603-9</Citation><ArticleIdList><ArticleId IdType="pubmed">199593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26194180</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis.</ArticleTitle><Pagination><MedlinePgn>216-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2015.54</ELocationID><Abstract><AbstractText>Peripheral blood brain-derived neurotrophic factor (BDNF) has been proposed as a potential biomarker related to disease activity and neuroprogression in bipolar disorder, speculated to mirror alterations in brain expression of BDNF. The research area is rapidly evolving; however, recent investigations have yielded conflicting results with substantial variation in outcomes, highlighting the need to critically assess the state of current evidence. The aims of the study were to investigate differences in peripheral blood BDNF concentrations between bipolar disorder patients and healthy control subjects and between affective states in bipolar disorder patients, including assessment of the effect of treatment of acute episodes on BDNF levels. A systematic review of English language studies without considering publication status was conducted in PubMed (January 1950-November 2014), Embase (1974-November 2014) and PsycINFO (1806-November 2014), and 35 studies comprising a total of 3798 participants were included in the meta-analysis. The results indicated that crude peripheral blood BDNF levels may be lower in bipolar disorder patients overall (Hedges' g=-0.28, 95% CI: -0.51 to -0.04, P=0.02) and in serum of manic (g=-0.77, 95% CI: -1.36 to -0.18, P=0.01) and depressed (g=-0.87, 95% CI: -1.42 to -0.32, P=0.002) bipolar disorder patients compared with healthy control subjects. No differences in peripheral BDNF levels were observed between affective states overall. Longer illness duration was associated with higher BDNF levels in bipolar disorder patients. Relatively low study quality, substantial unexplained between-study heterogeneity, potential bias in individual studies and indications of publication bias, was observed and studies were overall underpowered. It could thus not be excluded that identified differences between groups were due to factors not related to bipolar disorder. In conclusion, limitations in the evidence base prompt tempered conclusions regarding the role of peripheral BDNF as a biomarker in bipolar disorder and substantially improving the quality of further research is warranted. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munkholm</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>7171WSG8A2</RegistryNumber><NameOfSubstance UI="C579455">BDNF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26194180</ArticleId><ArticleId IdType="pii">mp201554</ArticleId><ArticleId IdType="doi">10.1038/mp.2015.54</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Cell Neurosci. 2009 Oct;42(2):81-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19577647</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2012 Nov;46(11):1511-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22939945</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2014 Feb 25;4:e365</Citation><ArticleIdList><ArticleId IdType="pubmed">24569695</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2004 Sep-Oct;66(5):744-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15385700</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2011 Mar;33(1):96-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21537727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Mar;137(1-3):151-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22252095</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Jul 1;56(1):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15219473</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2002 Aug 16;328(3):261-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12147321</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2014 Dec;59:8-13</Citation><ArticleIdList><ArticleId IdType="pubmed">25241277</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):578-9; author reply 580-1</Citation><ArticleIdList><ArticleId IdType="pubmed">17134810</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Sep;166:193-200</Citation><ArticleIdList><ArticleId IdType="pubmed">25012431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Feb;20(2):152-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25349167</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Sep;166:330-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25012449</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Sep;86(1-3):321-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16829047</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 2012 Aug;58(8):1192-204</Citation><ArticleIdList><ArticleId IdType="pubmed">22730449</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Feb;20(1):23-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25048003</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2012;65(2):65-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22222435</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014 Jul;205(1):29-35</Citation><ArticleIdList><ArticleId IdType="pubmed">24764546</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2012 Oct;37(10):2229-34</Citation><ArticleIdList><ArticleId IdType="pubmed">22851352</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2014 May 06;4:e389</Citation><ArticleIdList><ArticleId IdType="pubmed">24802307</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2005 Jun;35(6):897-905</Citation><ArticleIdList><ArticleId IdType="pubmed">15997610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2013 May;14 (5):365-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23571845</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2004 Jun 15;23(11):1663-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15160401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Jul;19(7):791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">23958957</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2008 Sep;30(3):243-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18833425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Clin Pract Oncol. 2005 Sep;2(9):466-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16265015</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 Aug;75(8):e794-801</Citation><ArticleIdList><ArticleId IdType="pubmed">25191916</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):308-12</Citation><ArticleIdList><ArticleId IdType="pubmed">20005280</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2007;76(5):278-88</Citation><ArticleIdList><ArticleId IdType="pubmed">17700048</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jun;162:116-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24767015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19689509</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2007 Jun 8;420(1):45-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17442489</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):441-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18922203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Calcium. 2008 Jul;44(1):92-102</Citation><ArticleIdList><ArticleId IdType="pubmed">18177933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2013 Jan;28(1):87-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23124710</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Aug;45(8):995-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">21550050</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jul;34(8):1904-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19295510</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2004 Mar 23;109(11):1349-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15023871</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2013 Mar;35(1):67-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23567603</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jun 3;51:99-104</Citation><ArticleIdList><ArticleId IdType="pubmed">24468644</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2015 Jun;16(4):272-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24824424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Feb;45(2):156-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20541770</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2012 Jun 21;519(1):78-83</Citation><ArticleIdList><ArticleId IdType="pubmed">22617010</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Mar;156:214-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24398043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2000 Sep;5(5):510-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11032384</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2002 Jun;12(3):269-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12007679</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1998 Dec;37(12):1553-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9886678</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2010 Feb;13(1):1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19995480</ArticleId></ArticleIdList></Reference><Reference><Citation>Control Clin Trials. 1986 Sep;7(3):177-88</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Mar;12(3):230-1</Citation><ArticleIdList><ArticleId IdType="pubmed">17325716</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1998 Jan 10;316(7125):140-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9462324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Dec;41(12):979-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17239400</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2014 Oct-Dec;36(4):340-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25076171</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2010 Jun;13(5):617-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20392298</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Jul;19(7):750-1</Citation><ArticleIdList><ArticleId IdType="pubmed">24342989</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Jul 21;339:b2535</Citation><ArticleIdList><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20604989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Feb;11(2):122-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16222333</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Mar;14(3):235-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19229202</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomarkers. 2009 Mar;14(2):103-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19330588</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 2000 Jun;56(2):455-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10877304</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2014 Aug;44(11):2409-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24467931</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jan 15;61(2):142-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16893527</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 May;42:157-69</Citation><ArticleIdList><ArticleId IdType="pubmed">24548785</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2014 Jul;17(7):1039-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23449044</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 May 1;57(9):1068-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15860348</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2011 Feb;36(2):228-39</Citation><ArticleIdList><ArticleId IdType="pubmed">20702043</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2010 Jul;44(9):561-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20060128</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Feb;10(1):95-100</Citation><ArticleIdList><ArticleId IdType="pubmed">18199246</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2007 Mar 19;415(1):87-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17234344</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Dec;70(12):1662-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19744406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Jun;9 Suppl 1:128-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17543031</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Dec;162(12):2399; author reply 2399-400</Citation><ArticleIdList><ArticleId IdType="pubmed">16330620</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 May;160:1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24709015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Feb;17(1):39-49</Citation><ArticleIdList><ArticleId IdType="pubmed">25039314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Aug;15(8):784-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20351717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr Neurosci. 2014 Jul;17(4):145-55</Citation><ArticleIdList><ArticleId IdType="pubmed">23883567</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Med Sci Sports. 2014 Feb;24(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23600729</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 May;129(5):393-400</Citation><ArticleIdList><ArticleId IdType="pubmed">23957567</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2014 Aug 15;218(1-2):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24794031</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2010 May 14;475(2):95-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20350583</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jun;162:67-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24767008</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2014 Sep;47:199-211</Citation><ArticleIdList><ArticleId IdType="pubmed">25001969</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2013 Feb;33(1):142-3</Citation><ArticleIdList><ArticleId IdType="pubmed">23288242</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2002 Nov 14;347(20):1557-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12432042</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;165:74-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24882181</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2010;62(4):229-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20714172</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2007 Feb;7(1):22-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17055337</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomarkers. 2012 Sep;17(6):524-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22672085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 20;143(1-3):131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22889524</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2012 Sep;17(3):155-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22883353</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2014 Oct-Dec;36(4):293-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24770657</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2014 Sep;17(9):1453-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24800824</ArticleId></ArticleIdList></Reference><Reference><Citation>J Eval Clin Pract. 2008 Oct;14(5):941-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19018929</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomark Med. 2010 Dec;4(6):871-87</Citation><ArticleIdList><ArticleId IdType="pubmed">21133708</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2005 Jan;26(1):115-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15585351</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2010 Jun;13(5):563-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19796445</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 Jun;129(6):437-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24628576</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav. 2014 May;4(3):418-30</Citation><ArticleIdList><ArticleId IdType="pubmed">24944871</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Sep 30;199(2):92-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22633012</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Sep;133(1-2):22-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21624682</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Oct;43(15):1200-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19501841</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jun 27;9(6):e100634</Citation><ArticleIdList><ArticleId IdType="pubmed">24971450</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Sep;47(9):1119-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23768870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Sep;43(14):1171-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19473667</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2007 Apr;41(4):321-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17464718</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2006 May 8;398(3):215-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16480819</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Oct;168:399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">25106037</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2014 Jun 18;5(6):422-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24697257</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2013 Dec;15(12):425</Citation><ArticleIdList><ArticleId IdType="pubmed">24243532</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2014 Nov;24(11):1753-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25262178</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2015 Feb;131(2):120-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25131388</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18771602</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 Feb;12(1):137-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18845016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Feb;17(1):27-38</Citation><ArticleIdList><ArticleId IdType="pubmed">25041243</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 15;174:432-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25553404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Mar;11(2):221-2; author reply 222-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19267706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Sep;125(1-3):345-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20172611</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2012 Jul;159B(5):501-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22514151</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 Mar 13;452(2):111-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19383424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep Breath. 2009 May;13(2):169-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18982372</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2014 Jun 18;5(6):484-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24730717</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2011 Dec;124(6):427-34</Citation><ArticleIdList><ArticleId IdType="pubmed">21848703</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2014 Jun;29(6):635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24273017</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1366-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19666076</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Methods. 2007 May;39(2):175-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17695343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Jan;43(3):247-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18511076</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2014 Dec 24;14:366</Citation><ArticleIdList><ArticleId IdType="pubmed">25539739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Jan;105(1-3):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17553570</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2012 Jul 26;215:59-68</Citation><ArticleIdList><ArticleId IdType="pubmed">22554780</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2011 Apr 20;494(1):54-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21362460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2014 Sep;56:18-27</Citation><ArticleIdList><ArticleId IdType="pubmed">24862657</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 2009 Nov;42(6):270-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19924587</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Med. 2011;42(3):211-26</Citation><ArticleIdList><ArticleId IdType="pubmed">22439294</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):645-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20227453</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Apr;29(4):805-12</Citation><ArticleIdList><ArticleId IdType="pubmed">14735135</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2014 Jan;39:179-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24112874</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Epidemiol. 2010 Sep;25(9):603-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15895956</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2005</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-2640</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>La Revue du praticien</Title><ISOAbbreviation>Rev Prat</ISOAbbreviation></Journal><ArticleTitle>[Bipolar disorder in MEDLINE].</ArticleTitle><Pagination><MedlinePgn>527</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eveillard</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Troubles bipolaires de l'humeur.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Prat</MedlineTA><NlmUniqueID>0404334</NlmUniqueID><ISSNLinking>0035-2640</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016239" MajorTopicYN="Y">MEDLINE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046650" MajorTopicYN="Y">Medical Subject Headings</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15895956</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31112601</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>01</Month><Day>04</Day></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>A Meta-analysis of Retinal Cytoarchitectural Abnormalities in Schizophrenia and Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>43-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbz029</ELocationID><Abstract><AbstractText Label="BACKGROUND">Schizophrenia (SZ) and bipolar disorder (BD) are characterized by reductions in gray matter and white matter. Limitations in brain imaging have led researchers to use optical coherence tomography (OCT) to explore retinal imaging biomarkers of brain pathology. We examine the retinal layers that may be associated with SZ or BD.</AbstractText><AbstractText Label="METHODS">Articles identified using PubMed, Web of Science, Cochrane Database. Twelve studies met inclusion for acutely/chronically ill patients. We used fixed or random effects meta-analysis for probands (SZ and BD), SZ or BD eyes vs healthy control (HC) eyes. We adjusted for sources of bias, cross-validated results, and report standardized mean differences (SMD). Statistical analysis performed using meta package in R.</AbstractText><AbstractText Label="RESULTS">Data from 820 proband eyes (SZ = 541, BD = 279) and 904 HC eyes were suitable for meta-analysis. The peripapillary retinal nerve fiber layer (RNFL) showed significant thinning in SZ and BD eyes compared to HC eyes (n = 12, SMD = -0.74, -0.51, -1.06, respectively). RNFL thinning was greatest in the nasal, temporal, and superior regions. The combined peripapillary ganglion cell layer and inner plexiform layer (GCL-IPL) showed significant thinning in SZ and BD eyes compared to HC eyes (n = 4, SMD = -0.39, -0.44, -0.28, respectively). No statistically significant differences were identified in other retinal or choroidal regions. Clinical variables were unrelated to the RNFL or GCL-IPL thickness by meta-regression.</AbstractText><AbstractText Label="CONCLUSION">The observed retinal layer thinning is consistent with the classic gray- and white-matter atrophy observed on neuroimaging in SZ and BD patients. OCT may be a useful biomarker tool in studying the neurobiology of psychosis.</AbstractText><CopyrightInformation>© The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lizano</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bannai</LastName><ForeName>Deepthi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutz</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Leo A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>Matcheri</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">choroid thickness</Keyword><Keyword MajorTopicYN="Y">ganglion cell layer</Keyword><Keyword MajorTopicYN="Y">macula volume</Keyword><Keyword MajorTopicYN="Y">optical coherence tomography</Keyword><Keyword MajorTopicYN="Y">retinal nerve fiber layer thickness</Keyword><Keyword MajorTopicYN="Y">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31112601</ArticleId><ArticleId IdType="pii">5494569</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbz029</ArticleId><ArticleId IdType="pmc">PMC6942159</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2000;250(6):274-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11153962</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2018 Dec;270:786-791</Citation><ArticleIdList><ArticleId IdType="pubmed">30551326</ArticleId></ArticleIdList></Reference><Reference><Citation>Invest Ophthalmol Vis Sci. 2013 Nov 21;54(12):7785-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24135757</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2013 Jan;9(1):44-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23165340</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2017 Feb;180:28-35</Citation><ArticleIdList><ArticleId IdType="pubmed">27567291</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2016 Feb;32:9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26800301</ArticleId></ArticleIdList></Reference><Reference><Citation>Vision Res. 2004 Nov;44(24):2793-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15342223</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Sep 30;229(1-2):230-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26213374</ArticleId></ArticleIdList></Reference><Reference><Citation>Handb Clin Neurol. 2016;133:353-76</Citation><ArticleIdList><ArticleId IdType="pubmed">27112687</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2019 Jan 1;85(1):70-78</Citation><ArticleIdList><ArticleId IdType="pubmed">29961564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2017 Oct;16(10):797-812</Citation><ArticleIdList><ArticleId IdType="pubmed">28920886</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Nov;170(11):1263-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23846857</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Dec;162(12):2233-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16330585</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Jul 3;288(1):67-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12090864</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Nov 11;468(7321):187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21068826</ArticleId></ArticleIdList></Reference><Reference><Citation>Retina. 2019 Oct;39(10):2012-2021</Citation><ArticleIdList><ArticleId IdType="pubmed">30015763</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2009 Jul 21;6(7):e1000097</Citation><ArticleIdList><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Aug 15;218:115-122</Citation><ArticleIdList><ArticleId IdType="pubmed">28472701</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2016 May;67:66-72</Citation><ArticleIdList><ArticleId IdType="pubmed">27095337</ArticleId></ArticleIdList></Reference><Reference><Citation>Contemp Clin Trials. 2007 Feb;28(2):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16807131</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabet Med. 2017 Aug;34(8):1061-1066</Citation><ArticleIdList><ArticleId IdType="pubmed">28430372</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2009 Mar;33(3):336-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18955079</ArticleId></ArticleIdList></Reference><Reference><Citation>Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):365-71</Citation><ArticleIdList><ArticleId IdType="pubmed">25808660</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2011 Nov;64(11):1187-97</Citation><ArticleIdList><ArticleId IdType="pubmed">21477993</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Sep;39(5):1129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">23042112</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2018 Sep;48(12):2023-2033</Citation><ArticleIdList><ArticleId IdType="pubmed">29233210</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neurol Neurosci Rep. 2017 Feb;17(2):16</Citation><ArticleIdList><ArticleId IdType="pubmed">28229400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Feb 11;530(7589):177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Ophthalmol. 2016 Jun 10;26(4):375-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26742871</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Feb 06;10(2):e0116820</Citation><ArticleIdList><ArticleId IdType="pubmed">25658103</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2014 Feb 18;14:25</Citation><ArticleIdList><ArticleId IdType="pubmed">24548571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 2011 Dec;17(12):1449-63</Citation><ArticleIdList><ArticleId IdType="pubmed">21865411</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2018 Jun 6;44(4):876-885</Citation><ArticleIdList><ArticleId IdType="pubmed">29272501</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Nov 28;67(10):1852-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17130422</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2016 Jun 14;86(24):2303-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27225223</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2010 Jun;133(Pt 6):1591-601</Citation><ArticleIdList><ArticleId IdType="pubmed">20410146</ArticleId></ArticleIdList></Reference><Reference><Citation>Eye (Lond). 2019 Apr;33(4):549-556</Citation><ArticleIdList><ArticleId IdType="pubmed">30382239</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1017-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Jul 30;203(1):89-94</Citation><ArticleIdList><ArticleId IdType="pubmed">22917503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28271715</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1364-6915</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>06</Month></PubDate></JournalIssue><Title>Aging &amp; mental health</Title><ISOAbbreviation>Aging Ment Health</ISOAbbreviation></Journal><ArticleTitle>Personal theories of substance use among middle-aged and older adults with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>813-818</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13607863.2017.1299689</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Most persons with bipolar disorder (BD) misuse alcohol and/or illicit drugs at some point, yet research specific to older adults with BD is nascent. The current study sought an in-depth understanding of the experiences and meanings of substance use in a sample of adults who self-reported substance misuse.</AbstractText><AbstractText Label="METHODS">Semi-structured interviews were conducted and thematically analyzed to understand the personal theories of substance use by 12 adults (9 women and 3 men; M = 49 years old) who self-reported diagnoses of BD and regular alcohol or illicit drug use.</AbstractText><AbstractText Label="RESULTS">Findings provide an in-depth picture of the theories middle-aged and older adults with BD have developed to explain their substance use. Participants' theories suggest multiple reasons for substance use, including self-medication; increased confidence with substance use; rejection of prescribed medications; easy access to alcohol; early social exposure/use as facilitator; and living in a culture of substance use.</AbstractText><AbstractText Label="CONCLUSION">Findings suggest multiple theories for the comorbid link between BD and substance use, primarily that persons with BD use drugs and/or alcohol to relieve stress or manage symptoms. It is clinically relevant to incorporate personal reasons for actively and regularly using substances as part of personalized substance treatment and BD symptom management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canham</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-0421-2612</Identifier><AffiliationInfo><Affiliation>a Gerontology Research Centre , Simon Fraser University , Vancouver , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahmood</LastName><ForeName>Atiya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>b Department of Gerontology , Simon Fraser University , Vancouver , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stalman</LastName><ForeName>Marissa N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>c IRMACS Centre , Simon Fraser University , Burnaby , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>c IRMACS Centre , Simon Fraser University , Burnaby , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Rourke</LastName><ForeName>Norm</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>d Department of Public Health and Center for Multidisciplinary Research in Aging , Ben-Gurion University of the Negev , Be'er Sheva , Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Ment Health</MedlineTA><NlmUniqueID>9705773</NlmUniqueID><ISSNLinking>1360-7863</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">comorbidity</Keyword><Keyword MajorTopicYN="Y">drug and alcohol misuse</Keyword><Keyword MajorTopicYN="Y">self-medication</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28271715</ArticleId><ArticleId IdType="doi">10.1080/13607863.2017.1299689</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17430299</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Differentiating bipolar disorder in Turkish prepubertal children with attention-deficit hyperactivity disorder.</ArticleTitle><Pagination><MedlinePgn>243-51</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Attention-deficit hyperactivity disorder (ADHD) and bipolar disorder (BPD) in children are frequently comorbid conditions. Because the coexistence of ADHD and mania seriously complicates the course of the condition and the treatment of children, diagnosing or missing this comorbidity has important clinical implications. There are very few systematic studies on the subject in the literature and BPD in children is not recognized or studied in most countries other than the USA. We aimed to differentiate Turkish prepubertal children with ADHD from those with comorbid ADHD and BPD and compare their clinical characteristics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 147 treatment- and drug-naïve children, aged 7 to 13 years, who had been consecutively referred to the ADHD clinic, were evaluated using the Schedule for Affective Disorders and Schizophrenia for School-age Children-Present and Lifetime version (K-SADS-PL). Parents completed the Child Behavior Checklist (CBCL) 4-18 and the Parent-Young Mania Rating Scale (P-YMRS) prior to the clinical interview.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve children (8.2%) had comorbid bipolar disorder (ADHD + BPD). The ADHD + BPD group had significantly higher rates of depressive disorders, oppositional defiant disorder, panic disorder and a family history of bipolar disorder compared with the ADHD group. The ADHD + BPD group had significantly more problems on the CBCL scale (anxiety/depression, social problems, thought problems, aggression, externalization, and total score) and on the P-YMRS (all items except for insight) compared with the ADHD group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We conclude that ADHD + BPD in Turkish children represents a clinical picture different to that of ADHD alone, in which the clinical characteristics resemble those of children reported in the literature. Further long-term follow-up studies are needed in larger clinical and community samples.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diler</LastName><ForeName>Rasim Somer</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA 15213, USA. dilerrs@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uguz</LastName><ForeName>Sukru</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Seydaoglu</LastName><ForeName>Gulsah</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Erol</LastName><ForeName>Nese</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Avci</LastName><ForeName>Ayse</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17430299</ArticleId><ArticleId IdType="pii">BDI347</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00347.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9433547</PMID><DateCompleted><Year>1998</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0741-0395</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>1997</Year></PubDate></JournalIssue><Title>Genetic epidemiology</Title><ISOAbbreviation>Genet Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Disease classification and transmission effects on linkage analyses in the NIMH1 bipolar disorder pedigrees.</ArticleTitle><Pagination><MedlinePgn>587-92</MedlinePgn></Pagination><Abstract><AbstractText>In this analysis of bipolar affective disorder, 22 families from the NIMH1 data set were further grouped into three transmission patterns: male to male, male to female, and maternal. The data were analyzed under three classifications of affection status: Bipolar I (BPI) only, BPI and Bipolar II (BPII), and BPI, BPII, and recurrent unipolar. LINKAGE was run on each of the subsets, and SIBPAL was run on the full and grouped data sets. A lod score of 1.09 was found for marker D18S62 in the maternal subset, when classifying affecteds as BPI, BPII, or recurrent unipolar. Affected sib-pair analysis showed evidence for linkage with markers D18S62, D18S37, D18S53, D18S40, D18S45, and D18S56 in the male to male transmission groups and the full data set. Linkage was not consistently found in the maternal and father/daughter groups. These results indicate that subsetting by parental transmission may result in less heterogeneity and have significant effects on linkage findings. Studies using a broader definition of affection status may provide considerably more information for linkage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Laboratory of Medical Genetics, University of Alabama at Birmingham, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Go</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RR03655</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genet Epidemiol</MedlineTA><NlmUniqueID>8411723</NlmUniqueID><ISSNLinking>0741-0395</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002887" MajorTopicYN="N">Chromosomes, Human, Pair 18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="Y">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016555" MajorTopicYN="N">Matched-Pair Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009315" MajorTopicYN="N">National Institute of Mental Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009679" MajorTopicYN="N">Nuclear Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9433547</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1098-2272(1997)14:6&lt;587::AID-GEPI6&gt;3.0.CO;2-X</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1098-2272(1997)14:6&lt;587::AID-GEPI6&gt;3.0.CO;2-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27471058</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-5300</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>Family process</Title><ISOAbbreviation>Fam Process</ISOAbbreviation></Journal><ArticleTitle>Family-Focused Therapy for Bipolar Disorder: Reflections on 30 Years of Research.</ArticleTitle><Pagination><MedlinePgn>483-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/famp.12237</ELocationID><Abstract><AbstractText>Family-focused therapy (FFT) is an evidence-based intervention for adults and children with bipolar disorder (BD) and their caregivers, usually given in conjunction with pharmacotherapy after an illness episode. The treatment consists of conjoint sessions of psychoeducation regarding bipolar illness, communication enhancement training, and problem-solving skills training. This paper summarizes over 30 years of research on FFT and family processes in BD. Across eight randomized controlled trials with adults and adolescents with BD, FFT and mood-stabilizing medications have been found to hasten recovery from mood episodes, reduce recurrences, and reduce levels of symptom severity compared to briefer forms of psychoeducation and medications over 1-2 years. Several studies indicate that the effects of FFT on symptom improvement are greater among patients with high-expressed emotion relatives. New research focuses on FFT as an early intervention for youth at risk for BD, neuroimaging as a means of evaluating treatment mechanisms, and progress in implementing FFT in community mental health settings.</AbstractText><CopyrightInformation>© 2016 Family Process Institute.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles, CA. dmiklowitz@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Bowen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH073871</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH093676</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH097007</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 MH097007</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Fam Process</MedlineTA><NlmUniqueID>0400666</NlmUniqueID><ISSNLinking>0014-7370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar Disorder</Keyword><Keyword MajorTopicYN="Y">Expressed Emotion</Keyword><Keyword MajorTopicYN="Y">FFT</Keyword><Keyword MajorTopicYN="Y">Family Interaction</Keyword><Keyword MajorTopicYN="Y">Family-Focused Therapy</Keyword><Keyword MajorTopicYN="Y">Functional Magnetic Resonance Imaging</Keyword><Keyword MajorTopicYN="Y">Psychosis</Keyword><Keyword MajorTopicYN="Y">emoción expresada</Keyword><Keyword MajorTopicYN="Y">interacciones familiares</Keyword><Keyword MajorTopicYN="Y">psicosis</Keyword><Keyword MajorTopicYN="Y">resonancia magnética funcional</Keyword><Keyword MajorTopicYN="Y">terapia centrada en la familia</Keyword><Keyword MajorTopicYN="Y">trastorno bipolar</Keyword><Keyword MajorTopicYN="Y">功能性核磁共振</Keyword><Keyword MajorTopicYN="Y">家庭互动</Keyword><Keyword MajorTopicYN="Y">表达情感</Keyword><Keyword MajorTopicYN="Y">躁郁症</Keyword><Keyword MajorTopicYN="Y">重性精神病</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27471058</ArticleId><ArticleId IdType="doi">10.1111/famp.12237</ArticleId><ArticleId IdType="pmc">PMC5922774</ArticleId><ArticleId IdType="mid">NIHMS959943</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 1972 Sep;121(562):241-58</Citation><ArticleIdList><ArticleId IdType="pubmed">5073778</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1984 Jul;145:62-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6743946</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1986 Feb;95(1):60-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3700849</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Process. 2001 Spring;40(1):5-14</Citation><ArticleIdList><ArticleId IdType="pubmed">11288369</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Jun;48(6):643-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19454920</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Modif. 1990 Oct;14(4):457-89</Citation><ArticleIdList><ArticleId IdType="pubmed">2252468</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1984 May;144:482-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6733371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1999 Nov;108(4):588-97</Citation><ArticleIdList><ArticleId IdType="pubmed">10609423</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1053-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18762591</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Apr;64(4):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17404119</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Nov 1;82(3):343-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15555685</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Mar;45(3):225-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3341878</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Sep;164(9):1340-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17728418</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2014 Feb;82(1):90-101</Citation><ArticleIdList><ArticleId IdType="pubmed">24188511</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):227-35</Citation><ArticleIdList><ArticleId IdType="pubmed">3616515</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1994;20(1):137-49</Citation><ArticleIdList><ArticleId IdType="pubmed">8197411</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Ther. 2012 Dec;43(4):837-47</Citation><ArticleIdList><ArticleId IdType="pubmed">23046785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 Nov;109(4):792-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11196006</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1986 Sep;149:279-87</Citation><ArticleIdList><ArticleId IdType="pubmed">3779290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2013 Feb;52(2):121-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23357439</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Process. 1989 Jun;28(2):169-81</Citation><ArticleIdList><ArticleId IdType="pubmed">2731609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1998 Aug;107(3):497-507</Citation><ArticleIdList><ArticleId IdType="pubmed">9715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2016 Apr;10 (2):137-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24725329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):848-58</Citation><ArticleIdList><ArticleId IdType="pubmed">25062592</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Oct;157:571-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2131140</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Process. 2009 Sep;48(3):417-28</Citation><ArticleIdList><ArticleId IdType="pubmed">19702927</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2015 Feb;83(1):81-91</Citation><ArticleIdList><ArticleId IdType="pubmed">25198285</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Sep;60(9):904-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12963672</ArticleId></ArticleIdList></Reference><Reference><Citation>Community Ment Health J. 2014 Oct;50(7):787-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24810982</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2007;3:329-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17716059</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2003 Jun;71(3):482-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12795572</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2000 Autumn;12(4):555-98</Citation><ArticleIdList><ArticleId IdType="pubmed">11202034</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Process. 1998 Spring;37(1):107-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9589285</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol (New York). 2001;8(1):66-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19997533</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1976 Aug;129:125-37</Citation><ArticleIdList><ArticleId IdType="pubmed">963348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Feb 1;172:291-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25451428</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Sep;42(9):887-96</Citation><ArticleIdList><ArticleId IdType="pubmed">2864032</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1988 May;152:618-24</Citation><ArticleIdList><ArticleId IdType="pubmed">3167433</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Psychiatry Hum Dev. 2015 Dec;46(6):863-73</Citation><ArticleIdList><ArticleId IdType="pubmed">25552241</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Jun;171(6):658-67</Citation><ArticleIdList><ArticleId IdType="pubmed">24626789</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fam Psychol. 2015 Dec;29(6):945-51</Citation><ArticleIdList><ArticleId IdType="pubmed">26168262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Jan 15;190:657-662</Citation><ArticleIdList><ArticleId IdType="pubmed">26590513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1995 May;104(2):268-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7790629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4823936</PMID><DateCompleted><Year>1974</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>158</Volume><Issue>5</Issue><PubDate><Year>1974</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Catecholamines and affective disorders revised: a critical assessment.</ArticleTitle><Pagination><MedlinePgn>369-83</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shopsin</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wilk</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sathananthan</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gershon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>534-82-7</RegistryNumber><NameOfSubstance UI="D008734">Methoxyhydroxyphenylglycol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.17.1</RegistryNumber><NameOfSubstance UI="D004299">Dopamine beta-Hydroxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004299" MajorTopicYN="N">Dopamine beta-Hydroxylase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008734" MajorTopicYN="N">Methoxyhydroxyphenylglycol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4823936</ArticleId><ArticleId IdType="doi">10.1097/00005053-197405000-00008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">21737143</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>1-3</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The impact of brief depressive episodes on the outcome of bipolar disorder and major depressive disorder: a 1-year prospective study.</ArticleTitle><Pagination><MedlinePgn>133-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2011.06.018</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brief depressive episodes (BDEs) cause psychosocial impairment and increased risk of suicide, worsening the outcome and long-term course of affective disorders. The aim of this naturalistic observational study was to assess the frequency of BDEs and very brief depressive episodes (VBDEs) and their impact on clinical outcome in a sample of patients with major depressive disorder (MDD) and bipolar disorder (BD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Seventy patients with a diagnosis of MDD or BD were followed up and monthly visited for a period of 12 months, assessing the eventual occurrence of BDEs and/or VBDEs. Clinical and demographic variables of the total sample and of the groups divided according to the presence of BDEs or VBDEs were collected and compared by one-way ANOVAs. Hamilton Depression Rating Scale 21 items (HDRS), Young Mania Rating Scale (YMRS), Clinical Global Impression (severity of illness) (CGIs) and the Short Form Health Survey (SF-36-item 1) were administered at baseline and logistic regression was performed to evaluate whether baseline scores were predictive of the onset of BDEs or VBDEs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BDEs (88.6% of the total sample), VBDEs (44.3% of the total sample) and BDEs+VBDEs (40.0% of the total sample) were found to occur frequently across the sample. BDE patients showed more death thoughts during major depressive episodes (χ(2) = 4.14, df = 1, p = 0.04, Phi = 0.24) compared to patients without BDEs. Indeed VBDE patients showed a higher rate of hospitalization (χ(2) = 5.71, df = 1, p = 0.031, phi = 0.29), a more frequent prescription of a combined treatment (χ(2) = 13.07, df = 7, p = 0.03, phi = 0.43) and higher scores at SF-36 item 1 (F = 6.65, p = 0.01) compared to patients without VBDEs. Finally, higher SF-36 item 1 scores were found to be predictive of VBDEs (odds ratio = 2.81, p = 0.03).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Major depressives, either unipolar or bipolar, with BDEs or VBDEs showed a worse outcome, represented by a more severe psychopathology and higher rates of hospitalization. VBDEs were predicted by a negative subjective general health perception. Studies with larger samples and longer follow-up are warranted to confirm the results of the present study.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altamura</LastName><ForeName>A Carlo</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buoli</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dell'osso</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Albano</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Serati</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pozzoli</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21737143</ArticleId><ArticleId IdType="pii">S0165-0327(11)00337-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2011.06.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4455728</PMID><DateCompleted><Year>1975</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-0651</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>1974</Year></PubDate></JournalIssue><Title>Journal of the American Psychoanalytic Association</Title><ISOAbbreviation>J Am Psychoanal Assoc</ISOAbbreviation></Journal><ArticleTitle>Vicissitudes of infantile omnipotence.</ArticleTitle><Pagination><MedlinePgn>588-602</MedlinePgn></Pagination><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Psychoanal Assoc</MedlineTA><NlmUniqueID>7505579</NlmUniqueID><ISSNLinking>0003-0651</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000184" MajorTopicYN="N">Acting Out</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002657" MajorTopicYN="Y">Child Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002668" MajorTopicYN="N">Child Rearing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003674" MajorTopicYN="N">Defense Mechanisms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005201" MajorTopicYN="Y">Fantasy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007062" MajorTopicYN="N">Identification, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007837" MajorTopicYN="N">Latency Period, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009034" MajorTopicYN="N">Mother-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009769" MajorTopicYN="N">Object Attachment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010287" MajorTopicYN="N">Parent-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010988" MajorTopicYN="N">Play and Playthings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011574" MajorTopicYN="Y">Psychoanalytic Theory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011606" MajorTopicYN="Y">Psychosexual Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4455728</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27434490</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>07</Month><Day>19</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Voice analysis as an objective state marker in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>e856</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/tp.2016.123</ELocationID><Abstract><AbstractText>Changes in speech have been suggested as sensitive and valid measures of depression and mania in bipolar disorder. The present study aimed at investigating (1) voice features collected during phone calls as objective markers of affective states in bipolar disorder and (2) if combining voice features with automatically generated objective smartphone data on behavioral activities (for example, number of text messages and phone calls per day) and electronic self-monitored data (mood) on illness activity would increase the accuracy as a marker of affective states. Using smartphones, voice features, automatically generated objective smartphone data on behavioral activities and electronic self-monitored data were collected from 28 outpatients with bipolar disorder in naturalistic settings on a daily basis during a period of 12 weeks. Depressive and manic symptoms were assessed using the Hamilton Depression Rating Scale 17-item and the Young Mania Rating Scale, respectively, by a researcher blinded to smartphone data. Data were analyzed using random forest algorithms. Affective states were classified using voice features extracted during everyday life phone calls. Voice features were found to be more accurate, sensitive and specific in the classification of manic or mixed states with an area under the curve (AUC)=0.89 compared with an AUC=0.78 for the classification of depressive states. Combining voice features with automatically generated objective smartphone data on behavioral activities and electronic self-monitored data increased the accuracy, sensitivity and specificity of classification of affective states slightly. Voice features collected in naturalistic settings using smartphones may be used as objective state markers in patients with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faurholt-Jepsen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busk</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>DTU Compute, Technical University of Denmark (DTU), Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Pervasive Interaction Laboratory, IT University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winther</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>DTU Compute, Technical University of Denmark (DTU), Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardram</LastName><ForeName>J E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>DTU Compute, Technical University of Denmark (DTU), Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068997" MajorTopicYN="Y">Smartphone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013689" MajorTopicYN="N">Telephone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060145" MajorTopicYN="N">Text Messaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014831" MajorTopicYN="Y">Voice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27434490</ArticleId><ArticleId IdType="pii">tp2016123</ArticleId><ArticleId IdType="doi">10.1038/tp.2016.123</ArticleId><ArticleId IdType="pmc">PMC5545710</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Med. 2015 Dec;45(16):3357-76</Citation><ArticleIdList><ArticleId IdType="pubmed">26235445</ArticleId></ArticleIdList></Reference><Reference><Citation>ScientificWorldJournal. 2015;2015:573068</Citation><ArticleIdList><ArticleId IdType="pubmed">26346654</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Soc Clin Psychol. 1967 Dec;6(4):278-96</Citation><ArticleIdList><ArticleId IdType="pubmed">6080235</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2013 Apr 3;309(13):1351-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23549579</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1980 Aug;15(4):575-87</Citation><ArticleIdList><ArticleId IdType="pubmed">7397288</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Jan;154(1):4-17</Citation><ArticleIdList><ArticleId IdType="pubmed">8988952</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 1992;25(2):109-16</Citation><ArticleIdList><ArticleId IdType="pubmed">1502292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 May;10(3):437-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18402632</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2016 Mar 30;237:166-74</Citation><ArticleIdList><ArticleId IdType="pubmed">26832835</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2014 Jun 30;217(1-2):124-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24679993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Sep;66(1):59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">11532533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Dec;17(12):1174-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22869033</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1974 Jun;30(6):765-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4832184</ArticleId></ArticleIdList></Reference><Reference><Citation>IEEE Trans Biomed Eng. 2008 Jan;55(1):96-107</Citation><ArticleIdList><ArticleId IdType="pubmed">18232351</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Oct 1;72(7):580-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22541039</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Feb;166(2):164-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19015231</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2016 Dec;25(4):309-323</Citation><ArticleIdList><ArticleId IdType="pubmed">27038019</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2010 Aug;30(6):794-804</Citation><ArticleIdList><ArticleId IdType="pubmed">20619520</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Syst. 2015 Jan;39(1):181</Citation><ArticleIdList><ArticleId IdType="pubmed">25486895</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 10;141(2-3):457-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22391514</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc IEEE Int Conf Acoust Speech Signal Process. 2014 May;2014:4858-4862</Citation><ArticleIdList><ArticleId IdType="pubmed">27630535</ArticleId></ArticleIdList></Reference><Reference><Citation>Conf Proc IEEE Eng Med Biol Soc. 2012;2012:2104-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23366336</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2014 May 14;311(18):1851-2</Citation><ArticleIdList><ArticleId IdType="pubmed">24664278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Jul 9;460(7252):202-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19587761</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Internet Res. 2013 Nov 15;15(11):e247</Citation><ArticleIdList><ArticleId IdType="pubmed">24240579</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1981 Sep;16(9):851-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7295844</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2013 Mar;41(3):886-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23328262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Nov;17(7):715-28</Citation><ArticleIdList><ArticleId IdType="pubmed">26395972</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2013 Mar;202(3):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23349295</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2014 Dec;16(12):523</Citation><ArticleIdList><ArticleId IdType="pubmed">25308392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Aug;16(5):531-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24330342</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2014 Apr 11;14:109</Citation><ArticleIdList><ArticleId IdType="pubmed">24725765</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Based Med. 2013 Jun;18(3):90-2</Citation><ArticleIdList><ArticleId IdType="pubmed">22923708</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2015 Dec;3(1):21</Citation><ArticleIdList><ArticleId IdType="pubmed">26440506</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2013 Jul 24;3(7):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23883891</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Jun;47(6):589-93</Citation><ArticleIdList><ArticleId IdType="pubmed">2190539</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1989 Feb;22 Suppl 1:2-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2654967</ArticleId></ArticleIdList></Reference><Reference><Citation>IEEE J Biomed Health Inform. 2015 Jan;19(1):140-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25073181</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26172983</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><PubDate><Year>2015</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Conversion from depression to bipolar disorder in a cohort of young people in England, 1999-2011: A national record linkage study.</ArticleTitle><Pagination><MedlinePgn>123-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.06.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)00392-4</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To estimate the conversion rate from unipolar depression (ICD10 codes F32-F33) to bipolar disorder (BP) (ICD10 codes F31) in an English national cohort. It was hypothesised that early-onset BP (age &lt;18 years) is a more severe form of the disorder, with a more rapid, and higher rate of conversion from depression to BP.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This record linkage study used English national Hospital Episode Statistics (HES) covering all NHS inpatient and day case admissions between 1999 and 2011.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall rate of conversion from depression to BP for all ages was 5.65% (95% CI: 5.48-5.83) over a minimum 4-year follow-up period. The conversion rate from depression to BP increased in a linear manner with age from 10-14 years - 2.21% (95% C: 1.16-4.22) to 30-34 years - 7.06% (95% CI: 6.44-7.55) (F1,23=77.6, p=0.001, R(2)=0.77). The time to conversion was constant across the age range. The rate of conversion was higher in females (6.77%; 95% CI: 6.53-7.02) compared to males, (4.17%; 95% CI: 3.95-4.40) (χ(2)=194, p&lt;0.0001), and in those with psychotic depression 8.12% (95% CI: 7.65-8.62) compared to non-psychotic depression 5.65% (95% CI: 5.48-5.83) (χ(2)=97.0, p&lt;0.0001).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The study was limited to hospital discharges and diagnoses were not standardised.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increasing conversion rate from depression to bipolar disorder with age, and constant time for conversion across the age range does not support the notion that early-onset BP is a more severe form of the disorder.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>James</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Highfield Unit, Warneford Hospital, Oxford OX3 7JX United Kingdom. Electronic address: anthony.james@psych.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wotton</LastName><ForeName>Clare J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Unit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mathison Centre for Mental Health Research and Education, Hospital Drive NW, Calgary, AB, Canada T2N.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang</LastName><ForeName>Uy</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Unit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldacre</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Conversion</Keyword><Keyword MajorTopicYN="N">Depression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26172983</ArticleId><ArticleId IdType="pii">S0165-0327(15)00392-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.06.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14609504</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.</ArticleTitle><Pagination><MedlinePgn>484-92</MedlinePgn></Pagination><Abstract><AbstractText>The importance of genes in the etiology of bipolar disorder has been substantiated through family, twin, and adoption studies. Bipolar disorder is treated at the prophylactic and episodic levels; lithium is one of the most common forms of prophylactic treatment. Recently, pharmacogenetics has come to play an active role in the elucidation of genetic factors that may play a role in modulating lithium response. This strategy has provided hope for advancements in understanding the genetics of lithium-responsive bipolar disorder. This review encompasses studies that have used populations of lithium responders and non-responders to carry out family, linkage, or association studies, as well as some insight into possible mechanisms by which lithium produces its prophylactic effect. Although data examining the pharmacogenetics of bipolar disorder remain scarce, this is a promising avenue of investigation to help genetically define more homogeneous populations or to search for genetic predictors of drug response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mamdani</LastName><ForeName>Firoza</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Douglas Hospital Research Centre, 6875 LaSalle Boulevard, Verdun, Quebec H4H 1R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaitovich Groisman</LastName><ForeName>Iris</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Turecki</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>68</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14609504</ArticleId><ArticleId IdType="doi">10.1007/s11920-003-0088-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 1991 Jun;48(6):505-12</Citation><ArticleIdList><ArticleId IdType="pubmed">1645513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2000 Mar-Apr;34(2):89-98</Citation><ArticleIdList><ArticleId IdType="pubmed">10758249</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2001 Jun;178(Suppl 41):S128-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11388951</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 1999 Mar;9(1):23-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10335549</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1999 Aug 20;88(4):411-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10402510</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Apr 15;45(8):1079-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10386198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1972 Mar 11;1(7750):599-600</Citation><ArticleIdList><ArticleId IdType="pubmed">4110088</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2000 Feb;21(2):61-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10664610</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Sep 15;42(6):425-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9285078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2000 Mar;5(2):172-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10822345</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Jun 15;47(12):1034-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10862802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mod Probl Pharmacopsychiatry. 1975;10:23-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1101046</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Jun;48(6):513-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1645514</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2002 Jun;8(6):557-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12042799</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1984 Apr;6(2):139-51</Citation><ArticleIdList><ArticleId IdType="pubmed">6233346</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1974 Aug;31(2):189-92</Citation><ArticleIdList><ArticleId IdType="pubmed">4368717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Sep;59 Suppl 1:S5-S30</Citation><ArticleIdList><ArticleId IdType="pubmed">11121824</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 1999 Mar;9(1):13-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10335547</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2001 Apr 8;105(3):301-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11353454</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2000 Apr 3;96(2):178-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10893493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1989 Nov 3;59(3):411-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2553271</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8710892</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 Oct;146(10):1251-60</Citation><ArticleIdList><ArticleId IdType="pubmed">2571304</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2001 Mar;11(1):41-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11409699</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1998 Dec;98(6):443-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9879785</ArticleId></ArticleIdList></Reference><Reference><Citation>Act Nerv Super (Praha). 1974 Aug;16(3):194-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4421964</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1999 Oct 15;88(5):567-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10490718</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1998 Sep;19(3):161-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9741960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7 Suppl 1:S35-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11986994</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 1993 Sep;(21):16-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8217062</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Jun 26;63(1):17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">8832770</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 1997 Oct 1;45(1):113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9339367</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Apr;58(1):63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10760559</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2000 Nov;67(5):1201-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11001582</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2000 Sep;25(4):353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Feb;8(2):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12610644</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Jan;54(1):21-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9006396</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2002 Apr;4(2):117-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11914172</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1998 Nov;3(6):534-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9857980</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Jul;44(2-3):153-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9241575</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1999 Sep-Oct;33(5):371-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10504005</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1973 Sep;130(9):1011-3</Citation><ArticleIdList><ArticleId IdType="pubmed">4580440</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Oct;90(4):304-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7832003</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2002 Mar;47(2):123-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11926073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Genet Metab. 2001 Apr;72(4):343-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11286509</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 1998 Dec;1(2):125-129</Citation><ArticleIdList><ArticleId IdType="pubmed">11281956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1999 May;4(3):220-1</Citation><ArticleIdList><ArticleId IdType="pubmed">10395210</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenomics J. 2001;1(1):71-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11913731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenetics. 1996 Feb;6(1):113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8845858</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 1994 Feb;40(2):309-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8313612</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Sep 27;64(2):91-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8912950</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jul 30;87(1):7-19</Citation><ArticleIdList><ArticleId IdType="pubmed">10512150</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1994 Oct;32(2):85-95</Citation><ArticleIdList><ArticleId IdType="pubmed">7829768</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Jan;54(1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9006397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Sep;6(5):570-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11526471</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1984 Jan;69(1):37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6422702</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2002 May 16;417(6886):292-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12015604</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Oct;63(10):942-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12416605</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 1994 Feb 9;47(3):429-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8117309</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1996 Apr;12(4):436-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8630501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Med. 2001 May;33(4):272-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11405549</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Jan 3;299(5603):76</Citation><ArticleIdList><ArticleId IdType="pubmed">12511643</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenetics. 1998 Jun;8(3):259-68</Citation><ArticleIdList><ArticleId IdType="pubmed">9682271</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2002 May 8;114(4):370-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11992559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1623316</PMID><DateCompleted><Year>1992</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0964-2633</ISSN><JournalIssue CitedMedium="Print"><Volume>36 ( Pt 3)</Volume><PubDate><Year>1992</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of intellectual disability research : JIDR</Title><ISOAbbreviation>J Intellect Disabil Res</ISOAbbreviation></Journal><ArticleTitle>Severe behaviour problems associated with rapid cycling bipolar disorder in two adults with profound mental retardation.</ArticleTitle><Pagination><MedlinePgn>269-81</MedlinePgn></Pagination><Abstract><AbstractText>The authors report the clinical histories of two adults with profound mental retardation, features of rapid cycling bipolar disorder, and periodic maladaptive behaviour. In each case, primary features of mania and depression were identified, operationally defined and measured with an ongoing data system, which was used to track SIB and aggression. In the first case, data analysis across days showed that 1-week episodes of depressive features alternated with 2-week episodes of manic features and that SIB was only associated with the depressive features. In the second case, episodes of manic and depressive features alternated every few days, and aggression was only associated with the manic features. These cases suggest that severe behaviour problems can be a state-dependent phenomenon of bipolar disorder. The behaviour monitoring system provided an objective methodology for aiding in the diagnosis of bipolar disorder with profoundly handicapped adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lowry</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychology, Belchertown State School, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sovner</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intellect Disabil Res</MedlineTA><NlmUniqueID>9206090</NlmUniqueID><ISSNLinking>0964-2633</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013239" MajorTopicYN="N">Stereotyped Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1623316</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2788.1992.tb00515.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27557821</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical factors associated with lithium response in bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>524-530</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867416664794</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder is a common chronic illness characterized by high levels of morbidity and all-cause mortality. Lithium is one of the gold standard mood stabilizer treatments, but the identification of good, partial and non-responders in clinical settings is inconsistent.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used an established rating scale (the Alda scale) to classify the degree of lithium response (good response, partial response, non-response) in a large, multicentre clinically representative sample of well-characterized cases of bipolar disorders I and II. Next, we examined previously reported clinical predictors of response to determine which factors significantly differentiated between the three response groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 754 cases, 300 received lithium, for at least 6 months, as a treatment for bipolar disorder (40%). Of these cases, 17% were classified as good response, 52% as partial response and 31% as non-response. Lifetime history of mixed episodes ( p = 0.017) and alcohol use disorders ( p = 0.015) both occurred in &gt;20% of partial response and non-response groups but &lt;10% of good response cases. Family history of bipolar disorder I was of borderline statistical significance, being more frequent in the good response group (38%) compared with the non-response group (18%). There was a trend ( p = 0.06) for bipolar disorder II to be associated with non-response.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Only three factors previously identified as predictors of lithium response significantly differentiated the response groups identified in our sample. Interestingly, these factors have all been found to co-occur more often than expected by chance, and it can be hypothesized that they may represent a shared underlying factor or dimension. Further prospective studies of predictors and the performance of the Alda scale are recommended.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sportiche</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 Inserm, U1144, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geoffroy</LastName><ForeName>Pierre Alexis</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>1 Inserm, U1144, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4 Université Paris Diderot and Sorbonne Paris Cité, UMR-S 1144, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>5 Université Paris Descartes, UMR-S 1144, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brichant-Petitjean</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1 Inserm, U1144, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gard</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6 Hôpital Charles Perrens, Centre Expert Bipolaire, Pôle de Psychiatrie Générale Universitaire, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>7 Service de Psychiatrie et Psychologie Clinique, CHU de Nancy, Centre Psychothérapique de Nancy-Laxou, Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>8 Université de Lorraine, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>9 Pôle de psychiatrie, Hôpital Sainte Marguerite, Assistance Publique Hôpitaux de Marseille, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10 EA 3279-Self-perceived Health Assessment Research Unit, School of Medicine, Timone University, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>11 Inserm, U955, Equipe de psychiatrie génétique et Université Paris Est, Faculté de médecine et AP-HP, Pôle de psychiatrie, Hôpitaux Universitaires Henri Mondor, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>12 Institut Pasteur, Unité Perception et Mémoire, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>11 Inserm, U955, Equipe de psychiatrie génétique et Université Paris Est, Faculté de médecine et AP-HP, Pôle de psychiatrie, Hôpitaux Universitaires Henri Mondor, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>1 Inserm, U1144, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4 Université Paris Diderot and Sorbonne Paris Cité, UMR-S 1144, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>13 Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>14 Centre for Affective Disorders, Institute of Psychiatry, Psychology &amp; Neuroscience (IoPPN), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>1 Inserm, U1144, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 Fondation FondaMental, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4 Université Paris Diderot and Sorbonne Paris Cité, UMR-S 1144, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">alcohol misuse</Keyword><Keyword MajorTopicYN="N">clinical predictors</Keyword><Keyword MajorTopicYN="N">lithium response</Keyword><Keyword MajorTopicYN="N">mixed state</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27557821</ArticleId><ArticleId IdType="pii">0004867416664794</ArticleId><ArticleId IdType="doi">10.1177/0004867416664794</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9401318</PMID><DateCompleted><Year>1998</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>12</Issue><PubDate><Year>1997</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania in children with PDD.</ArticleTitle><Pagination><MedlinePgn>1646-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Am Acad Child Adolesc Psychiatry. 1997 Nov;36(11):1552-9; discussion 1559-60</RefSource><PMID Version="1">9394940</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002659" MajorTopicYN="N">Child Development Disorders, Pervasive</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>12</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>12</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9401318</ArticleId><ArticleId IdType="pii">S0890-8567(09)62695-2</ArticleId><ArticleId IdType="doi">10.1097/00004583-199712000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6439057</PMID><DateCompleted><Year>1984</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><Issue>12</Issue><PubDate><Year>1984</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antimanic effects of verapamil.</ArticleTitle><Pagination><MedlinePgn>1602-3</MedlinePgn></Pagination><Abstract><AbstractText>When the authors compared the antimanic effects of verapamil, lithium carbonate, and placebo, no differences were seen between lithium and verapamil and both were more effective than placebo in reducing symptoms. No major side effects emerged during the study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Houser</LastName><ForeName>W L</ForeName><Initials>WL</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Loiselle</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>W A</ForeName><Initials>WA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>CJ0O37KU29</RegistryNumber><NameOfSubstance UI="D014700">Verapamil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014700" MajorTopicYN="N">Verapamil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6439057</ArticleId><ArticleId IdType="doi">10.1176/ajp.141.12.1602</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">27597465</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>388</Volume><Issue>10047</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder: defining symptoms and comorbidities.</ArticleTitle><Pagination><MedlinePgn>869</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(16)31430-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(16)31430-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dervaux</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service d'addictologie, Centre Hospitalier Sainte-Anne, 1 Rue Cabanis, 75014, Paris, France. Electronic address: a.dervaux@ch-sainte-anne.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laqueille</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Service d'addictologie, Centre Hospitalier Sainte-Anne, 1 Rue Cabanis, 75014, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet. 2016 Apr 9;387(10027):1561-72</RefSource><PMID Version="1">26388529</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27597465</ArticleId><ArticleId IdType="pii">S0140-6736(16)31430-1</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)31430-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10721497</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0272-7358</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Clinical psychology review</Title><ISOAbbreviation>Clin Psychol Rev</ISOAbbreviation></Journal><ArticleTitle>The co-occurrence of bipolar and substance use disorders.</ArticleTitle><Pagination><MedlinePgn>191-206</MedlinePgn></Pagination><Abstract><AbstractText>Substance use disorders are exceptionally common in bipolar patients. Although the frequency of this co-occurrence is well-documented, the reasons for this association are not clear. In this review, the authors examine four potential hypotheses for why substance use and bipolar disorders co-occur: (a) substance abuse occurs as a symptom of bipolar disorder; (b) substance abuse is an attempt by bipolar patients to self-medicate symptoms; (c) substance abuse causes bipolar disorder; and (d) substance use and bipolar disorders share a common risk factor. None of these four hypotheses have unequivocal support for explaining all cases of bipolar and substance use disorder co-occurrence, and it is probable that all four mechanisms play some role in the excess of substance abuse observed in bipolar patients. Additional studies are warranted to clarify the complex relationships between these two conditions as better understanding of this co-occurrence could lead to better treatment for patients afflicted with both disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267-0559, USA. strakosm@email.uc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DelBello</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>DA10594</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH54317</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH58170</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Psychol Rev</MedlineTA><NlmUniqueID>8111117</NlmUniqueID><ISSNLinking>0272-7358</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>67</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>18</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>18</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10721497</ArticleId><ArticleId IdType="pii">S0272-7358(99)00025-2</ArticleId><ArticleId IdType="doi">10.1016/s0272-7358(99)00025-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15534020</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1075-2730</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>11</Issue><PubDate><Year>2004</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Psychiatric services (Washington, D.C.)</Title><ISOAbbreviation>Psychiatr Serv</ISOAbbreviation></Journal><ArticleTitle>Sexual and reproductive behaviors among persons with mental illness.</ArticleTitle><Pagination><MedlinePgn>1299-301</MedlinePgn></Pagination><Abstract><AbstractText>For this study, 200 women and men with a major mood disorder or schizophrenia were interviewed about their sexual and reproductive behaviors. The responses of the women and men were compared with those of persons from a national health survey who were matched for age and race. Compared with women from the national survey, women with mental illness had fewer pregnancies and live births but were more likely to have had a pregnancy that did not result in a live birth. Women with mental illness had more lifetime sexual partners. The findings suggest that clinicians should pay attention to patients' sexual and reproductive health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Faith B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Sheppard Pratt Health System, 6501 North Charles Street, Baltimore, MD 21204, USA. fdickerson@sheppardpratt.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Clayton H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Kreyenbuhl</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Li Juan</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Dixon</LastName><ForeName>Lisa B</ForeName><Initials>LB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH066009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Serv</MedlineTA><NlmUniqueID>9502838</NlmUniqueID><ISSNLinking>1075-2730</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Psychiatr Serv. 2004 Dec;55(12):1442</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015142" MajorTopicYN="N" Type="Geographic">Baltimore</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005191" MajorTopicYN="N">Family Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010298" MajorTopicYN="N">Parity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043762" MajorTopicYN="N">Reproductive Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012747" MajorTopicYN="N">Sexual Partners</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15534020</ArticleId><ArticleId IdType="pii">55/11/1299</ArticleId><ArticleId IdType="doi">10.1176/appi.ps.55.11.1299</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25881114</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Reward Processing in Unipolar and Bipolar Depression: A Functional MRI Study.</ArticleTitle><Pagination><MedlinePgn>2623-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/npp.2015.110</ELocationID><Abstract><AbstractText>Differentiating bipolar disorders (BD) from unipolar depression (UD) remains a major clinical challenge. The identification of neurobiological markers may help to differentiate these disorders, particularly during depressive episodes. This cross-sectional study, including 33 patients with UD, 33 patients with BD, and 34 healthy controls, is one of the first to directly compare UD and BD with respect to reward processing. A card-guessing paradigm was employed and brain activity associated with reward processing was investigated by means of fMRI. A 3 (group) × 2 (condition: reward&gt;control, loss&gt;control) ANOVA was conducted using the nucleus accumbens (NAcc) as ROI. Furthermore, a whole-brain approach was applied. A functional connectivity analysis was performed to characterize diagnosis-related alterations in the functional coupling between the NAcc and other brain areas. The ANOVA revealed higher activity for healthy controls (HCs) than for BD and UD in the NAcc during reward processing. Moreover, UD showed a higher functional connectivity between the NAcc and the VTA than HC. The patients groups could be differentiated in that BD showed a decreased activation, in the reward condition, of the NAcc, caudate nucleus, thalamus, putamen, insula, and prefrontal areas compared with UD. These results may help to refine the understanding of neural correlates of reward processing in both disorders, and to understand the neural underpinnings of anhedonia, a core symptom of depressive episodes. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Redlich</LastName><ForeName>Ronny</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dohm</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grotegerd</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opel</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwitserlood</LastName><ForeName>Pienie</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heindel</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Radiology, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arolt</LastName><ForeName>Volker</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kugel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Radiology, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dannlowski</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008606" MajorTopicYN="N">Mental Processes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012815" MajorTopicYN="N">Signal Processing, Computer-Assisted</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>04</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25881114</ArticleId><ArticleId IdType="pii">npp2015110</ArticleId><ArticleId IdType="doi">10.1038/npp.2015.110</ArticleId><ArticleId IdType="pmc">PMC4569953</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychopharmacology (Berl). 2007 Apr;191(3):823-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17265148</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Sep 15;68(6):560-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20598288</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Dec;15(8):839-54</Citation><ArticleIdList><ArticleId IdType="pubmed">24148027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2014 Jul;35(7):2995-3007</Citation><ArticleIdList><ArticleId IdType="pubmed">24038516</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2014 Jul;39(8):1914-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24535101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Oct;168:243-53</Citation><ArticleIdList><ArticleId IdType="pubmed">25069080</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2014 Nov;71(11):1222-30</Citation><ArticleIdList><ArticleId IdType="pubmed">25188810</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2014 Nov;62:74-87</Citation><ArticleIdList><ArticleId IdType="pubmed">25241675</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Cogn Affect Neurosci. 2015 Feb;10(2):278-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24752071</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Mar;20(3):398-404</Citation><ArticleIdList><ArticleId IdType="pubmed">24776739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2015 Jun;36(6):2330-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25704752</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2013 Oct;38(7):3036-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23841846</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 Aug 15;20(16):6159-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10934265</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2000 Nov 22-29;284(20):2606-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11086367</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2000 Dec;1(3):199-207</Citation><ArticleIdList><ArticleId IdType="pubmed">11257908</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2001 Dec 4;12(17):3683-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11726774</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Jan;15(1):273-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12633125</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Jul;19(3):1233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12880848</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Aug;19(4):1273-302</Citation><ArticleIdList><ArticleId IdType="pubmed">12948688</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 1995 May;33(5):636-47</Citation><ArticleIdList><ArticleId IdType="pubmed">7596267</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 Jul;167(1):99-103</Citation><ArticleIdList><ArticleId IdType="pubmed">7551619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 1998 Jul;80(1):1-27</Citation><ArticleIdList><ArticleId IdType="pubmed">9658025</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortschr Neurol Psychiatr. 1998 Sep;66(9):407-13</Citation><ArticleIdList><ArticleId IdType="pubmed">9782420</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Apr;35(5):1219-36</Citation><ArticleIdList><ArticleId IdType="pubmed">21185861</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2011 Aug;49(10):2825-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21703286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Apr;138(1-2):9-18</Citation><ArticleIdList><ArticleId IdType="pubmed">21511342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 May;14(3):249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22548898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):375-410</Citation><ArticleIdList><ArticleId IdType="pubmed">22631621</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):111-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22784485</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Feb 15;73(4):360-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22981656</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 May;170(5):533-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23558337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23663952</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2013 Sep;229(1):73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23624852</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 May 1;25(4):1279-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15850746</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Nov 15;58(10):779-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16018986</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Dec 1;58(11):843-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16043128</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Mar;64(3):327-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17339521</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Mar;165(3):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18245175</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 1;63(7):686-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17916330</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Rev. 2008 Nov;59(1):164-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18675846</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Nov 30;164(2):106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18930635</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 Feb;12(1):11-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18544183</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Jan;14(1):60-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17893706</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jun;166(6):702-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19411368</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Sep 1;66(5):451-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19450794</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2009;9:285</Citation><ArticleIdList><ArticleId IdType="pubmed">19664203</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Jan 27;30(4):1488-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20107076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioessays. 2010 Sep;32(9):748-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20730946</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Oct;47(10):1319-28</Citation><ArticleIdList><ArticleId IdType="pubmed">23791396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31726423</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Early-onset bipolar disorder and suicide.</ArticleTitle><Pagination><MedlinePgn>101854</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(19)31103-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2019.101854</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sher</LastName><ForeName>Leo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>James J. Peters Veterans' Administration Medical Center, New York, NY, USA; Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: Leo.Sher@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31726423</ArticleId><ArticleId IdType="pii">S1876-2018(19)31103-7</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2019.101854</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23623740</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>1-3</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>MDQ positive people's searching for effective and ineffective treatments for bipolar disorders: a screening study in France.</ArticleTitle><Pagination><MedlinePgn>84-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.01.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00039-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The objective was to estimate the rate of subjects who tested positive at a screening for bipolar disorders among the people insured by a French Health Company, and subsequently to measure treatment patterns.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional postal survey on the "Mutuelle Générale de l'Education Nationale" (MGEN) policyholders. A self-rated questionnaire was sent by mail to 20,099 individuals randomly selected among MGEN policyholders. Tools: questionnaire on socio-demographic variables and health-care use; Mood Disorder Questionnaire (MDQ); Composite International Diagnostic Interview Short Form Self-Administered (CIDI-SA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Responders were 10,288 (53%). The prevalence of MDQ positivity (MDQ(+)) was 3.6%. The respondents older than 65 showed the lowest frequencies. High frequencies were recorded by the people who had left work because of long term sickness and by people with invalidity. Subjects having a diagnosis of ICD-10 major depression were found to be at risk. Positive subjects had no more contacts with general practitioners than negative subjects; on the contrary they had more contacts with psychiatrists, alternative medicine professionals, psychologists, psychoanalysts, spiritual guides or welfare workers. MDQ+ subjects had a higher risk to use all kinds of psychodrugs, including antidepressants (27.7%, OR=2.7, CI95% 1.9-3.9).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The prevalence of MDQ(+) was similar to the surveys in the USA and Italy. The use of ADs in people with MDQ(+) and MDD diagnosis needs to be taken into account when managing the public health-care system. A large rate of positive subjects reported to have used ineffective treatments for bipolar disorders.</AbstractText><AbstractText Label="LIMITS" NlmCategory="CONCLUSIONS">Relative low response rate and observational design.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carta</LastName><ForeName>Mauro Giovanni</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Public Health and Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy. mgcarta@tiscali.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zairo</LastName><ForeName>Fausta</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Saphino</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sevilla-Dedieu</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Maria Francesca</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Massidda</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kovess</LastName><ForeName>Viviane</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23623740</ArticleId><ArticleId IdType="pii">S0165-0327(13)00039-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.01.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30087257</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Na⁺, K⁺-ATPase Signaling and Bipolar Disorder.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">E2314</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms19082314</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a severe and common chronic mental illness characterized by recurrent mood swings between depression and mania. The biological basis of the disease is poorly understood and its treatment is unsatisfactory. Although in past decades the "monoamine hypothesis" has dominated our understanding of both the pathophysiology of depressive disorders and the action of pharmacological treatments, recent studies focus on the involvement of additional neurotransmitters/neuromodulators systems and cellular processes in BD. Here, evidence for the participation of Na⁺, K⁺-ATPase and its endogenous regulators, the endogenous cardiac steroids (ECS), in the etiology of BD is reviewed. Proof for the involvement of brain Na⁺, K⁺-ATPase and ECS in behavior is summarized and it is hypothesized that ECS-Na⁺, K⁺-ATPase-induced activation of intracellular signaling participates in the mechanisms underlying BD. We propose that the activation of ERK, AKT, and NFκB, resulting from ECS-Na⁺, K⁺-ATPase interaction, modifies neuronal activity and neurotransmission which, in turn, participate in the regulation of behavior and BD. These observations suggest Na⁺, K⁺-ATPase-mediated signaling is a potential target for drug development for the treatment of BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lichtstein</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. davidli@ekmd.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilani</LastName><ForeName>Asher</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. asheri@ekmd.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Haim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. haimr@ekmd.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horesh</LastName><ForeName>Noa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. noa.rosenthal1@mail.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Shiv Vardan</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. vardanshiva@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buzaglo</LastName><ForeName>Nahum</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. buzaglo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodes</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. anastasi.singalevich@mail.huji.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 7.2.2.13</RegistryNumber><NameOfSubstance UI="D000254">Sodium-Potassium-Exchanging ATPase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000254" MajorTopicYN="N">Sodium-Potassium-Exchanging ATPase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AKT</Keyword><Keyword MajorTopicYN="N">ERK</Keyword><Keyword MajorTopicYN="N">Na+, K+-ATPase</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">cardiac steroids</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">mania</Keyword><Keyword MajorTopicYN="N">signaling</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30087257</ArticleId><ArticleId IdType="pii">ijms19082314</ArticleId><ArticleId IdType="doi">10.3390/ijms19082314</ArticleId><ArticleId IdType="pmc">PMC6121236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurosci. 2018 Apr 25;38(17):4093-4103</Citation><ArticleIdList><ArticleId IdType="pubmed">29555853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2018 Apr 3;8(1):5530</Citation><ArticleIdList><ArticleId IdType="pubmed">29615645</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Renal Physiol. 2006 Feb;290(2):F241-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16403837</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2014 Dec;87:188-97</Citation><ArticleIdList><ArticleId IdType="pubmed">24530829</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6259-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1648735</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1955 Aug 12;122(3163):284-5</Citation><ArticleIdList><ArticleId IdType="pubmed">13246633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bioenerg Biomembr. 2007 Dec;39(5-6):385-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18044013</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Cardiovasc Genet. 2015 Oct;8(5):736-45</Citation><ArticleIdList><ArticleId IdType="pubmed">26374826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Sep 8;275(36):27832-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10874030</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2016;2016:7027949</Citation><ArticleIdList><ArticleId IdType="pubmed">26881128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Assoc. 1955 Oct 29;159(9):836-9</Citation><ArticleIdList><ArticleId IdType="pubmed">13263127</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2018 Feb;19(3):203-222</Citation><ArticleIdList><ArticleId IdType="pubmed">29361880</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1971 Feb;118(543):219-23</Citation><ArticleIdList><ArticleId IdType="pubmed">5576284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Jun;12(4):414-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20636639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Mar;11(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16288314</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2017 Mar;74(Pt A):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">28093238</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 2011 Jun;65(6):520-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20936682</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2013 Sep;15(9):387</Citation><ArticleIdList><ArticleId IdType="pubmed">23955004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 2015 May;26(5):1103-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25294233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurogenet. 2016 Mar;30(1):42-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27276195</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H1972-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19855053</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Heart Circ Physiol. 2001 Nov;281(5):H1899-907</Citation><ArticleIdList><ArticleId IdType="pubmed">11668049</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Aug;54(3):261-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10467969</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2015 Oct;42(8):2568-76</Citation><ArticleIdList><ArticleId IdType="pubmed">26153524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Feb;61:114-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25467060</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2016 Aug;24(8):602-603</Citation><ArticleIdList><ArticleId IdType="pubmed">27426208</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2013 Jul 10;24(10):560-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23652158</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Sci (Lond). 2018 Jun 21;132(12):1215-1242</Citation><ArticleIdList><ArticleId IdType="pubmed">29930141</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1998 Nov;275(5 Pt 2):F633-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9815123</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 1995 Oct;75(4):689-723</Citation><ArticleIdList><ArticleId IdType="pubmed">7480159</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Jan;47(1):26-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22711881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 2016 Sep;68(3):526-32</Citation><ArticleIdList><ArticleId IdType="pubmed">27456525</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2017 Apr;42(4):1202-1210</Citation><ArticleIdList><ArticleId IdType="pubmed">28032295</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Feb;21(2):216-28</Citation><ArticleIdList><ArticleId IdType="pubmed">26194180</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2017 Nov;257:327-337</Citation><ArticleIdList><ArticleId IdType="pubmed">28800512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000;61 Suppl 6:4-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10775017</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23643758</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18144-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22025725</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 May 20;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">28689605</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2011 Feb 1;519(2):376-404</Citation><ArticleIdList><ArticleId IdType="pubmed">21165980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 1997 Jan 3;126(1):7-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9027358</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2015 Feb;30:131-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25544106</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):721-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17166394</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 2004 Mar;50(3):469-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14981025</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2012 Jan;22(1):72-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21700431</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2017 Jun 14;22(6):null</Citation><ArticleIdList><ArticleId IdType="pubmed">28613263</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1998;62(23):2109-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9627090</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jun 30;178(1):116-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20452675</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2016 Mar;81(3):488-95</Citation><ArticleIdList><ArticleId IdType="pubmed">26505271</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1990 Dec 31;173(3):1093-101</Citation><ArticleIdList><ArticleId IdType="pubmed">2176483</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1991 Feb;11(2):381-91</Citation><ArticleIdList><ArticleId IdType="pubmed">1846906</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2015 May 15;95(2):81-97</Citation><ArticleIdList><ArticleId IdType="pubmed">25813654</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2009 Dec;55(7):491-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19447152</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2017 Apr;15(3):353-358</Citation><ArticleIdList><ArticleId IdType="pubmed">28503106</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2014 Feb 28;260:195-204</Citation><ArticleIdList><ArticleId IdType="pubmed">24342563</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2007 May 16;80(23):2093-107</Citation><ArticleIdList><ArticleId IdType="pubmed">17499813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2018 May;55(5):3946-3958</Citation><ArticleIdList><ArticleId IdType="pubmed">28550530</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2017 Jan 12;18(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">28085108</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Nov 1;20(11):877-885</Citation><ArticleIdList><ArticleId IdType="pubmed">29020306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pflugers Arch. 2015 Mar;467(3):465-74</Citation><ArticleIdList><ArticleId IdType="pubmed">25491503</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2016 Jun 14;7:209</Citation><ArticleIdList><ArticleId IdType="pubmed">27378932</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Jun 1;65(11):985-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19058785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 2014 Oct;64(4):680-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25001271</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 1994 Aug;135(2):794-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8033829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol Sci. 2017 Sep;67(5):587-593</Citation><ArticleIdList><ArticleId IdType="pubmed">27660058</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1993 Aug 15;216(1):261-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8396030</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2016 May 3;321:163-188</Citation><ArticleIdList><ArticleId IdType="pubmed">26314632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Pharmacol. 1992 Dec;44(12):1023-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1361550</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2011 Feb;14(1):123-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20633320</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1637-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18590792</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 1997;5(2):53-65</Citation><ArticleIdList><ArticleId IdType="pubmed">9262935</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2017 Jun 06;8:371</Citation><ArticleIdList><ArticleId IdType="pubmed">28634454</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Jun 19;38(6):915-28</Citation><ArticleIdList><ArticleId IdType="pubmed">12818177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Feb 05;6:20442</Citation><ArticleIdList><ArticleId IdType="pubmed">26847162</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2011 Jan 27;12:16</Citation><ArticleIdList><ArticleId IdType="pubmed">21272290</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Hypertens. 1998 Jul-Aug;20(5-6):593-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9682915</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2018 Apr 2;20(4):29</Citation><ArticleIdList><ArticleId IdType="pubmed">29607445</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2017;23(21):3154-3163</Citation><ArticleIdList><ArticleId IdType="pubmed">28078988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):362-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14525557</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2007 Feb 20;500(6):1106-16</Citation><ArticleIdList><ArticleId IdType="pubmed">17183534</ArticleId></ArticleIdList></Reference><Reference><Citation>Phytochemistry. 1998 May;48(1):1-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9621450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2017 Nov;54(9):7156-7170</Citation><ArticleIdList><ArticleId IdType="pubmed">27796752</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2009 Mar;61(1):9-38</Citation><ArticleIdList><ArticleId IdType="pubmed">19325075</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2016 May;357(2):345-56</Citation><ArticleIdList><ArticleId IdType="pubmed">26941172</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Dec;1802(12):1237-45</Citation><ArticleIdList><ArticleId IdType="pubmed">20144708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2016 Sep;26(9):1149-67</Citation><ArticleIdList><ArticleId IdType="pubmed">27068236</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1964 Aug;30:237-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14205552</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2018 Mar;137:356-362</Citation><ArticleIdList><ArticleId IdType="pubmed">29374602</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2017 May 31;15(2):100-114</Citation><ArticleIdList><ArticleId IdType="pubmed">28449557</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Sep 1;60(5):491-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16712803</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Biochem. 2005 Jan;38(1):36-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15607315</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Psychosom Med. 2013;33:15-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23816860</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Cell Physiol. 2018 Jan 1;314(1):C3-C26</Citation><ArticleIdList><ArticleId IdType="pubmed">28971835</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Jul 1;44(1):47-51</Citation><ArticleIdList><ArticleId IdType="pubmed">9646882</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Dev Biol. 2015 Oct 26;3:66</Citation><ArticleIdList><ArticleId IdType="pubmed">26579519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Aug;18(5):451-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27393337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Jan 17;27(3):616-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17234593</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Endocrinol (Lausanne). 2014 Nov 28;5:201</Citation><ArticleIdList><ArticleId IdType="pubmed">25506340</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chim Acta. 2014 Apr 20;431:87-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24508998</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Cell Physiol. 2018 May 1;314(5):C640</Citation><ArticleIdList><ArticleId IdType="pubmed">29749761</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):888-94</Citation><ArticleIdList><ArticleId IdType="pubmed">20403403</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 May 15;81(10):886-897</Citation><ArticleIdList><ArticleId IdType="pubmed">27449797</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Endocrinol (Lausanne). 2015 Apr 13;6:49</Citation><ArticleIdList><ArticleId IdType="pubmed">25918512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1996 Aug 3;348(9023):303-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Jan 1;41(1):58-64</Citation><ArticleIdList><ArticleId IdType="pubmed">8988796</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Jun;65:63-70</Citation><ArticleIdList><ArticleId IdType="pubmed">25959616</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Cell Physiol. 2012 Jan 15;302(2):C442-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22031604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Feb 25;6:22047</Citation><ArticleIdList><ArticleId IdType="pubmed">26911348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Dec;169 Suppl 1:S12-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25533909</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2015 May;40(6):1448-55</Citation><ArticleIdList><ArticleId IdType="pubmed">25518754</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 1992 Jan;20(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1363909</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1982 Sep;17(9):981-92</Citation><ArticleIdList><ArticleId IdType="pubmed">6291647</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2016;73(2):116-22</Citation><ArticleIdList><ArticleId IdType="pubmed">27023678</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2008 Apr;18(2):64-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18349697</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2015;13(6):739-49</Citation><ArticleIdList><ArticleId IdType="pubmed">26630954</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Chronic Kidney Dis. 2015 May;22(3):232-44</Citation><ArticleIdList><ArticleId IdType="pubmed">25908473</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurol Disord Drug Targets. 2017;16(2):176-186</Citation><ArticleIdList><ArticleId IdType="pubmed">27978794</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16649825</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Persistent posttraumatic stress disorder following September 11 in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>394-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We examined the development of posttraumatic stress disorder (PTSD) following indirect exposure to the September 11, 2001, terrorist attacks in a cohort at high risk for adverse trauma-related sequelae as a result of having bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Subjects (N = 137) were participants in the ongoing, naturalistic, longitudinal study Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) prior to September 11, 2001. The present study examined prospectively collected pre-event information about bipolar disorder and other potential predictors of PTSD, along with assessment of the level of indirect trauma exposure (i.e., via media) and peritraumatic distress in the aftermath of September 11, and their association with 9/11-related, new-onset PTSD as assessed by a self-report measure, the Posttraumatic Stress Diagnostic Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Posttrauma assessments were completed a mean +/- SD of 430.6 +/- 78.7 days (range, 0.5-1.5 years) after September 11. Twenty percent (N = 27) of patients reported development of new-onset PTSD in response to the September 11 attacks. Rates of PTSD were significantly associated with the presence of a hypomanic, manic, or mixed mood state at the time of trauma (chi(2) = 4.25; p &lt; .05); 62% of patients in these states developed PTSD. Mania/hypomania remained a significant predictor of PTSD in response to the September 11 attacks after controlling for peritraumatic exposure and distress variables, suggestive of a substantial increase in risk compared with those in recovery (OR = 17; 95% CI = 2.6 to 115.6; p = .0034).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Rates of persistent new-onset PTSD among bipolar patients were elevated in the aftermath of the September 11 attacks. Our findings suggest that the presence of a manic state may be the most critical risk factor for adverse sequelae following indirect traumatic exposure in bipolar individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pollack</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, Mass, USA. mpollack@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Naomi M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Fagiolini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pitman</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McNally</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachicko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Perlman</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ghaemi</LastName><ForeName>S Nassir</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5 R01 MH 663901</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008402" MajorTopicYN="N">Mass Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047851" MajorTopicYN="N">September 11 Terrorist Attacks</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16649825</ArticleId><ArticleId IdType="doi">10.4088/jcp.v67n0309</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18199242</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2008</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Retrospective parent report of psychiatric histories: do checklists reveal specific prodromal indicators for postpubertal-onset pediatric bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>56-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2008.00533.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study retrospectively investigated the relationship between prodromal symptoms described in the literature for pediatric bipolar disorder (BD) and the diagnosis of BD by comparing adolescents with BD to those in control and attention-deficit hyperactivity disorder (ADHD) groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Semi-structured interviews [Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime version (K-SADS-PL) and Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS)] and checklists (Conners' Rating Scales and Child Behavior Checklist) identified participants (13-17 years) as either normal controls (NC; n = 28), ADHD (n = 29) or BD (n = 25). Bipolar disorder included BD I, BD II and BD not otherwise specified (NOS). Parents completed a widely used but unvalidated symptom checklist published by Papolos and Papolos (The Bipolar Child: the Definitive and Reassuring Guide to Childhood's Most Misunderstood Disorder) assessing across three developmental periods (preschool, latency, adolescence) for the presence/absence of psychiatric symptoms, many of which have been described in the literature as prodromal to the emergence of manic symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While both clinical groups had more psychiatric symptoms than the NC group, more problems were reported in the ADHD group, most of which were symptoms seen as cardinal features of ADHD (e.g., being easily distracted, interrupting, having trouble concentrating). Differences were present by the latency period. Depressed mood was higher in the BD group during latency, and elated mood and fire-setting were higher in the BD group during adolescence. Results were more similar when comparing adolescents with BD only versus those with both ADHD and BD. Frequency of symptoms was comparable regardless of whether or not there was a family history of BD. Frequency of symptoms was also similar across the BD subtypes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Using retrospective parent report, a cluster of prodromal psychiatric symptoms specific to BD was not identified, which both questions the utility of a widely used yet unvalidated clinical scale and encourages caution when interpreting information collected via retrospective checklists. Although these data suggest that the presence of prodromal non-specific psychiatric symptoms flags a more global risk for psychopathology, significant limitations exist when using retrospective report and, as such, further prospective research is required to investigate the progression of psychiatric symptoms across childhood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rucklidge</LastName><ForeName>Julia J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Canterbury, Christchurch, New Zealand. julia.rucklidge@canterbury.ac.nz</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="Y">Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010372" MajorTopicYN="Y">Pediatrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18199242</ArticleId><ArticleId IdType="pii">BDI533</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2008.00533.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11356238</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Group cognitive behavioral therapy for bipolar disorder: a feasibility and effectiveness study.</ArticleTitle><Pagination><MedlinePgn>145-53</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BD) is a common disorder that results in significant psychosocial impairment, including diminished quality of life and functioning, despite aggressive pharmacotherapy. Psychosocial interventions that target functional factors could be beneficial for this population, and we hypothesized that the addition of group cognitive behavioral therapy (CBT) to maintenance pharmacotherapy would improve functioning and quality of life.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients diagnosed (by SCID) with bipolar disorder attending an outpatient clinic of a mood disorders program participated in the study. All patients were on maintenance mood stabilizers, and were required to have controlled symptoms before entering the study. Mood symptoms were assessed with the Hamilton Depression Rating scale and Young Mania scale at baseline and 14 weeks. Objective and subjective functioning was rated at the same interval using the Global Assessment of Functioning scale and the Medical Outcomes Survey SF-36. Treatment was provided via a specific manual based on CBT principles that could be applied to this population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty nine patients participated in this open trial, and 38 patients completed treatment. Objective and subjective indices of impairment showed improvement after 14 weeks. Both GAF and MOS scores increased significantly by the end of treatment.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study was an open trial, and lack of control groups limits the interpretation of results. Because the study concerned effectiveness, the results do not clarify whether the improvement represents the normal course of illness or whether it is the result of the CBT intervention.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The addition of group CBT to standard pharmacological treatment was acceptable to patients, and nearly 80% of patients complied with treatment. Despite the fact that mood symptoms were controlled at entry into the study, psychosocial functioning increased significantly at the end of treatment. Adjunctive CBT should be further investigated in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patelis-Siotis</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hamilton Psychiatric Hospital, Mood Disorders Program, 100 West 5th St., Hamilton, Ontario L8N 3K7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>L T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Robb</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Marriott</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bieling</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>L C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Joffe</LastName><ForeName>R T</ForeName><Initials>RT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="Y">Psychotherapy, Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>13</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11356238</ArticleId><ArticleId IdType="pii">S0165032700002779</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(00)00277-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16551670</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0269-8811</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2 Suppl</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of psychopharmacology (Oxford, England)</Title><ISOAbbreviation>J Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Olanzapine - relapse prevention following mania.</ArticleTitle><Pagination><MedlinePgn>31-8</MedlinePgn></Pagination><Abstract><AbstractText>This review describes the pharmacological characteristics of olanzapine (ZYPREXA), outlines the European licensed indications and examines four peer reviewed, randomized, controlled, double blind clinical trials investigating the efficacy of olanzapine as maintenance therapy in patients with bipolar I disorder. These studies range in duration from 47 to 78 weeks and support the view that olanzapine is an effective and well-tolerated pharmacological therapy for relapse prevention in bipolar disorder. Evidence is presented that olanzapine is effective in preventing relapse following an index manic or a mixed episode with or without psychotic features and in patients with a history of rapid cycling. The safety and tolerability of the medicine is also examined, focusing on weight gain and metabolic issues.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dando</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company Limited, Basingstoke, UK. dando_simon@lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychopharmacol</MedlineTA><NlmUniqueID>8907828</NlmUniqueID><ISSNLinking>0269-8811</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>55</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16551670</ArticleId><ArticleId IdType="pii">20/2_suppl/31</ArticleId><ArticleId IdType="doi">10.1177/1359786806063076</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22842799</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5857</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International clinical psychopharmacology</Title><ISOAbbreviation>Int Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period:  focus on mood stabilizers.</ArticleTitle><Pagination><MedlinePgn>256-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YIC.0b013e328356ac92</ELocationID><Abstract><AbstractText>The increasing number of pharmacological treatment options for bipolar disorder seems to be paralleled by the number of evidence-based guidelines published previously. The aim of this study was to systematically examine the adherence to published guidelines and any change in prescription habits over time in a psychiatric hospital setting. This is a retrospective study of 531 bipolar in patients who were consecutively admitted to the Department for Psychiatry and Psychotherapy in Innsbruck. Their complete medical histories were evaluated for psychotropic medications, with a special focus on mood stabilizers (MSs). To compare the use of individual MSs or combinations with other psychotropic medications in two preselected observation periods (1999-2003 and 2004-2007), we used Fisher's exact test. Overall, the proportion of patients receiving at least one MS increased significantly from 1999-2003 to 2004-2007 (74.1 vs. 83.1%, P=0.011). Among the individual MSs, valproate was used most frequently in both time periods, showing a significant increase (P&lt;0.001). Prescriptions of quetiapine (P&lt;0.001) and lamotrigine (P=0.033) increased significantly, carbamazepine showed a significant decrease (P&lt;0.001). Prescriptions of lithium and olanzapine decreased without reaching significance. The significant increase in the prescription of MS reflects the increasing awareness and implementation of recent evidence-based medicine guidelines into clinical practice. Clinical decision making, usually made on the basis of individual clinical experience, should always be reevaluated using periodically updated evidence-based medicine guidelines.</AbstractText><CopyrightInformation>© 2012 Wolters Kluwer Health | Lippincott Williams &amp; Wilkins.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walpoth-Niederwanger</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria. michaela.walpoth@i-med.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemmler</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Hörtnagl</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Strauss</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Blasko</LastName><ForeName>Imrich</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Hausmann</LastName><ForeName>Armand</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Clin Psychopharmacol</MedlineTA><NlmUniqueID>8609061</NlmUniqueID><ISSNLinking>0268-1315</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22842799</ArticleId><ArticleId IdType="doi">10.1097/YIC.0b013e328356ac92</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1757575</PMID><DateCompleted><Year>1992</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9762</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>1991</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of clinical psychology</Title><ISOAbbreviation>J Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>Thought disorder and verbal recall in acutely psychotic patients.</ArticleTitle><Pagination><MedlinePgn>735-44</MedlinePgn></Pagination><Abstract><AbstractText>This study examined the relationship between thought disorder and verbal recall in schizophrenic, manic, and schizoaffective inpatients. Based on previous research, it was predicted that subjects who demonstrated only positive thought-disorder would differ from those with positive and negative thought-disorder in terms of their ability to encode short descriptive passages. Unlike controls, who were able to encode organized material better than unorganized material, neither thought-disorder group improved its encoding when the material to be remembered was more organized. Both thought-disorder groups remembered more when the material was less organized. These findings raise a number of issues with regard to the interrelationship among thought disorders, psychiatric diagnoses, and information-processing deficits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Speed</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toner</LastName><ForeName>B B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Shugar</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Di Gasbarro</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychol</MedlineTA><NlmUniqueID>0217132</NlmUniqueID><ISSNLinking>0021-9762</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003210" MajorTopicYN="N">Concept Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="Y">Mental Recall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012564" MajorTopicYN="Y">Schizophrenic Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013067" MajorTopicYN="N">Speech Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="Y">Thinking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="Y">Verbal Learning</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1757575</ArticleId><ArticleId IdType="doi">10.1002/1097-4679(199111)47:6&lt;735::aid-jclp2270470602&gt;3.0.co;2-z</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29803226</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms.</ArticleTitle><Pagination><MedlinePgn>165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-018-1197-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Over the past 30 years, evidence has been accumulating for an immunological component to schizophrenia etiology, including genetic links to the major histocompatibility complex, microglia activation, and dysregulated cytokine profiles. However, the degree of similarity in cytokine profiles for schizophrenia and bipolar disorder, as well as the relationship between cytokine levels and brain structure, is less well understood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To address this, we recruited 69 first-episode schizophrenia-spectrum patients, 16 first-episode bipolar patients with psychotic features, and 53 healthy controls, from the UC Davis EDAPT clinic. Blood plasma was collected and analyzed for all participants with a subset of participants that also underwent structural MRI on a 1.5T GE scanner.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Plasma levels of interleukin (IL)-1β, IL-2, IL-6, and interferon (IFN)-γ were elevated in schizophrenia patients compared to those in controls. Patients with bipolar disorder had elevated plasma IL-10 levels compared to controls, and the two patient groups did not differ significantly on any immunological measure. Percent whole-brain gray matter was inversely correlated with IFN-γ and IL-12 levels in patients with schizophrenia, with a trend relationship between IFN-γ and IL-12 and prefrontal cortical thickness. Furthermore, psychotic symptoms were positively related to IL-1β levels in individuals with schizophrenia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest a partially overlapping pattern of elevated blood cytokine levels in patients with first-episode schizophrenia and bipolar disorder with psychotic features. Furthermore, our findings suggest that elevated pro-inflammatory cytokines may be particularly involved in schizophrenia etiology, given evidence of cytokine-related decreases in total gray matter.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lesh</LastName><ForeName>Tyler A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California at Davis, Sacramento, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Careaga</LastName><ForeName>Milo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California at Davis, Sacramento, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIND Institute, University of California at Davis, 2805, 50th Street, Sacramento, CA, 95817, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Destanie R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of California at Davis, 3146 Tupper Hall, 1 Shields Avenue, Davis, CA, 95616, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIND Institute, University of California at Davis, 2805, 50th Street, Sacramento, CA, 95817, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAllister</LastName><ForeName>A Kimberley</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Center for Neuroscience, University of California at Davis, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van de Water</LastName><ForeName>Judy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MIND Institute, University of California at Davis, 2805, 50th Street, Sacramento, CA, 95817, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Cameron S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California at Davis, Sacramento, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashwood</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of California at Davis, 3146 Tupper Hall, 1 Shields Avenue, Davis, CA, 95616, USA. pashwood@ucdavis.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIND Institute, University of California at Davis, 2805, 50th Street, Sacramento, CA, 95817, USA. pashwood@ucdavis.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 ES011269</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD079125</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD086669</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RISE Program</GrantID><Agency>University of California, Davis</Agency><Country/></Grant><Grant><GrantID>R21 HD065269</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01MH49883</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cortical thickness</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Immune</Keyword><Keyword MajorTopicYN="N">Psychosis</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword><Keyword MajorTopicYN="N">Structural MRI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29803226</ArticleId><ArticleId IdType="doi">10.1186/s12974-018-1197-2</ArticleId><ArticleId IdType="pii">10.1186/s12974-018-1197-2</ArticleId><ArticleId IdType="pmc">PMC5970482</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2009 Aug 6;460(7256):753-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19571809</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Neurosci. 2007 Nov;25(7):415-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17949937</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1695-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21627977</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2001;24:677-736</Citation><ArticleIdList><ArticleId IdType="pubmed">11520916</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Mar;37(2):284-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21134972</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 15;63(8):801-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18005941</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2014 Feb 15;75(4):262-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24199663</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Nov;50(11):1801-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19837763</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12776-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22802640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2013 Feb;18(2):206-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22869038</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacol Immunotoxicol. 2013 Oct;35(5):573-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23981042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Dec;21(12 ):1696-1709</Citation><ArticleIdList><ArticleId IdType="pubmed">26903267</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2013 Jul;31:54-68</Citation><ArticleIdList><ArticleId IdType="pubmed">22841693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Nov;11(7):726-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19839997</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2014 Feb 15;75(4):258-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24439553</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1999 Feb;9(2):195-207</Citation><ArticleIdList><ArticleId IdType="pubmed">9931269</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 1995 May-Jun;36(3):267-75</Citation><ArticleIdList><ArticleId IdType="pubmed">7638314</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Feb;45(2):189-92</Citation><ArticleIdList><ArticleId IdType="pubmed">3337616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2006 Jan;7(1):41-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16371949</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2011 Sep;33(3):268-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21971780</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rep. 2015 Apr;67(2):353-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25712663</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Immunol Ther Exp (Warsz). 2004 Jan-Feb;52(1):59-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15053234</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Sep 15;64(6):484-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18514163</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2014 May;38:220-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24566386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Feb 11;530(7589):177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 12:9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10372603</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Nov 1;64(9):820-2</Citation><ArticleIdList><ArticleId IdType="pubmed">18534557</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2006 Nov;20(6):532-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16580814</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Dec;151(1-3):43-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24200418</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 6;460(7256):744-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19571808</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2013 Dec;11(3):144-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24465251</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2015 Jan 15;77(2):147-57</Citation><ArticleIdList><ArticleId IdType="pubmed">25034946</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2013 Oct;33:33-45</Citation><ArticleIdList><ArticleId IdType="pubmed">23643646</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2014 Apr;154(1-3):23-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24582037</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2012 Sep;12(9):1143-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23039393</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Sep;152(9):1291-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7653683</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1982 Sep;38(3):715-24</Citation><ArticleIdList><ArticleId IdType="pubmed">7171697</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Dec 5;322(5907):1562-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19056990</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Oct 15;64(1):93-109</Citation><ArticleIdList><ArticleId IdType="pubmed">19840552</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 Feb;161(2-3):222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25433965</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Oct 1;70(7):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21641581</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Dec;72 (12 ):1677-1684</Citation><ArticleIdList><ArticleId IdType="pubmed">21672499</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2002 Feb;12(1):115-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11861174</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2002 Sep-Oct;36(5):331-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12127601</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1999 Feb;9(2):179-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Aug;21(8):1090-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26194183</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):303-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19138716</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Oct 15;64(1):61-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19840550</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2011 Jul;25(5):863-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20854892</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jul 1;74(1):15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23419545</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1415828</PMID><DateCompleted><Year>1992</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>149</Volume><Issue>11</Issue><PubDate><Year>1992</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features.</ArticleTitle><Pagination><MedlinePgn>1580-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to determine the significance of mood congruence of psychotic features in mania as a predictor of outcome.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Fifty-four patients with bipolar disorder were followed prospectively for 4 years after recovery from an episode of mania with psychotic features. Assessments of residential and occupational status, interepisode symptoms, and episode recurrences were made at 6 and 48 months after recovery. Categorical outcomes were evaluated by logistic regression and recurrence risk with survival analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mood-incongruent psychotic features during the index manic episode predicted a shorter time in remission at 4 years (hazard ratio = 2.6), and Schneiderian first-rank symptoms predicted poor residential status at 4 years (odds ratio = 20.1).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Differentiation of mood congruence of psychotic features in mania evidently has prognostic validity and, therefore, has utility as a nosological characteristic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-17119</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-31154</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-36224</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004651" MajorTopicYN="N">Employment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1415828</ArticleId><ArticleId IdType="doi">10.1176/ajp.149.11.1580</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3587458</PMID><DateCompleted><Year>1987</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>4</Issue><PubDate><Year>1987</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Combined preventive treatment of recurrent manic-depressive disease with lithium and carbamazepine or oxcarbazepine].</ArticleTitle><Pagination><MedlinePgn>245-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cabrera</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Albrecht</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Müller-Oerlinghausen</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Kombinierte rezidiv-prophylaktische Behandlung der manisch-depressiven Erkrankung mit Lithium und Carbamazepin oder Oxcarbazepin.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>VZI5B1W380</RegistryNumber><NameOfSubstance UI="D000078330">Oxcarbazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078330" MajorTopicYN="N">Oxcarbazepine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3587458</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26144587</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>229</Volume><Issue>1-2</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Impaired conflict resolution and vigilance in euthymic bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>490-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2015.06.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(15)00382-0</ELocationID><Abstract><AbstractText>Difficulty attending is a common deficit of euthymic bipolar patients. However, it is not known whether this is a global attentional deficit or relates to a specific attentional network. According to the attention network approach, attention is best understood in terms of three functionally and neuroanatomically distinct networks-alerting, orienting, and executive control. In this study, we explored whether and which of the three attentional networks are altered in euthymic Bipolar Disorder (BD). A sample of euthymic BD patients and age-matched healthy controls completed the Attention Network Test for Interactions and Vigilance (ANTI-V) that provided not only a measure of orienting, executive, and alerting networks, but also an independent measure of vigilance (tonic alerting). Compared to healthy controls, BD patients have impaired executive control (greater interference), reduced vigilance (as indexed by a decrease in the d' sensitivity) as well as slower overall reaction times and poorer accuracy. Our results show that deficits in executive attention and sustained attention often persist in BD patients even after complete remission of affective symptoms, thus suggesting that cognitive enhancing treatments programmed to improve these deficits could contribute to improve their functional recovery. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marotta</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Psicologia, "Sapienza" Università di Roma, Italy. Electronic address: andrea.marotta@uniroma1.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiaie</LastName><ForeName>Roberto Delle</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Acute Psychiatric Ward (Servizio Psichiatrico di Diagnosi e Cura - SPDC), Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spagna</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Psicologia, "Sapienza" Università di Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernabei</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Acute Psychiatric Ward (Servizio Psichiatrico di Diagnosi e Cura - SPDC), Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciarretta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Psicologia, "Sapienza" Università di Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roca</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ERI-Lectura - Departamento de Psicología Evolutiva y de la Educación, Universidad de Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biondi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Acute Psychiatric Ward (Servizio Psichiatrico di Diagnosi e Cura - SPDC), Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casagrande</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Psicologia, "Sapienza" Università di Roma, Italy. Electronic address: maria.casagrande@uniroma1.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="Y">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017008" MajorTopicYN="Y">Negotiating</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009949" MajorTopicYN="N">Orientation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alerting</Keyword><Keyword MajorTopicYN="N">Attention Network Test (ANT)</Keyword><Keyword MajorTopicYN="N">Bipolar disorders</Keyword><Keyword MajorTopicYN="N">Executive control</Keyword><Keyword MajorTopicYN="N">Orienting</Keyword><Keyword MajorTopicYN="N">Vigilance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26144587</ArticleId><ArticleId IdType="pii">S0165-1781(15)00382-0</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2015.06.026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">436097</PMID><DateCompleted><Year>1979</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>1979</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Manic depressive illness in adolescence and childhood: review and case report.</ArticleTitle><Pagination><MedlinePgn>255-63</MedlinePgn></Pagination><Abstract><AbstractText>The literature on this topic from its inception by Kraepelin is reviewed. While Kraepelin and the French school always recognized juvenile mania, the Anglo-American school has no such unanimity of opinion. Less than 100 cases are described in the world literature. In Canada affective psychoses are rarely diagnosed under age 10 and of all affective psychoses admitted to institutions less than 5% are under age 20. The differences between child and adult mania are outlined. It is proposed that manic-depressive illness occurs in children but is not diagnosed more often because of its dissimilar presentation to the adult form and doubts about its existence in childhood. The case history of a 14 year old boy who presented in a hypomanic state is described. There was a strong family history of affective disorder. Both his parents and his half-sister were already on lithium for manic-depressive illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coll</LastName><ForeName>P G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Bland</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000662">Amphetamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000662" MajorTopicYN="N">Amphetamines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">436097</ArticleId><ArticleId IdType="doi">10.1177/070674377902400311</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12633120</PMID><DateCompleted><Year>2003</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Can long-term treatment with antidepressant drugs worsen the course of depression?</ArticleTitle><Pagination><MedlinePgn>123-33</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The possibility that antidepressant drugs, while effectively treating depression, may worsen its course has received inadequate attention.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A review of the literature suggesting potential depressogenic effects of long-term treatment with antidepressant drugs was performed. A MEDLINE search was conducted using the keywords tolerance, sensitization, antidepressive agents, and switching. This was supplemented by a manual search of Index Medicus under the heading "antidepressant agents" and a manual search of the literature for articles pointing to paradoxical effects of antidepressants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A number of reported clinical findings point to the following possibilities: very unfavorable long-term outcome of major depression treated by pharmacologic means, paradoxical (depression-inducing) effects of antidepressant drugs in some patients with mood and anxiety disturbances, antidepressant-induced switching and cycle acceleration in bipolar disorder, occurrence of tolerance to the effects of antidepressants during long-term treatment, onset of resistance upon rechallenge with the same antidepressant drug in a few patients, and withdrawal syndromes following discontinuation of mood-elevating drugs. These phenomena in susceptible individuals may be explained on the basis of the oppositional model of tolerance. Continued drug treatment may recruit processes that oppose the initial acute effects of a drug and may result in loss of clinical effect. When drug treatment ends, these processes may operate unopposed, at least for some time, and increase vulnerability to relapse.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The possibility that antidepressant drugs may worsen the course of depression needs to be tested, even though its scientific exploration is likely to encounter considerable methodological and ideological difficulties. The clinical implications of this hypothesis in depression are considerable. Antidepressant drugs are crucial in the treatment of major depressive episodes. However, appraisal of paradoxical effects that may occur in susceptible patients during long-term treatment may lead to more effective use of the drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>Giovanni A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, State University of New York at Buffalo, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004361" MajorTopicYN="N">Drug Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010601" MajorTopicYN="N">Pharmacology, Clinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>136</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12633120</ArticleId><ArticleId IdType="doi">10.4088/jcp.v64n0204</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24999863</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>167</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and gambling disorder comorbidity: current evidence and implications for pharmacological treatment.</ArticleTitle><Pagination><MedlinePgn>285-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.06.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00384-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The co-occurrence of bipolar disorder (BD) and gambling disorder (GD), though of clinical and public health importance, is still scarcely investigated. Comorbid BD-GD subjects experience a more severe course of illness and poorer treatment outcome, due to a range of clinical and psychosocial factors that collectively impede remission and recovery. The aim of our paper is to review the role of pharmacotherapy in the treatment of comorbid BD-GD, in order to support clinical decisions according to the best available evidence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A qualitative systematic review of studies on pharmacological treatment in comorbid BD-GD was performed. A comprehensive literature search of online databases, bibliographies of published articles and gray literature was conducted. Data on efficacy, safety and tolerability were extracted and levels of evidence were assessed. We also provide a brief overview of current epidemiological, neurobiological and clinical findings, with the intention of proposing a dimensional approach to the choice of available drugs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The only drug with a high level of evidence is lithium. Considering the inclusion of GD in DSM-5 'Substance-related and Addictive Disorders' category, we discuss the use of other drugs with a high level of evidence currently used in BD subjects with co-occurring substance use disorders.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Only few clinical trials are available and the population is limited; therefore no conclusive evidence can be inferred.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Further randomized controlled trials are required to evaluate the efficacy of pharmacological treatment strategies in large samples of patients with comorbid BD-GD. Also, attempts should be made to identify other shared clinical and psychopathological domains that are amenable to treatment.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Nicola</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Clinical Psychology, Catholic University of Sacred Heart, Rome, Italy; University Consortium Humanitas, Rome, Italy. Electronic address: mdnicola@libero.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Risio</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Clinical Psychology, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettorruso</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Clinical Psychology, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Clinical Psychology, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Crescenzo</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Clinical Psychology, Catholic University of Sacred Heart, Rome, Italy; Department of Neuroscience, Bambino Gesù Children׳s Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swierkosz-Lenart</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre neuchâtelois de psychiatrie, République et Canton de Neuchâtel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinotti</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Imaging, Institute of Psychiatry, "G. d'Annunzio" University of Chieti-Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camardese</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Clinical Psychology, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Giannantonio</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Imaging, Institute of Psychiatry, "G. d'Annunzio" University of Chieti-Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janiri</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Clinical Psychology, Catholic University of Sacred Heart, Rome, Italy; University Consortium Humanitas, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005715" MajorTopicYN="N">Gambling</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Addictive behaviors</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">DSM-5</Keyword><Keyword MajorTopicYN="N">Gambling disorder</Keyword><Keyword MajorTopicYN="N">Pharmacological treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24999863</ArticleId><ArticleId IdType="pii">S0165-0327(14)00384-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.06.023</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18956262</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2009</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1814-1412</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4 Pt 2</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Augmentative transcranial magnetic stimulation (TMS) combined with brain navigation in drug-resistant rapid cycling bipolar depression: a case report of acute and maintenance efficacy.</ArticleTitle><Pagination><MedlinePgn>673-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15622970701806192</ELocationID><Abstract><AbstractText>The efficacy of transcranial magnetic stimulation (TMS) has been poorly investigated in the acute and maintenance treatment of bipolar depression. The present case supports the efficacy of low-frequency repetitive TMS (rTMS) of the right dorsolateral pre-frontal cortex (RDLPFC) combined to brain navigation in a drug-resistant, bipolar depressed subject with rapid cycling. While continuing the pharmacological treatment at stable doses, the patient was stimulated for 3 weeks at 1 Hz, 110% of motor threshold, 300 stimuli/day showing a significant improvement on the Hamilton Depression Rating Scale (HDRS(21)), the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression, improvement scale (CGI-I) total scores. On completion of the 3-week rTMS, the patient was treated with periodic maintenance sessions of rTMS at the same parameters of acute phase for an additional 6 months, at the end of which the therapeutic gains were maintained according to rating scales scores. Larger controlled trials assessing the acute and maintenance efficacy of rTMS in bipolar depression are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dell'osso</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Francesco Sforza 35, 20122, Milano, Italy. bernado.dellosso@mssm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altamura</LastName><ForeName>A Carlo</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038361" MajorTopicYN="N">Neuronavigation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18956262</ArticleId><ArticleId IdType="pii">788607214</ArticleId><ArticleId IdType="doi">10.1080/15622970701806192</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10904433</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0306-9877</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Clock genes, feedback loops and their possible role in the etiology of bipolar disorders: an integrative model.</ArticleTitle><Pagination><MedlinePgn>155-9</MedlinePgn></Pagination><Abstract><AbstractText>Clock genes, which are found in all higher organisms including humans, play a central role in the generation and control of circadian rhythms. For example, the amount of protein encoded by the per gene in mice oscillates with a circadian frequency. The per gene is activated by a constitutively expressed heterodimeric protein encoded by the bmal1 and clock genes, and this activation is suppressed by the PER protein itself. The negative feedback of the PER protein on the expression of the per gene provides a framework for a basic circadian autoregulatory loop in mammals. These elements of biomolecular feedback loops are interpreted within a system theory as an elementary behavioral cycle consisting of intentional programs (the per gene), environmental objects (the BMAL1-CLOCK heterodimer) and the experiential realization of the intended programs (the level of PER protein). This single model enables the deduction of disturbances, which can be transferred to the criteria of bipolar disorders. It is hypothesized that mutations in clock genes lead to disturbances in molecular feedback loops, which on a behavioral level could appear as bipolar disorders. Finally, some implications for research and treatment of bipolar disorders are discussed.</AbstractText><CopyrightInformation>Copyright 2000 Harcourt Publishers Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitterauer</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Forensic Neuropsychiatry, University of Salzburg, Austria.bernhard.mitterauer@sbg.ac.at</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001683" MajorTopicYN="N">Biological Clocks</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005246" MajorTopicYN="Y">Feedback</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>21</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10904433</ArticleId><ArticleId IdType="doi">10.1054/mehy.1999.1039</ArticleId><ArticleId IdType="pii">S0306-9877(99)91039-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2572209</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>10</Issue><PubDate><Year>1989</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Idazoxan: a selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients.</ArticleTitle><Pagination><MedlinePgn>958-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>O T</ForeName><Initials>OT</Initials></Author><Author ValidYN="Y"><LastName>Rudorfer</LastName><ForeName>M V</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>W Z</ForeName><Initials>WZ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004146">Dioxanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004147">Dioxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011942">Receptors, Adrenergic, alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>Y310PA316B</RegistryNumber><NameOfSubstance UI="D019329">Idazoxan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000317" MajorTopicYN="N">Adrenergic alpha-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004146" MajorTopicYN="N">Dioxanes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004147" MajorTopicYN="N">Dioxins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019329" MajorTopicYN="N">Idazoxan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011942" MajorTopicYN="N">Receptors, Adrenergic, alpha</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2572209</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1989.01810100100021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30926912</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5454</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>12</Month></PubDate></JournalIssue><Title>Eye (London, England)</Title><ISOAbbreviation>Eye (Lond)</ISOAbbreviation></Journal><ArticleTitle>Peripapillary retinal nerve fiber layer and ganglion cell complex degeneration in Egyptian patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1852-1858</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-019-0403-5</ELocationID><Abstract><AbstractText Label="PURPOSE">To determine if changes in OCT parameters including peripapillary RNFL thickness and GCC thickness in Egyptian patients with bipolar disorder exist, and to correlate them with disease severity and clinical characteristics.</AbstractText><AbstractText Label="METHODS">A case-control study conducted on 40 patients with bipolar disorder were compared to 40 matched healthy controls. Both patients and controls were subjected to ophthalmic examination including: BCVA, slit-lamp examination, fundus examination, and OCT imaging. Patients were also subjected to Young Mania Rating Scale (YMRS).</AbstractText><AbstractText Label="RESULTS">Thinning of average (RNFL) and average (GCC) thickness of right and left eye in patients with BPD (whether received electroconvulsive therapy or not) when compared with control subjects. Number of episodes, age at onset and severity of disease showed insignificant correlation with OCT parameters.</AbstractText><AbstractText Label="CONCLUSIONS">Significant degenerative changes were detected by OCT in patients with bipolar disorder that were not affected by receiving ECT and not related to disease severity or duration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalil</LastName><ForeName>Dalia H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Faculty of Medicine, Cairo University, Giza, Egypt. Daliahamed_76@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Said</LastName><ForeName>Mohamed M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Faculty of Medicine, Fayoum University, Faiyum, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye (Lond)</MedlineTA><NlmUniqueID>8703986</NlmUniqueID><ISSNLinking>0950-222X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eye (Lond). 2019 Jun 3;:</RefSource><PMID Version="1">31160701</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004534" MajorTopicYN="N" Type="Geographic">Egypt</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009412" MajorTopicYN="N">Nerve Fibers</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012162" MajorTopicYN="N">Retinal Degeneration</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="Y">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>02</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30926912</ArticleId><ArticleId IdType="doi">10.1038/s41433-019-0403-5</ArticleId><ArticleId IdType="pii">10.1038/s41433-019-0403-5</ArticleId><ArticleId IdType="pmc">PMC7002616</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2012;7(4):e34823</Citation><ArticleIdList><ArticleId IdType="pubmed">22536333</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Retina Vitreous. 2016 Oct 17;2:24</Citation><ArticleIdList><ArticleId IdType="pubmed">27847642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Dec;11(8):807-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19922551</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Nervenarzt. 2013 Apr;84(4):483-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23423630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Indian Acad Neurol. 2018 Apr-Jun;21(2):119-125</Citation><ArticleIdList><ArticleId IdType="pubmed">30122836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocul Immunol Inflamm. 2017 Jun;25(3):315-322</Citation><ArticleIdList><ArticleId IdType="pubmed">27070049</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2008 Oct;18(10):717-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18554875</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1017-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Afr Med. 2016 Apr-Jun;15(2):52-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27044727</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2016 May;67:66-72</Citation><ArticleIdList><ArticleId IdType="pubmed">27095337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Glaucoma. 2013 Sep;22(7):532-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22549477</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2016 Aug;31(5):430-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26888864</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):894-900</Citation><ArticleIdList><ArticleId IdType="pubmed">17617385</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2016 Feb;32:9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26800301</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res Neuroimaging. 2016 May 30;251:60-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27124425</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2017;56(3):1101-1107</Citation><ArticleIdList><ArticleId IdType="pubmed">28106555</ArticleId></ArticleIdList></Reference><Reference><Citation>Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):365-71</Citation><ArticleIdList><ArticleId IdType="pubmed">25808660</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Ophthalmol. 2014 Mar;62(3):316-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24008793</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14662219</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0029-7844</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Obstetrics and gynecology</Title><ISOAbbreviation>Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Suicide in pregnancy.</ArticleTitle><Pagination><MedlinePgn>1306-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pregnant women with bipolar disorder often elicit conflicts between maternal and fetal considerations.</AbstractText><AbstractText Label="CASE" NlmCategory="METHODS">A 26-year-old primigravida at 12 weeks' gestation presented for emergency psychiatric evaluation after discontinuing psychotropic medications when starting prenatal care. She developed worsening depression and was suicidal. She was admitted to an inpatient psychiatric unit, medication was reinitiated, and she appeared to stabilize well enough to be followed as an outpatient. Two days after discharge, she shot herself in the left chest, resulting in her death and that of her fetus.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">When choosing to maintain or discontinue mood stabilizers during pregnancy, decisions are best made by the use of a risk-benefit model that takes into account the health and well-being of both mother and fetus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dell</LastName><ForeName>Diana L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA. dell0001@mc.duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Benjamin W</ForeName><Initials>BW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obstet Gynecol</MedlineTA><NlmUniqueID>0401101</NlmUniqueID><ISSNLinking>0029-7844</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>01ZG3TPX31</RegistryNumber><NameOfSubstance UI="D016642">Bupropion</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016642" MajorTopicYN="N">Bupropion</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="Y">Pregnancy Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="Y">Suicide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14662219</ArticleId><ArticleId IdType="pii">S0029784403007634</ArticleId><ArticleId IdType="doi">10.1016/s0029-7844(03)00763-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21041258</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>167</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antidepressant use in bipolar disorder: continuing an age-old debate.</ArticleTitle><Pagination><MedlinePgn>1408; author reply 1408-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2010.10040496</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eppel</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2010 Jul;167(7):792-800</RefSource><PMID Version="1">20360317</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21041258</ArticleId><ArticleId IdType="pii">167/11/1408</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2010.10040496</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14982905</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>291</Volume><Issue>8</Issue><PubDate><Year>2004</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy and risk of suicidal behaviors among patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>939; author reply 940</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yerevanian</LastName><ForeName>Boghos I</ForeName><Initials>BI</Initials></Author><Author ValidYN="Y"><LastName>Koek</LastName><ForeName>Ralph J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Feusner</LastName><ForeName>Jamie D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA. 2003 Sep 17;290(11):1467-73</RefSource><PMID Version="1">13129986</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="Y">Suicide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14982905</ArticleId><ArticleId IdType="doi">10.1001/jama.291.8.939-b</ArticleId><ArticleId IdType="pii">291/8/939-a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24729763</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1550-4271</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Journal of dual diagnosis</Title><ISOAbbreviation>J Dual Diagn</ISOAbbreviation></Journal><ArticleTitle>N-acetyl aspartate levels in adolescents with bipolar and/or cannabis use disorders.</ArticleTitle><Pagination><MedlinePgn>39-43</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Bipolar and cannabis use disorders commonly co-occur during adolescence, and neurochemical studies may help clarify the pathophysiology underlying this co-occurrence. This study compared metabolite concentrations in the left ventral lateral prefrontal cortex among adolescents with bipolar disorder (bipolar group; n = 14), adolescents with a cannabis use disorder (cannabis use group; n = 13), adolescents with cannabis use and bipolar disorders (bipolar and cannabis group; n = 25), and healthy adolescents (healthy controls; n = 15). We hypothesized that adolescents with bipolar disorder (with or without cannabis use disorder) would have decreased N-acetyl aspartate levels in the ventral lateral prefrontal cortex compared to the other groups and that the bipolar and cannabis group would have the lowest N-acetyl aspartate levels of all groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">N-acetyl aspartate concentrations in the left ventral lateral prefrontal cortex were obtained using proton magnetic resonance spectroscopy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Adolescents with bipolar disorder showed significantly lower left ventral lateral prefrontal cortex N-acetyl aspartate levels, but post hoc analyses indicated that this was primarily due to increased N-acetyl aspartate levels in the cannabis group. The cannabis use disorder group had significantly higher N-acetyl aspartate levels compared to the bipolar disorder and the bipolar and cannabis groups (p = .0002 and p = .0002, respectively). Pearson correlations revealed a significant positive correlation between amount of cannabis used and N-acetyl aspartate concentrations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adolescents with cannabis use disorder showed higher levels of N-acetyl aspartate concentrations that were significantly positively associated with the amount of cannabis used; however, this finding was not present in adolescents with comorbid bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bitter</LastName><ForeName>Samantha M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Neuroscience, Division of Bipolar Disorder Research , University of Cincinnati College of Medicine , Cincinnati , OH 45219 , USA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Wade A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Wen-Jang</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Caleb M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Eliassen</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>DelBello</LastName><ForeName>Melissa P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA022221</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000077</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Dual Diagn</MedlineTA><NlmUniqueID>101197457</NlmUniqueID><ISSNLinking>1550-4271</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>997-55-7</RegistryNumber><NameOfSubstance UI="C000179">N-acetylaspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002189" MajorTopicYN="N">Marijuana Abuse</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066244" MajorTopicYN="N">Proton Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24729763</ArticleId><ArticleId IdType="doi">10.1080/15504263.2013.869077</ArticleId><ArticleId IdType="pmc">PMC3979563</ArticleId><ArticleId IdType="mid">NIHMS548339</ArticleId></ArticleIdList><?nihms ?><ReferenceList><Reference><Citation>Biol Psychiatry. 2007 Mar 15;61(6):776-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17027928</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2008 Dec;18(6):557-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19108660</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Jul 1;57(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">21349338</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Addict. 1991 Feb;26(2):219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">1889921</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 1999 Sep;94(9):1361-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10615721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Oct;10(10):900-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16027739</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2001 Oct 4;413(6855):527-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11586361</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Aug-Sep;203(2-3):111-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22981426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Stud Alcohol. 1994 Mar;55(2):149-58</Citation><ArticleIdList><ArticleId IdType="pubmed">8189735</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 25;150(3):1109-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23706839</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jun 1;61(11):1281-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17239356</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1980 Jan;168(1):26-33</Citation><ArticleIdList><ArticleId IdType="pubmed">7351540</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1979 Oct;64(4):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">492809</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 3;302(5642):84-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14526074</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 1993 Dec;30(6):672-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8139448</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2004 Dec;6(6):466-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15538996</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry (Edgmont). 2009 Dec;6(12):44-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20104292</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 1;60(9):998-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">17056394</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1992 Mar;31(2):252-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1564026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Dual Diagn. 2012 Jan;8(1):13-18</Citation><ArticleIdList><ArticleId IdType="pubmed">23087600</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2006 Jun;31(6):1264-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16292323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21831906</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2012</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-2854</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The International journal of social psychiatry</Title><ISOAbbreviation>Int J Soc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A qualitative study of perceptions related to family risk of bipolar disorder among patients and family members from India.</ArticleTitle><Pagination><MedlinePgn>463-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0020764011408543</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Over the past decade there have been rapid advances in psychiatry genetics and there is a growing concern about the clinical and practical relevance of this knowledge. Efforts are being made to know the perspectives of patients and family members regarding family risk and genetic counselling. However, the area remains largely unexplored in psychiatric research from Asian countries.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The primary purpose of the study was to explore the perceptions related to family risk among Indian patients with bipolar disorder and their family members. The study also aimed to explore the related perceptions for etiology of bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients with bipolar disorder type I and family members of patients with bipolar disorder type I were invited to take part in in-depth interviews after informed consent, targeting a sample of diversity. The qualitative data were analysed using thematic analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight key themes emerged: (1) higher emphasis on external or situational causes; (2) causal explanations are governed by cultural beliefs; (3) help-seeking is a shared, rather than a personal, decision; (4) the perceived genetic risk is low but worrisome; (5) worries and apprehensions are focused mainly on future generations; (6) there is a desire to modify the perceived genetic risk; (7) knowledge of precise risk can be beneficial as well as anxiety provoking; and (8) there is a need for information on preventive measures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study provides culture-specific perspectives on the causation of illness and explores a sensitive and personal matter of perceived family risk in an Indian sample. It emphasizes the need to further explore the perceptions of family risk in a given cultural context.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pattanayak</LastName><ForeName>Raman Deep</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagar</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Soc Psychiatry</MedlineTA><NlmUniqueID>0374726</NlmUniqueID><ISSNLinking>0020-7640</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21831906</ArticleId><ArticleId IdType="pii">0020764011408543</ArticleId><ArticleId IdType="doi">10.1177/0020764011408543</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16343842</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0891-4222</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>6</Issue><PubDate><MedlineDate>2006 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Research in developmental disabilities</Title><ISOAbbreviation>Res Dev Disabil</ISOAbbreviation></Journal><ArticleTitle>An evaluation of social and adaptive skills in adults with bipolar disorder and severe/profound intellectual disability.</ArticleTitle><Pagination><MedlinePgn>681-7</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this study was to explore the interrelationship of social and adaptive skills in adults with bipolar disorder and severe or profound intellectual disability. A bipolar group (N=14), a severe psychopathology group without bipolar disorder (N=14), and a control group with no DSM-IV Axis I diagnosis (N=14) were compared on the Vineland Adaptive Behavior Scale (VABS) and the Matson Evaluation of Social Skills for Individuals with sEvere Retardation (MESSIER). Bipolar patients had significantly more negative verbal social skills than the other two groups on the MESSIER, but no group differences on the VABS were noted. The implications of these data are discussed for a better understanding of bipolar disorder in persons with intellectual disability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matson</LastName><ForeName>Johnny L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychology, Louisiana State University, Baton Rouge, LA 70803, USA. johnmatson@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terlonge</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>González</LastName><ForeName>Melissa L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Rivet</LastName><ForeName>Tessa</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Dev Disabil</MedlineTA><NlmUniqueID>8709782</NlmUniqueID><ISSNLinking>0891-4222</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="Y">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16343842</ArticleId><ArticleId IdType="pii">S0891-4222(05)00092-2</ArticleId><ArticleId IdType="doi">10.1016/j.ridd.2005.10.001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25315819</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-4665</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Health care for women international</Title><ISOAbbreviation>Health Care Women Int</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder in women.</ArticleTitle><Pagination><MedlinePgn>475-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/07399332.2014.962138</ELocationID><Abstract><AbstractText>This article summarizes research pertinent to the clinical care of women with bipolar disorder. With bipolar disorder, female gender correlates with more depressive symptoms and different comorbidities. There is a high risk of symptom recurrence postpartum and possibly during perimenopause. Women with bipolar disorder have increased risk of sexually transmitted diseases, unplanned pregnancies, excessive weight gain, metabolic syndrome, and cardiovascular disease. Mood stabilizing medications, specific psychotherapies, and lifestyle changes can stabilize mood and improve functioning. Pharmacologic considerations include understanding interactions between mood stabilizing medications and contraceptive agents and risks and benefits of mood stabilizing medication during pregnancy and lactation. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>a Department of Psychiatry, Loyola Stritch School of Medicine, Edward Hines Jr. VA Hospital , Hines , Illinois , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghadiali</LastName><ForeName>Nafisa Y</ForeName><Initials>NY</Initials></Author><Author ValidYN="Y"><LastName>Larusso</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Wahlen</LastName><ForeName>Kelly J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Avni-Barron</LastName><ForeName>Orit</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Mittal</LastName><ForeName>Leena</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Judy A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Care Women Int</MedlineTA><NlmUniqueID>8411543</NlmUniqueID><ISSNLinking>0739-9332</ISSNLinking></MedlineJournalInfo><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019052" MajorTopicYN="N">Depression, Postpartum</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020073" MajorTopicYN="N">Gravidity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008572" MajorTopicYN="N">Menarche</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008593" MajorTopicYN="N">Menopause</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010298" MajorTopicYN="N">Parity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25315819</ArticleId><ArticleId IdType="doi">10.1080/07399332.2014.962138</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8137104</PMID><DateCompleted><Year>1994</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>164</Volume><Issue>1</Issue><PubDate><Year>1994</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium dosage and inositol levels.</ArticleTitle><Pagination><MedlinePgn>133-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grisaru</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Belmaker</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4L6452S749</RegistryNumber><NameOfSubstance UI="D007294">Inositol</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007294" MajorTopicYN="N">Inositol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011565" MajorTopicYN="N">Psoriasis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8137104</ArticleId><ArticleId IdType="pii">S0007125000050534</ArticleId><ArticleId IdType="doi">10.1192/bjp.164.1.133</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">937566</PMID><DateCompleted><Year>1976</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>133</Volume><Issue>7</Issue><PubDate><Year>1976</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Agitated psychotic depression associated with severe hypomanic episodes: a rare syndrome.</ArticleTitle><Pagination><MedlinePgn>765-71</MedlinePgn></Pagination><Abstract><AbstractText>The authors present detailed clinical and follow-up data on 12 patients with agitated psychotic depressions who developed serious hypomanic or manic episodes. In six patients, each type of affective episode seemed to merge into the others, while in the other patients there was always a clear temporal distinction between each type of episode. The authors suggest that the older ages of their patients may have contributed to the syndrome. They also offer several possible theoretical explanations: the patients 1) had mixed affective states and were trapped in the "switch" state from depression to mania, 2) inherited both unipolar and bipolar diseases, 3) represent a subgroup of bipolar patients, and 4) were schizoaffective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Himmelhoch</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Coble</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>K J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Ingenito</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1976</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1976</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1976</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">937566</ArticleId><ArticleId IdType="doi">10.1176/ajp.133.7.765</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31159601</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>14</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy for the peripartum management of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1731-1741</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14656566.2019.1626826</ELocationID><Abstract><AbstractText><b>Introduction</b>: The peripartum period in bipolar disorder (BD) patients is associated with high risk of relapse. Relapse during this period may affect fetal and child development. The consequences of psychotropic medication during pregnancy are also a major concern. The extent to which mood stabilizers may potentially affect the embryogenesis or the child development varies from high (e.g. valproate) to less clear and more debated (e.g. lithium). <b>Areas covered</b>: This review describes the current state of evidence with respect to the impact of recommended pharmacological interventions for BD during the peripartum period. It compares recent international treatment guidelines for the management of BD during the peripartum period. Last, this review presents a summary of key recommendations for BD women of childbearing age, for BD women during pregnancy and postpartum period from the international guidelines. <b>Expert opinion</b>: Management of the pharmacological treatment for BD patients during the perinatal period is challenging. Although treatment guidelines may be of significant help, high heterogeneity exists across them. Shared decision-making represents a useful patient-centered approach during the perinatal period. Large cohort studies are needed to better identify risk associated to treatment discontinuation or treatment exposure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belzeaux</LastName><ForeName>Raoul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>APHM, Department of psychiatry and INT-UMR7289, CNRS Aix Marseille University , Marseille , France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondation FondaMental , Créteil , France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanguinetti</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>APHM, Department of psychiatry and INT-UMR7289, CNRS Aix Marseille University , Marseille , France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM , Barcelona , Catalonia , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdolini</LastName><ForeName>Norma</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM , Barcelona , Catalonia , Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FIDMAG Germanes Hospitalaries Research Foundation , Barcelona , Catalonia , Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, Clinical Psychology and Rehabilitation, University of Perugia , Perugia , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM , Barcelona , Catalonia , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo-Mazzei</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM , Barcelona , Catalonia , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Lola</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>APHM, Department of psychiatry and INT-UMR7289, CNRS Aix Marseille University , Marseille , France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anmella</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM , Barcelona , Catalonia , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbuti</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinic Medicine, Section of Psychiatry, University of Pisa , Pisa , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM , Barcelona , Catalonia , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorca</LastName><ForeName>Pierre-Michel</ForeName><Initials>PM</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7438-8990</Identifier><AffiliationInfo><Affiliation>Fondation FondaMental , Créteil , France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, CHU Clermont-Ferrand and University of Clermont Auvergne, EA 7280 , Clermont-Ferrand , France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samalin</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fondation FondaMental , Créteil , France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, CHU Clermont-Ferrand and University of Clermont Auvergne, EA 7280 , Clermont-Ferrand , France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017408" MajorTopicYN="N">Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058725" MajorTopicYN="N">Peripartum Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">breastfeeding</Keyword><Keyword MajorTopicYN="N">childbearing age</Keyword><Keyword MajorTopicYN="N">guidelines</Keyword><Keyword MajorTopicYN="N">pharmacotherapy</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31159601</ArticleId><ArticleId IdType="doi">10.1080/14656566.2019.1626826</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16427137</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Toward a definition of a cyclothymic behavioral endophenotype: which traits tap the familial diathesis for bipolar II disorder?</ArticleTitle><Pagination><MedlinePgn>233-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although the cyclothymic temperament appears to be related to the familial diathesis of bipolar disorder, exhibiting high sensitivity for bipolar II (BP-II) disorder, it is presently uncertain which of its constituent traits are specific for this disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a sample of 446 major depressive patients (BP-II and unipolar), in the French National EPIDEP study, the cyclothymic temperament was assessed by using clinician- and self-rated scales. We computed the frequency of individual traits and relative risk for family history of bipolarity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From both clinician- and self-rated scales, four items related to mood reactivity, energy, psychomotor and mental activity were significantly highly represented in the subgroup with positive family history of bipolarity. The item "rapid shifts in mood and energy" obtained the highest relative risk (OR=3.42) for positive family history of bipolarity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings delineate those cyclothymic traits which are most likely to tap a familial-genetic diathesis for BP-II, thereby identifying traits which can best serve as a behavioral endophenotype for this bipolar subtype. Such an endophenotype might underlie the cyclic course of bipolar disorder first described in France 150 years ago by Falret and Baillarger.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hantouche</LastName><ForeName>E G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Université Paris VI Mood Center, Hôpital Pitiè-Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Affect Disord. 2008 Jan;105(1-3):315</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="Y">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>05</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16427137</ArticleId><ArticleId IdType="pii">S0165-0327(04)00279-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2004.08.013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27459029</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2016</Year><Month>11</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>A combined analysis of genome-wide expression profiling of bipolar disorder in human prefrontal cortex.</ArticleTitle><Pagination><MedlinePgn>23-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2016.07.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(16)30154-6</ELocationID><Abstract><AbstractText>Numbers of gene expression profiling studies of bipolar disorder have been published. Besides different array chips and tissues, variety of the data processes in different cohorts aggravated the inconsistency of results of these genome-wide gene expression profiling studies. By searching the gene expression databases, we obtained six data sets for prefrontal cortex (PFC) of bipolar disorder with raw data and combinable platforms. We used standardized pre-processing and quality control procedures to analyze each data set separately and then combined them into a large gene expression matrix with 101 bipolar disorder subjects and 106 controls. A standard linear mixed-effects model was used to calculate the differentially expressed genes (DEGs). Multiple levels of sensitivity analyses and cross validation with genetic data were conducted. Functional and network analyses were carried out on basis of the DEGs. In the result, we identified 198 unique differentially expressed genes in the PFC of bipolar disorder and control. Among them, 115 DEGs were robust to at least three leave-one-out tests or different pre-processing methods; 51 DEGs were validated with genetic association signals. Pathway enrichment analysis showed these DEGs were related with regulation of neurological system, cell death and apoptosis, and several basic binding processes. Protein-protein interaction network further identified one key hub gene. We have contributed the most comprehensive integrated analysis of bipolar disorder expression profiling studies in PFC to date. The DEGs, especially those with multiple validations, may denote a common signature of bipolar disorder and contribute to the pathogenesis of disease.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinglu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Susu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Weixiao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Liyuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kunlin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Suhua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China. Electronic address: changsh@psych.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China. Electronic address: wangjing@psych.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Differentially expressed genes</Keyword><Keyword MajorTopicYN="Y">Gene expression</Keyword><Keyword MajorTopicYN="Y">Mega-analysis</Keyword><Keyword MajorTopicYN="Y">Prefrontal cortex</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27459029</ArticleId><ArticleId IdType="pii">S0022-3956(16)30154-6</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2016.07.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23419545</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies.</ArticleTitle><Pagination><MedlinePgn>15-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2013.01.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(13)00047-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We conducted a meta-analysis of studies comparing cytokine concentrations between patients with bipolar disorder (BD) and healthy control subjects (HCs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched ISI Web of Science, MEDLINE, BIOSIS Previews, Scopus, Current Contents Connect, and Biological Abstracts for relevant studies. Based on heterogeneity status, we used fixed-effect or restricted maximal likelihood model to perform meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty studies with a total of 2599 participants (1351 BD and 1248 HCs) were eligible for the analysis. Concentrations of interleukin (IL)-4 (p = .008), IL-6 (p = .073), IL-10 (p = .013), soluble IL-2 receptor (sIL-2R; p &lt; .001), sIL-6R (p = .021), tumor necrosis factor (TNF)-α (p = .010), soluble TNF receptor-1 (sTNFR1; p &lt; .001), and IL-1 receptor antagonist (p value in mania &lt; .001 and euthymia = .021) were significantly elevated in patients compared with HCs. Moreover, IL-1β (p = .059), and IL-6 (p = .073) tended to show higher values in patients. Levels of IL-2 (p = .156), interferon (INF)-γ (p = .741), C-C motif ligand 2 (p = .624), and IL-8 (p = .952) did not significantly differ between patients and HCs. Subgroup analysis based on mitogen stimulation status partially or completely resolved heterogeneity for most of the cytokines. Concentrations of IL-2, IL-4, sIL-6R, and INF-γ were unrelated to medication status. Phasic difference was present for TNF-α, sTNFR1, sIL-2R, IL-6, and IL-1RA, whereas it was absent for IL-4 and IL-10.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This meta-analysis provides evidence for significant elevation of proinflammatory, anti-inflammatory, and regulatory cytokines in BD.</AbstractText><CopyrightInformation>Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Modabbernia</LastName><ForeName>Amirhossein</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychiatry Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. amirh899@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taslimi</LastName><ForeName>Shervin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brietzke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ashrafi</LastName><ForeName>Mandana</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>01</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23419545</ArticleId><ArticleId IdType="pii">S0006-3223(13)00047-4</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2013.01.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11869755</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>1-3</Issue><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Toward a refined phenomenology of mania: combining clinician-assessment and self-report in the French EPIMAN study.</ArticleTitle><Pagination><MedlinePgn>89-96</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Because manic patients lack insight, they are generally considered unreliable observers of their own psychopathology. The present analyses sought to examine to what extent patient reports could improve formal diagnostic criteria for mania--and be validated against the Carroll-Klein (CK) psychobiological model of bipolarity.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">104 DSM-IV acutely manic (hospitalized) patients provided self-assessment on the Ahearn--Carroll scale, the Multiple Visual Analogue Scales of Bipolarity (MVAS-BP). A principal component analysis (PCA) was performed on MVAS-BP, and the data on factorial scores were then compared to dimensional scores according to the CK model and to factors on the Beigel-Murphy Manic State Rating Scale (MSRS) completed by psychiatrists.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The PCA identified a general factor accounting for 33% of the total variance; after varimax rotation, seven independent factors emerged, essentially in coherence with the signs and symptoms of DSM-IV mania, except for the 'social disinhibition' factor, which does not figure out as a distinct criterion in DSM-IV. Strong correlations were obtained (r &gt; or = 0.80) between the four major factors of MVAS-BP and the four dimensional categories of the CK model: 'Consummatory Reward' with F1 'Elation and Inflated Self-esteem' (r=0.93), 'Incentive Reward' with F2 'Activation' (r=0.84), 'Psychomotor Pressure' with F3 'Acceleration' (r=0.85), and 'Central Pain' with F4 'Anxiety-Depression' (r=0.84). The F2 'Activation' appeared to be strongly correlated (r &gt; or = 0.70) to all categories of the CK model. Correlational analysis between the factor structure of MVAS-BP and the MSRS showed significant coefficients on the scores assessing the emotional factors of 'Elation' and 'Depression.' Among the MVAS-BP factors, only 'Activation' was correlated to the majority of clinician ratings as obtained by the MSRS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings provide overall construct validity to the DSM-IV criteria for mania. Self-assessment of this disorder appears feasible and potentially useful in practice; lack of insight, poor judgment, and distractibility obviously require assessment by a clinician. Although our data are correlational and require prospective validation, they nonetheless suggest that (1) activation should be raised to the status of the stem criterion for mania, (2) to specify mood as elated, depressive, anxious, or irritable, and (3) to give individual status to social disinhibition (indiscriminate gregariousness) as a core pathological behavior in mania. Combining clinician- and self-observation thus produces a more precise and complete phenomenology of mania. We finally submit that the foregoing reformulation provides a psychobiological basis to the manic construct as formulated in the Carroll-Klein model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Mood Center, University of California at San Diego, VA Psychiatry Service (116A), 3350 La Jolla Village Drive, San Diego, CA 92161, USA. hakiskal@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hantouche</LastName><ForeName>E G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Sechter</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Allilaire</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Chatenêt-Duchêne</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lancrenon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012647" MajorTopicYN="Y">Self-Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11869755</ArticleId><ArticleId IdType="pii">S0165032701004414</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(01)00441-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9861637</PMID><DateCompleted><Year>1999</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-8829</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>1998</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>European Collaborative Project on Affective Disorders: interactions between genetic and psychosocial vulnerability factors.</ArticleTitle><Pagination><MedlinePgn>197-205</MedlinePgn></Pagination><Abstract><AbstractText>Despite strong evidence provided by genetic epidemiology of genetic involvement in the aetiology of bipolar and unipolar affective disorders, the exact nature of the predisposing gene(s) is still being investigated through linkage and association studies. The interaction of susceptibility genes and environmental factors in these diseases is also of fundamental importance and requires proper investigation. Interesting theories have recently been proposed examining the possible role of various chromosomal regions, candidate genes and mutations in affective disorders. Reliable multicentre-based methodology is currently being employed to examine these theories, with attention given to statistical analysis and the statistical power of the sample. The present article describes the European Collaborative Project on Affective Disorders (ECPAD) 'Interactions between genetic and psychosocial vulnerability factors', involving 15 European centres. A description is given of the association and family samples collected for the project and also the methodology used to analyse interactions in the gene-psychosocial environment. This material provides a powerful tool in the search for susceptibility genes in affective disorders and takes into account non-genetic aetiological factors.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Souery</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Clinics of Brussels, Erasme Hospital, Free University of Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipp</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mahieu</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rivelli</LastName><ForeName>S K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Cavallini</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ackenheil</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Adolfsson</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Aschauer</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Blackwood</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dam</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Delcoigne</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Demartelaer</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dikeos</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fuchshuber</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Heiden</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jablensky</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jakovljevic</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lerer</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Macedo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mellerup</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Milanova</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Muir</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011584" MajorTopicYN="N">Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>12</Month><Day>23</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>12</Month><Day>23</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9861637</ArticleId><ArticleId IdType="doi">10.1097/00041444-199808040-00001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2494153</PMID><DateCompleted><Year>1989</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>50 Suppl</Volume><PubDate><Year>1989</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>U.S. experience with valproate in manic depressive illness: a multicenter trial.</ArticleTitle><Pagination><MedlinePgn>13-6</MedlinePgn></Pagination><Abstract><AbstractText>Valproic acid and its enteric-coated derivative, divalproex sodium, have been used extensively in a wide variety of seizure disorders. Recent preliminary research demonstrates the effectiveness of valproate in the treatment of manic-depressive illness, including acute mania, prevention of bipolar episodes, and schizoaffective disorder. In uncontrolled and controlled studies, treatment-resistant patients with these disorders have responded well to valproate. Preliminary results of an ongoing community-based open trial of valproate treatment of those affective illnesses reveal that valproate is frequently effective and has a favorable side effect profile. Overall, approximately two out of three patients with refractory bipolar disorder respond to acute therapy with valproate. Response in schizoaffective patients has been moderate, and valproate seems to be less effective in the treatment of depression. Experience suggests the importance of monitoring plasma drug levels to maximize efficacy and minimize potential toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>16</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2494153</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27609245</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>173</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Postpartum Psychosis: Madness, Mania, and Melancholia in Motherhood.</ArticleTitle><Pagination><MedlinePgn>1179-1188</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Psychosis or mania after childbirth is a psychiatric emergency with risk for suicide and infanticide.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors reviewed the epidemiologic and genetic research and physiological postpartum triggers (endocrine, immunological, circadian) of psychosis. They also summarized all systematic reviews and synthesized the sparse clinical studies to provide diagnostic recommendations, treatment options, and strategies for prevention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of first-lifetime onset postpartum psychosis/mania from population-based register studies of psychiatric admissions varies from 0.25 to 0.6 per 1,000 births. After an incipient episode, 20%-50% of women have isolated postpartum psychosis. The remaining women have episodes outside the perinatal period, usually within the bipolar spectrum. Presumably, the mechanism of onset is related to physiological changes after birth (e.g., hormonal, immunological, circadian), which precipitate disease in genetically vulnerable women. Some women have treatable causes and comorbidities, such as autoimmune thyroiditis or infections. N-methyl-d-aspartate-encephalitis or inborn errors of metabolism may present after birth with psychosis. Fewer than 30 publications have focused on the treatment of postpartum psychosis. The largest study (N=64) provided evidence that lithium is highly efficacious for both acute and maintenance treatment. Another report (N=34) described successful ECT treatment. Inpatient care is usually required to ensure safety, complete the diagnostic evaluation, and initiate treatment. The relapse risk after a subsequent pregnancy for women with isolated postpartum psychoses is 31% (95% CI=22-42). Strategies for prevention of postpartum psychosis include lithium prophylaxis immediately postpartum and proactive safety monitoring.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Postpartum psychosis offers an intriguing model to explore etiologic contributions to the neurobiology of affective psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bergink</LastName><ForeName>Veerle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Erasmus Medical Center, Department of Psychiatry, Rotterdam, the Netherlands; the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif., and the Department of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasgon</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Erasmus Medical Center, Department of Psychiatry, Rotterdam, the Netherlands; the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif., and the Department of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisner</LastName><ForeName>Katherine L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>From the Erasmus Medical Center, Department of Psychiatry, Rotterdam, the Netherlands; the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif., and the Department of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019052" MajorTopicYN="Y">Depression, Postpartum</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="N">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Epidemiology</Keyword><Keyword MajorTopicYN="Y">Lithium</Keyword><Keyword MajorTopicYN="Y">Molecular Biology</Keyword><Keyword MajorTopicYN="Y">Mood Disorders-Bipolar</Keyword><Keyword MajorTopicYN="Y">Mood Disorders-Postpartum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27609245</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2016.16040454</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26433762</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>189</Volume><PubDate><Year>2016</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A genome-wide association study of bipolar disorder with comorbid eating disorder replicates the SOX2-OT region.</ArticleTitle><Pagination><MedlinePgn>141-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.09.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)30569-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder is a heterogeneous mood disorder associated with several important clinical comorbidities, such as eating disorders. This clinical heterogeneity complicates the identification of genetic variants contributing to bipolar susceptibility. Here we investigate comorbidity of eating disorders as a subphenotype of bipolar disorder to identify genetic variation that is common and unique to both disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a genome-wide association analysis contrasting 184 bipolar subjects with eating disorder comorbidity against both 1370 controls and 2006 subjects with bipolar disorder only from the Bipolar Genome Study (BiGS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The most significant genome-wide finding was observed bipolar with comorbid eating disorder vs. controls within SOX2-OT (p=8.9×10(-8) for rs4854912) with a secondary peak in the adjacent FXR1 gene (p=1.2×10(-6) for rs1805576) on chromosome 3q26.33. This region was also the most prominent finding in the case-only analysis (p=3.5×10(-7) and 4.3×10(-6), respectively). Several regions of interest containing genes involved in neurodevelopment and neuroprotection processes were also identified.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">While our primary finding did not quite reach genome-wide significance, likely due to the relatively limited sample size, these results can be viewed as a replication of a recent study of eating disorders in a large cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings replicate the prior association of SOX2-OT with eating disorders and broadly support the involvement of neurodevelopmental/neuroprotective mechanisms in the pathophysiology of both disorders. They further suggest that different clinical manifestations of bipolar disorder may reflect differential genetic contributions and argue for the utility of clinical subphenotypes in identifying additional molecular pathways leading to illness.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Bipolar Genome Study (BiGS)</CollectiveName></Author><Author ValidYN="Y"><LastName>Kelsoe</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA; San Diego Veterans Affairs Healthcare System, San Diego, CA, USA; Institute for Genomic Medicine, University of California, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwood</LastName><ForeName>Tiffany A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH087889</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH078151</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH081804</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002893" MajorTopicYN="N">Chromosomes, Human, Pair 3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001068" MajorTopicYN="N">Feeding and Eating Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Eating disorders</Keyword><Keyword MajorTopicYN="N">Genome-wide association (GWAS)</Keyword><Keyword MajorTopicYN="N">SOX2-OT</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26433762</ArticleId><ArticleId IdType="pii">S0165-0327(15)30569-3</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.09.029</ArticleId><ArticleId IdType="pmc">PMC4640946</ArticleId><ArticleId IdType="mid">NIHMS725539</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuron. 1998 Jul;21(1):13-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9697848</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1993 Oct 22;262(5133):563-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7692601</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2004 May;15(3):271-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15097006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 May;8(5):558-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12808435</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Eat Disord. 2002 Mar;31(2):191-201</Citation><ArticleIdList><ArticleId IdType="pubmed">11920980</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 Dec;148(12):1627-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1842216</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Eat Disord. 1996 Jan;19(1):45-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8640201</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2004 Jun;14(2):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15167697</ArticleId></ArticleIdList></Reference><Reference><Citation>J Proteomics. 2012 Jun 27;75(12):3617-29</Citation><ArticleIdList><ArticleId IdType="pubmed">22554909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jun;86(2-3):107-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15935230</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):680-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12668356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1995 Dec;4(12):2209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">8634689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2012 Jan;46(1):33-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21647709</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2008 Jan 5;147B(1):18-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17525972</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(10):e76295</Citation><ArticleIdList><ArticleId IdType="pubmed">24146854</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Mar;158(3):420-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11229983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2009 Aug 1;87(10):2255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19301426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jul 24;511(7510):421-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25056061</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Aug 1;44(3):151-62</Citation><ArticleIdList><ArticleId IdType="pubmed">9693387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Apr;7(2):119-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15762852</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Apr;130(1-2):162-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21071093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Jun;19(6):724-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23999524</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2011 Oct;36(11):2222-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21750581</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jul;55(7):603-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9672050</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2013 Dec;18(12):1302-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23070075</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Mol Med. 2003 Aug;3(5):472-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12943000</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Mar;157(3):393-401</Citation><ArticleIdList><ArticleId IdType="pubmed">10698815</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jul;167(7):854-65</Citation><ArticleIdList><ArticleId IdType="pubmed">20516154</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jan 17;373(9659):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 2007;76:367-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17506640</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Jan 1;23(1):103-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12514206</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1995 Jan;25(1):143-56</Citation><ArticleIdList><ArticleId IdType="pubmed">7792349</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 2008 Apr 22;94(1):121-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18164737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):1181-211</Citation><ArticleIdList><ArticleId IdType="pubmed">17064434</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Aug;164(8):1229-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17671286</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">18538910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2008 Sep;40(9):1056-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18711365</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1995 Jun 1;14(11):2401-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7781595</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Oct;161(10):1814-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15465978</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Feb 1;61(3):348-58</Citation><ArticleIdList><ArticleId IdType="pubmed">16815322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(6):594-603</Citation><ArticleIdList><ArticleId IdType="pubmed">12140782</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):107-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12772088</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jun;115(3):309-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19007998</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 Oct;43(10):977-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21926972</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 25;150(3):981-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23742827</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 2009 Nov;15(11):2013-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19767420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Sep;10(9):811-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15970930</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2005 Mar 15;118(Pt 6):1267-77</Citation><ArticleIdList><ArticleId IdType="pubmed">15741237</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;24(4):721-38</Citation><ArticleIdList><ArticleId IdType="pubmed">21321390</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):585-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11149935</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2011 Jun;7(6):e1002134</Citation><ArticleIdList><ArticleId IdType="pubmed">21738484</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1994 Nov;8(3):291-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7874172</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1999 Jan;64(1):210-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9915960</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Feb 15;51(4):288-97</Citation><ArticleIdList><ArticleId IdType="pubmed">11958779</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2013 Apr;16(3):549-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22831755</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Jan 2;28(1):264-78</Citation><ArticleIdList><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene. 2013 Oct 15;529(1):7-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23939472</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2005 Jun 15;135(2):165-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15922456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2013 Feb;18(2):195-205</Citation><ArticleIdList><ArticleId IdType="pubmed">22182935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Jun 1;178:206-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25827505</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Jul 1;179:1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25837715</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2012 Nov;126(5):332-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22676371</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2011 Mar 11;88(3):372-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21353194</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Nov;6(6):678-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11673796</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Apr;14(4):351-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19308021</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Oct 1;48(7):665-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11032978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Sep;16(9):949-59</Citation><ArticleIdList><ArticleId IdType="pubmed">21079607</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1993 Jul 30;74(2):291-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7688265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Med. 2009;41(3):186-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18821183</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2004 May;14 Suppl 2:S94-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15142614</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Eat Disord. 2005 May;37(4):299-306</Citation><ArticleIdList><ArticleId IdType="pubmed">15856503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2010 Sep 15;26(18):2336-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2008 Sep;106(6):2385-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18643873</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Mol Med. 2004 Oct 18;6(21):1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15488156</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2007 Sep;81(3):559-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Nov;51(11):849-59; discussion 863-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7944874</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e53804</Citation><ArticleIdList><ArticleId IdType="pubmed">23326512</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Oct;19(10):1115-24</Citation><ArticleIdList><ArticleId IdType="pubmed">25178163</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2002 Apr;4(2):130-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11914174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2014;5:3339</Citation><ArticleIdList><ArticleId IdType="pubmed">24618891</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Apr;162(4):732-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15800146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Oct;19(10):1085-94</Citation><ArticleIdList><ArticleId IdType="pubmed">24514567</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;165:151-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24882193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Dec;8(6):686-95</Citation><ArticleIdList><ArticleId IdType="pubmed">17156155</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2013 Aug 06;1:13</Citation><ArticleIdList><ArticleId IdType="pubmed">25505680</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2014 May 20;8:132</Citation><ArticleIdList><ArticleId IdType="pubmed">24904279</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Nov;6(6):671-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11673795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Aug;14(8):755-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19488044</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Dev Brain Res. 2003 Aug 12;144(1):83-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12888219</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2007 Nov-Dec;48(6):516-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17954136</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 Dec;124(1-3):192-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20889312</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2007 Apr 20;129(2):371-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17448995</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Feb;128(3):191-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20674033</ArticleId></ArticleIdList></Reference><Reference><Citation>Subcell Biochem. 2007;45:365-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18193644</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29925436</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1472-1465</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>09</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Attention-deficit hyperactivity disorder and anxiety disorders as precursors of bipolar disorder onset in adulthood.</ArticleTitle><Pagination><MedlinePgn>555-560</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.2018.111</ELocationID><Abstract><AbstractText Label="BACKGROUND">Attention-deficit hyperactivity disorder (ADHD) and anxiety disorders have been proposed as precursors of bipolar disorder, but their joint and relative roles in the development of bipolar disorder are unknown.AimsTo test the prospective relationship of ADHD and anxiety with onset of bipolar disorder.</AbstractText><AbstractText Label="METHOD">We examined the relationship between ADHD, anxiety disorders and bipolar disorder in a birth cohort of 2 409 236 individuals born in Denmark between 1955 and 1991. Individuals were followed from their sixteenth birthday or from January 1995 to their first clinical contact for bipolar disorder or until December 2012. We calculated incidence rates per 10 000 person-years and tested the effects of prior diagnoses on the risk of bipolar disorder in survival models.</AbstractText><AbstractText Label="RESULTS">Over 37 394 865 person-years follow-up, 9250 onsets of bipolar disorder occurred. The incidence rate of bipolar disorder was 2.17 (95% CI 2.12-2.19) in individuals with no prior diagnosis of ADHD or anxiety, 23.86 (95% CI 19.98-27.75) in individuals with a prior diagnosis of ADHD only, 26.05 (95% CI 24.47-27.62) in individuals with a prior diagnosis of anxiety only and 66.16 (95% CI 44.83-87.47) in those with prior diagnoses of both ADHD and anxiety. The combination of ADHD and anxiety increased the risk of bipolar disorder 30-fold (95% CI 21.66-41.40) compared with those with no prior ADHD or anxiety.</AbstractText><AbstractText Label="CONCLUSIONS">Early manifestations of both internalising and externalising psychopathology indicate liability to bipolar disorder. The combination of ADHD and anxiety is associated with a very high risk of bipolar disorder.Declaration of interestNone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Sandra M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Postdoctoral Fellow, Child and Adolescent Mental Health Centre-Mental Health Services Capital Region,Copenhagen Region,Psychosis Research Unit,Aarhus University HospitalandThe Lundbeck Foundation Initiative for Integrative Psychiatric Research,iPSYCH,Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlova</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Assistant Professor,Department of Psychiatry,Dalhousie University and Nova Scotia Health Authority,Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalsgaard</LastName><ForeName>Søren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Lundbeck Foundation Initiative for Integrative Psychiatric Research,iPSYCH,National Centre for Register-Based Research, NCRR,Aarhus University,DenmarkandDepartment for Child and Adolescent Psychiatry,Hospital of Telemark,Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordentoft</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Professor, The Lundbeck Foundation Initiative for Integrative Psychiatric Research,iPSYCH, and Copenhagen University Hospital, Mental Health Center Copenhagen,Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mors</LastName><ForeName>Ole</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Professor, Psychosis Research Unit,Aarhus University Hospital andThe Lundbeck Foundation Initiative for Integrative Psychiatric Research,iPSYCH,Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortensen</LastName><ForeName>Preben B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Professor, The Lundbeck Foundation Initiative for Integrative Psychiatric Research,iPSYCH,National Centre for Register-Based Research, NCRR,Aarhus UniversityandCIRRAU - Centre for Integrated Register-based Research,Aarhus University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uher</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2998-0546</Identifier><AffiliationInfo><Affiliation>Professor, Department of Psychiatry,Dalhousie University and Senior Researcher, Nova Scotia Health Authority,Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">anxiety disorders</Keyword><Keyword MajorTopicYN="Y">attention-deficit/hyperactivity disorder</Keyword><Keyword MajorTopicYN="Y">developmental psychopathology</Keyword><Keyword MajorTopicYN="Y">early identification of risk</Keyword><Keyword MajorTopicYN="Y">externalising disorders</Keyword><Keyword MajorTopicYN="Y">internalizing disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29925436</ArticleId><ArticleId IdType="pii">S0007125018001113</ArticleId><ArticleId IdType="doi">10.1192/bjp.2018.111</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32505904</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7506</ISSN><JournalIssue CitedMedium="Internet"><Volume>302</Volume><PubDate><Year>2020</Year><Month>08</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research. Neuroimaging</Title><ISOAbbreviation>Psychiatry Res Neuroimaging</ISOAbbreviation></Journal><ArticleTitle>Comparison of first-episode and multiple-episode bipolar disorder: A surface-based morphometry study.</ArticleTitle><Pagination><MedlinePgn>111110</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0925-4927(20)30082-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pscychresns.2020.111110</ELocationID><Abstract><AbstractText>It is still unclear whether the structural abnormalities in Bipolar disorder (BD) are static or progressive. We aimed to compare differences in cortical thickness, surface area, and volume between patients with BD and healthy volunteers (HV) and to examine whether there are differences between patients who have had a single manic episode and those with multiple episodes. We recruited 30 patients with Type I BD and 30 age and sex matched HV. All participants underwent structural magnetic resonance imaging. Cortical volume, thickness, and surface area were measured using the QDEC tool from the Freesurfer software with age and intracranial volume as covariates. Study groups were comparable across age, sex distribution, and intracranial volume. Patients had significantly lower surface area in bilateral cuneus, right postcentral gyrus, and rostral middle frontal gyri; and lower cortical volume in the left middle temporal gyrus, right postcentral gyrus, and right cuneus. BD patients with multiple episodes had lower cortical measures while those with single episode had cortical measures comparable to HV. Findings indicate that the pathophysiological processes in BD are possibly progressive in nature. Our findings underscore the potential importance of early diagnosis and intervention in preventing deterioration and improving functional recovery.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Achalia</LastName><ForeName>Rashmin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Government Medical College, Aurangabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raju</LastName><ForeName>Vikas B</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health and Neurosciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Arpitha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health and Neurosciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahar</LastName><ForeName>Abhinav</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health and Neurosciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Achalia</LastName><ForeName>Garimaa</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Achalia Neuropsychiatry Clinic, Aurangabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagendra</LastName><ForeName>Bhargavi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health and Neurosciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaginalkar</LastName><ForeName>Varsha</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Government Medical College, Aurangabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Government Medical College, Aurangabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatasubramanian</LastName><ForeName>Ganesan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health and Neurosciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Naren P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health and Neurosciences, Bangalore, India. Electronic address: docnaren@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Psychiatry Res Neuroimaging</MedlineTA><NlmUniqueID>101723001</NlmUniqueID><ISSNLinking>0925-4927</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009778" MajorTopicYN="N">Occipital Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Cortical thickness</Keyword><Keyword MajorTopicYN="Y">MRI</Keyword><Keyword MajorTopicYN="Y">Mood disorder</Keyword><Keyword MajorTopicYN="Y">Surface area</Keyword><Keyword MajorTopicYN="Y">Volume</Keyword></KeywordList><CoiStatement>Declaration of Competing Interests None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>01</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>02</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32505904</ArticleId><ArticleId IdType="pii">S0925-4927(20)30082-2</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2020.111110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3485926</PMID><DateCompleted><Year>1986</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>143</Volume><Issue>5</Issue><PubDate><Year>1986</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A case of mania induced by high-dose fluoxetine treatment.</ArticleTitle><Pagination><MedlinePgn>686</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chouinard</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>W</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011437">Propylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008508" MajorTopicYN="N">Medication Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011437" MajorTopicYN="N">Propylamines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3485926</ArticleId><ArticleId IdType="doi">10.1176/ajp.143.5.686</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25682377</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>176</Volume><PubDate><Year>2015</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Can unipolar and bipolar pediatric major depression be differentiated from each other? A systematic review of cross-sectional studies examining differences in unipolar and bipolar depression.</ArticleTitle><Pagination><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.01.037</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)00041-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">While pediatric mania and depression can be distinguished from each other, differentiating between unipolar major depressive disorder (unipolar MDD) and bipolar major depression (bipolar MDD) poses unique clinical and therapeutic challenges. Our aim was to examine the current body of knowledge on whether unipolar MDD and bipolar MDD in youth could be distinguished from one another in terms of clinical features and correlates.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search was conducted on studies assessing the clinical characteristics and correlates of unipolar MDD and bipolar MDD in youth.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four scientific papers that met our priori inclusion and exclusion criteria were identified. These papers reported that bipolar MDD is distinct from unipolar MDD in its higher levels of depression severity, associated impairment, psychiatric co-morbidity with oppositional defiant disorder, conduct disorder and anxiety disorders, and family history of mood and disruptive behavior disorders in first-degree relatives.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Though we examined a sizeable and diverse sample, we were only able to identify four cross sectional informative studies in our review. Therefore, our conclusions should be viewed as preliminary.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings can aid clinicians in differentiating the two forms of MDD in youth.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uchida</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Pediatric Psychopharmacology, Boston, MA, United States; Harvard Medical School, Department of Psychiatry, Boston, MA, United States. Electronic address: muchida@partners.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sant׳Andrea Hospital, Sapienza University, NESMOS Department, Rome, Italy; Harvard Medical School, Department of Psychiatry, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zayas</LastName><ForeName>Lazaro</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Psychiatry, Boston, MA, United States; Harvard Medical School, Department of Psychiatry, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenworthy</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Pediatric Psychopharmacology, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faraone</LastName><ForeName>Stephen V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>SUNY Upstate Medical University, Departments of Psychiatry and of Neuroscience and Physiology, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Pediatric Psychopharmacology, Boston, MA, United States; Harvard Medical School, Department of Psychiatry, Boston, MA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Major depressive disorder</Keyword><Keyword MajorTopicYN="N">Pediatric</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25682377</ArticleId><ArticleId IdType="pii">S0165-0327(15)00041-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.01.037</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9858088</PMID><DateCompleted><Year>1999</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>2-3</Issue><PubDate><Year>1998</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Rating scales for mania: is self-rating reliable?</ArticleTitle><Pagination><MedlinePgn>283-6</MedlinePgn></Pagination><Abstract><AbstractText>This commentary addresses the issue of whether self-rating mania scales are reliable. After a brief introduction, several newly developed self-rating mania scales are described and critically reviewed. Among the issues discussed are: the practical utility of self-assessment in patients with mania; the influence of severity of illness on ability to self-report; and, the extent to which the presence of psychosis or the absence of insight significantly interferes with a patients' ability to reliably complete self-rating measures. Data from recent studies suggests that self-rating mania scales are both reliable and valid for patients with manic symptoms, including those with psychotic features and those having little or no insight into their illness. The merits of including self-rating measures in the assessment of mania are discussed in terms of their value for both clinical and research purposes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altman</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Psychiatric Institute, University of Illinois, Chicago 60612, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012647" MajorTopicYN="Y">Self-Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>12</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>12</Month><Day>19</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>12</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9858088</ArticleId><ArticleId IdType="pii">S0165-0327(98)00018-4</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(98)00018-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1395552</PMID><DateCompleted><Year>1992</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>5</Issue><PubDate><MedlineDate>1992 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Development, use, and factor analysis of a self-report inventory for mania.</ArticleTitle><Pagination><MedlinePgn>325-31</MedlinePgn></Pagination><Abstract><AbstractText>This report describes the development and initial psychometric evaluation of a 47-item self-report inventory for mania developed by the authors. Twenty-five subjects with a diagnosis of mania and 82 subjects with other diagnoses were tested during a hospital admission. The manic group scored significantly higher than the nonmanic group. The questionnaire correctly classified 71% of subjects. Manic patients who lacked insight endorsed as many items as manic patients with insight. A reliability analysis indicated that the items comprising the questionnaire are homogeneous. Test-retest reliability was high. A rotated factor analysis produced two factors, energized dysphoria and hedonistic euphoria. The authors discuss diagnostic, research, and clinical implications and applications of the Self-Report Manic Inventory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shugar</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Adult General Psychiatry Unit, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schertzer</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Toner</LastName><ForeName>B B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Di Gasbarro</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="N">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012803" MajorTopicYN="N">Sick Role</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1395552</ArticleId><ArticleId IdType="pii">0010-440X(92)90040-W</ArticleId><ArticleId IdType="doi">10.1016/0010-440x(92)90040-w</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15094255</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>80</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A comparison of the phenomenology and treatment of youths and adults with bipolar I disorder in a state mental health system.</ArticleTitle><Pagination><MedlinePgn>29-35</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Presenting symptoms of and treatments used for child/adolescent and adult patients diagnosed with bipolar I disorder in a state mental health system are described and compared.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Medical records were reviewed for 267 cases of bipolar I disorder reported in the statewide patient information system.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The child/adolescent patients were significantly more likely to have irritability documented, be treated with stimulant medications, and meet the criteria for major depression while adults were significantly more likely to have a broader array of documented symptoms: euphoria, fatigue, trouble concentrating, and hyper-religiosity. Suicidality (thoughts and gestures) was higher in both age groups than previously reported in the clinical literature. No difference was evident in the mood-related pharmacotherapy. Child/adolescent cases were seen more often for re-evaluations, medication visits, and individual and family therapy sessions, whereas adult cases were more likely to receive case management services and less-frequent medication monitoring visits.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Youths with bipolar I disorder were more likely to present with irritability and depressive symptoms, and be treated with stimulants and a range of therapeutic interventions, whereas adults with more broadly documented symptoms were receiving minimal treatment services.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jerrell</LastName><ForeName>Jeanette M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, SC 29203, USA. jjerrell@medpark.sc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shugart</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="N">Community Mental Health Services</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006292" MajorTopicYN="N">Health Priorities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15094255</ArticleId><ArticleId IdType="doi">10.1016/S0165-0327(03)00045-4</ArticleId><ArticleId IdType="pii">S0165032703000454</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29578271</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>02</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial.</ArticleTitle><Pagination><MedlinePgn>76-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12642</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The aim of the present study was to evaluate the effectiveness of psychoeducation for bipolar I inpatients following remission of a manic episode in a Chinese population.</AbstractText><AbstractText Label="METHOD">The study recruited currently medicated bipolar I patients, aged 18-60 years, who were in remission from a manic episode, as determined using the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5). Patients were randomized (1:1) to either eight sessions of group-based psychoeducation (active treatment group) or regular free discussions (control group). The primary outcomes were the rates of any type of recurrence and rehospitalization following treatment. The secondary outcomes were changes in mood symptoms, medication adherence, global functioning, as well as treatment response (as measured using the Clinical Global Impression scale). Subjects were assessed at baseline and then at 2 weeks, and 1, 2, 3, 5, 7, 9, and 12 months following treatment.</AbstractText><AbstractText Label="RESULTS">At 1 year, patients receiving the psychoeducation treatment demonstrated significantly less recurrence. Those in the treatment group also showed a significant reduction in mania recurrence but not depressive recurrence, and psychoeducation increased time to remission. Notably, lower rates of rehospitalization were found in the active treatment group. Those receiving the psychoeducation treatment also revealed higher change from baseline on measures of depression (17-item Hamilton Rating Scale for Depression), mania (Young Mania Rating Scale), global functioning (Clinical Global Impression-severity scale and World Health Organization Disability Assessment Schedule) (P&lt;.05). However, there were no significant group differences for the medication adherence scores.</AbstractText><AbstractText Label="CONCLUSION">This preliminary evidence suggests that short, group-based psychoeducation benefits currently medicated inpatients following the remission of mania in bipolar I disorder. This intervention warrants further investigation, especially in other Chinese populations. If future studies confirm its benefits, group-based psychoeducation could be incorporated into routine psychiatric inpatient care for bipolar patients in China.</AbstractText><CopyrightInformation>© 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Runsen</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2145-8630</Identifier><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xuequan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capitão</LastName><ForeName>Liliana P</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huijun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jiong</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7211-2429</Identifier><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xiuping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yancun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Liuzhong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>Gin S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Academic Department of Psychiatry, Northern Sydney Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School Northern, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Chinese population</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">group-based psychoeducation</Keyword><Keyword MajorTopicYN="Y">psychiatric inpatients</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29578271</ArticleId><ArticleId IdType="doi">10.1111/bdi.12642</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22070662</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-5949</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>CNS neuroscience &amp; therapeutics</Title><ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation></Journal><ArticleTitle>The effect of pharmacotherapy on suicide rates in bipolar patients.</ArticleTitle><Pagination><MedlinePgn>238-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1755-5949.2011.00261.x</ELocationID><Abstract><AbstractText>Suicide is a complex and multicausal human behavior and also a great challenge for psychiatry. We review the evidence available concerning pharmacological prevention of suicide in bipolar disorder patients. Several clinical trials provide evidence that effective acute and long-term treatment of bipolar depression provides a strong protection against suicide, suicide attempts, and probably against other complications of this disorder. Current major mood disorder is the most important risk factor of suicide, and bipolar II patients carry the highest risk. In bipolar patients suicidal behavior is most likely to occur during pure or mixed depressive episodes. Since bipolar disorder is a highly recurrent illness, adequate long-term pharmacotherapy is needed to prevent suicidal behavior.</AbstractText><CopyrightInformation>© 2011 Blackwell Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rihmer</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Clinical and Theoretical Mental Health, Semmelweis University, Budapest, Hungary. rihmerz@kut.sote.hu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonda</LastName><ForeName>Xenia</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>CNS Neurosci Ther</MedlineTA><NlmUniqueID>101473265</NlmUniqueID><ISSNLinking>1755-5930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22070662</ArticleId><ArticleId IdType="doi">10.1111/j.1755-5949.2011.00261.x</ArticleId><ArticleId IdType="pmc">PMC6493529</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 2010 Nov;122(5):345-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20384598</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 2001 Jul;34(4):132-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11518473</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1996 May;29(3):103-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8738314</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Aug;118(2):106-15</Citation><ArticleIdList><ArticleId IdType="pubmed">18397362</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Sep 17;290(11):1467-73</Citation><ArticleIdList><ArticleId IdType="pubmed">13129986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):5-11</Citation><ArticleIdList><ArticleId IdType="pubmed">17628692</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Dec;116(6):395-402</Citation><ArticleIdList><ArticleId IdType="pubmed">17997720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):23-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17604119</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jul;162(7):1281-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15994710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 2):625-39</Citation><ArticleIdList><ArticleId IdType="pubmed">17042835</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Jun;69(6):916-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18399724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Feb;73(3):223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12547290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jun;92(2-3):227-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16546264</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Feb;60(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12578431</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Apr;62(4):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11379838</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17617467</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jul;159(7):1160-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12091194</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Mar;68(3):380-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17388706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 2:89-93; discussion 111-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10073394</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2003 Mar-Apr;72(2):107-8; author reply 109</Citation><ArticleIdList><ArticleId IdType="pubmed">12601229</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 May;11(3):225-55</Citation><ArticleIdList><ArticleId IdType="pubmed">19419382</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 2:63-9; discussion 75-6, 113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10073390</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2007 Jan;20(1):17-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17143077</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Nov;69(11):1831-2</Citation><ArticleIdList><ArticleId IdType="pubmed">19200432</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Dec;118(6):469-79</Citation><ArticleIdList><ArticleId IdType="pubmed">18808400</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Dec;116(6):419-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17997721</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Apr;107(1-3):23-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17707087</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Jul;151(7):1020-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8010358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Feb;10(1):87-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18199245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Feb;113(1-2):21-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18676024</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Aug;94(1-3):3-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16712945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Jul;10(5):588-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18657243</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 May;194(5):464-5; discussion 446</Citation><ArticleIdList><ArticleId IdType="pubmed">19407280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Apr;68(2-3):167-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12063145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21034187</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Managing pregnant women with serious mental illness: using the Edinburgh Postnatal Depression Scale as a marker of anxiety and depressive symptoms.</ArticleTitle><Pagination><MedlinePgn>1036-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/00048674.2010.503185</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the course of depressive and anxiety symptoms using serial measurements of the Edinburgh Postnatal Depression Scale (EPDS) in pregnant women with serious mental illness (SMI) attending a specialist multi-disciplinary antenatal clinic in Perth, Western Australia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A retrospective review of case notes was undertaken for 48 Western Australian pregnant women with schizophrenia and related psychoses and bipolar affective disorders who attended the Childbirth and Mental Illness (CAMI) antenatal clinic between December 2007 and November 2009. Of these patients, 27 completed the EPDS at booking (first appointment) and at 32 weeks gestation. Additional variables collected were demographic data, gestation at booking, and attendance rates for these 27 women, and for comparison another 21 women who did not complete the EPDS for one or both screening periods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean total EPDS score decreased from 12.2 (SD 7.6) at booking to 8.5 (SD 6.4) at 32 weeks gestation (p = 0.007). Overall mean attendance rates and number of appointments were similar to the non-SMI population and in keeping with standard guidelines.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We speculate from these preliminary findings that being managed by a consistent small multi-disciplinary team and knowing that they will be supported throughout their pregnancy could lead to improvement of anxiety and depressive symptoms in pregnant women with SMI, and has the potential to increase their attendance for antenatal care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thinh N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>King Edward Memorial Hospital, University of Western Australia, Australia. nguyent@meddent.uwa.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faulkner</LastName><ForeName>Deb</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Suzanna</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hauck</LastName><ForeName>Yvonne L</ForeName><Initials>YL</Initials></Author><Author ValidYN="Y"><LastName>Frayne</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rock</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rampono</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005865" MajorTopicYN="N">Gestational Age</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21034187</ArticleId><ArticleId IdType="doi">10.3109/00048674.2010.503185</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6622726</PMID><DateCompleted><Year>1983</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-264X</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2-4</Issue><PubDate><Year>1983</Year></PubDate></JournalIssue><Title>Psychiatria clinica</Title><ISOAbbreviation>Psychiatr Clin (Basel)</ISOAbbreviation></Journal><ArticleTitle>Long-term prognosis and course of schizo-affective, schizophreniform, and cycloid psychoses.</ArticleTitle><Pagination><MedlinePgn>156-68</MedlinePgn></Pagination><Abstract><AbstractText>From the Bonn study including 502 patients followed up an average 22.4 years after onset of schizophrenic disease diagnosed according to the criteria of K. Schneider, we selected 113 cases of schizo-affective, schizophreniform, and cycloid psychoses in accordance to the definitions given by Kasanin, Retterstøl, Angst, and Leonhard. These psychoses have a better prognosis than the whole sample: characteristic residues are seen more rarely, complete remissions and noncharacteristic residues more frequently. This group of psychoses differs from the whole sample in the hereditary taint, too: the morbidity risk with affective psychoses and with schizophrenic psychoses in first- and second-degree relatives is higher than in the total sample of the Bonn study. In spite of the better prognosis and other differences described in the paper, we believe that these results do not justify the classification of schizo-affective and related disorders as an independent disease group. Between these different subtypes of schizophrenia only a differential typology and not a differential diagnostic is possible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Armbruster</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychiatr Clin (Basel)</MedlineTA><NlmUniqueID>0150761</NlmUniqueID><ISSNLinking>0033-264X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6622726</ArticleId><ArticleId IdType="doi">10.1159/000283964</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1990073</PMID><DateCompleted><Year>1991</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>179</Volume><Issue>2</Issue><PubDate><Year>1991</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Characteristics and long-term follow-up of patients hospitalized for mood disorders in the Phipps Clinic, 1913-1940.</ArticleTitle><Pagination><MedlinePgn>64-73</MedlinePgn></Pagination><Abstract><AbstractText>From a sample of 2809 mood disorder patients hospitalized between 1913 and 1940, we selected for detailed study 914 patients with at least a 5 year follow-up and 103 patients who committed suicide within 5 years of discharge. Patients with clearly mood incongruent delusions or an onset associated with a physical illness were excluded. Based on the presence or absence of manic symptoms, this cohort of 1017 cases was divided into 297 bipolar and 945 unipolar patients. Bipolar patients had an earlier age of onset and admission and were more likely to be delusional and hallucinated. They also had more sudden onsets, more previous admissions, worse premorbid characteristics, and more problems with alcohol, but more patients were discharged as recovered. Unipolar patients were more often female and married, more likely to have made previous suicidal attempts, and more likely to have experienced a precipitating event. On a mean follow-up of 13.5 years, only 11% of the bipolar and 22% of the unipolar patients experienced no further episodes of mania or depression. Of the bipolar group, 77% had to be rehospitalized, as did 56% of the unipolars. Only 2% of the sample had manic episodes with no lifetime depressions; this small group had the best outcome. One third of all the patients were rated unimproved on follow-up. Thirteen percent committed suicide, usually within 1 year of discharge. Bipolar patients had the worst outcome, with 43% rated unimproved. The sample was split by odd or even case number and one half was used to construct a prognostic scale significantly correlated with long-term outcome. It was cross-validated on the other half of the sample with little shrinkage. Patients with non-drug-treated affective disorders hospitalized half a century ago were found to have polyepisodic illnesses with a frequently chronic course.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>J H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008393" MajorTopicYN="N">Marriage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="N">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1990073</ArticleId><ArticleId IdType="doi">10.1097/00005053-199102000-00002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30201969</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>09</Month><Day>10</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-018-0242-3</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is highly heterogeneous in symptomatology. Narrowing the clinical phenotype may increase the power to identify risk genes that contribute to particular BD subtypes. This study was designed to test the hypothesis that genetic overlap between schizophrenia (SZ) and BD is higher for BD with a history of manic psychosis. Analyses were conducted using a Mayo Clinic Bipolar Biobank cohort of 957 bipolar cases (including 333 with history of psychosis during mania, 64 with history of psychosis only during depression, 547 with no history of psychosis, and 13 with unknown history of psychosis) and 778 controls. Polygenic risk score (PRS) analysis was performed by calculating a SZ-PRS for the BD cases and controls, and comparing the calculated SZ risk between different psychosis subgroups and bipolar types. The SZ-PRS was significantly higher for BD-I cases with manic psychosis than BD-I cases with depressive psychosis (Nagelkerke's R<sup>2</sup> = 0.021; p = 0.045), BD-I cases without psychosis (R<sup>2</sup> = 0.015; p = 0.007), BD-II cases without psychosis (R<sup>2</sup> = 0.014; p = 0.017), and controls (R<sup>2</sup> = 0.065; p = 2 × 10<sup>-13</sup>). No other significant differences were found. Our results show that BD-I with manic psychosis is genetically more similar to SZ than any other tested BD subgroup. Further investigations on genetics of distinct clinical phenotypes composing major psychoses may help refine the current diagnostic classification system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Markota</LastName><ForeName>Matej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coombes</LastName><ForeName>Brandon J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larrabee</LastName><ForeName>Beth R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Lindner Center of HOPE/University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldic</LastName><ForeName>Marin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colby</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Mohit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuellar-Barboza</LastName><ForeName>Alfredo B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Universidad Autónoma de Nuevo León, Monterrey, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinica Alemana, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto</LastName><ForeName>Miguel L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Departamento de Psiquiatría, Facultad de Medicina, Universidad de los Andes, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rummans</LastName><ForeName>Teresa A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lindner Center of HOPE/University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobo</LastName><ForeName>William V</ForeName><Initials>WV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biernacka</LastName><ForeName>Joanna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-9350-4440</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. Biernacka.Joanna@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Biernacka.Joanna@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>04</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30201969</ArticleId><ArticleId IdType="doi">10.1038/s41398-018-0242-3</ArticleId><ArticleId IdType="pii">10.1038/s41398-018-0242-3</ArticleId><ArticleId IdType="pmc">PMC6131184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Genet. 2008 Sep;40(9):1053-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18677311</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2012 Sep;69(9):943-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22566563</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2099-107</Citation><ArticleIdList><ArticleId IdType="pubmed">14638578</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2011 Apr;198(4):284-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21972277</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2008 Jan 5;147B(1):18-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17525972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jul 24;511(7510):421-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25056061</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2018 Jun 14;173(7):1705-1715.e16</Citation><ArticleIdList><ArticleId IdType="pubmed">29906448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2015 May 1;31(9):1466-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25550326</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 Mar 15;81(6):536-547</Citation><ArticleIdList><ArticleId IdType="pubmed">27259817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jan 17;373(9659):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Feb;19(2):153-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24365866</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2012 Jul 22;44(8):955-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Feb;69(2):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18232725</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2015 Dec;3(1):30</Citation><ArticleIdList><ArticleId IdType="pubmed">26105627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigascience. 2015 Feb 25;4:7</Citation><ArticleIdList><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 Jul 1;82(1):26-39</Citation><ArticleIdList><ArticleId IdType="pubmed">27817844</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2016 Apr 1;173(4):373-84</Citation><ArticleIdList><ArticleId IdType="pubmed">26651391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Sep;19(9):1017-1024</Citation><ArticleIdList><ArticleId IdType="pubmed">24280982</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 May;35(3):482-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19329560</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2017 Jan 10;7(1):e993</Citation><ArticleIdList><ArticleId IdType="pubmed">28072414</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Mar 15;73(6):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22980587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Med. 2009;41(3):186-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18821183</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2004 May;14 Suppl 2:S94-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15142614</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Feb 13;506(7487):185-90</Citation><ArticleIdList><ArticleId IdType="pubmed">24463508</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2015 Jan 20;5:e496</Citation><ArticleIdList><ArticleId IdType="pubmed">25603412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Oct;15(10):1016-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19621016</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2018 Jan 1;75(1):28-35</Citation><ArticleIdList><ArticleId IdType="pubmed">29167880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 6;460(7256):748-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;165:151-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24882193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2013 Sep;88(9):952-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24001487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 Apr 20;381(9875):1371-1379</Citation><ArticleIdList><ArticleId IdType="pubmed">23453885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19418383</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-3522</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie-Psychiatrie</Title><ISOAbbreviation>Fortschr Neurol Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Psychopharmacological combination therapy in bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>252-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0028-1109324</ELocationID><Abstract><AbstractText>In the course of time, the treatment regime of bipolar disorder has changed: in mild cases of manic and depressive episodes, monotherapeutic approaches are still commonly used. Besides the use of the common agents like lithium, valproatic acid and carbamazepine, other agents such as atypical antipsychotics (AAP) are used more frequently. For the therapy of manic episodes, most of the usual AAP are approved; some of them are or will be approved in the near future even for the continuation therapy and for depressive episodes. For moderate and severe courses of depressive or manic episodes, combination therapy strategies are used more often. Combination strategies seem to be more effective than monotherapeutic treatments, because of faster effects and better tolerance. In a lot of studies, these positive effects and advantages in contrast to monotherapeutic treatments could be proven. In this review article, studies and results with the focus on combination therapy will be summarised to recommend the "state-of-the-art"-treatment for bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quante</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité-Campus Benjamin Franklin, Eschenallee 3, Berlin. arnim.quante@charite.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hall</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Anghelescu</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Pharmakologische Kombinationsbehandlung bipolarer Störungen.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr</MedlineTA><NlmUniqueID>8103137</NlmUniqueID><ISSNLinking>0720-4299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>81</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19418383</ArticleId><ArticleId IdType="doi">10.1055/s-0028-1109324</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20022640</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Pituitary volume in patients with bipolar disorder and their first-degree relatives.</ArticleTitle><Pagination><MedlinePgn>256-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.12.002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hypothalamic-pituitary-adrenal (HPA) axis dysregulation has been reported in bipolar disorder (BD), but previous magnetic resonance imaging (MRI) studies of pituitary gland volume in BD have yielded inconsistent findings. In addition, the contribution of genetic factors to the pituitary changes in BD remains largely unknown.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We used MRI to investigate the pituitary volume in 29 remitted patients with BD, 49 of their first-degree relatives (of whom 15 had a diagnosis of Major Depressive Disorder), and 52 age- and gender-matched healthy controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BD patients had a significantly larger pituitary volume compared with their relatives and healthy controls. Pituitary volume did not differ between controls and healthy relatives or relatives diagnosed with major depression.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Direct measures of HPA function (i.e., hormonal levels) were not available.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that enlarged pituitary volume is associated with disease expression but not genetic susceptibility to BD.</AbstractText><CopyrightInformation>Copyright  2009 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Victoria, Australia. tsutomu@med.u-toyama.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walterfang</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Kempton</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Jogia</LastName><ForeName>Jigar</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lorenzetti</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Soulsby</LastName><ForeName>Bridget</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Michio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Velakoulis</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pantelis</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Frangou</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010902" MajorTopicYN="N">Pituitary Gland</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20022640</ArticleId><ArticleId IdType="pii">S0165-0327(09)00534-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.12.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30339112</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1472-1465</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>11</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Are rating scales for bipolar disorders fit for purpose?</ArticleTitle><Pagination><MedlinePgn>627-629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.2018.189</ELocationID><Abstract><AbstractText>The DSM-5 definition of bipolar disorder elevates increased activity or energy as a cardinal symptom (alongside mood changes) for mania and hypomania ('hypo/mania'). The ICD-10 likewise requires increases in activity and energy (alongside mood) for hypo/mania, as well as decreases for bipolar depression. Using bipolar disorder as an example, we propose that, when diagnostic criteria are revised, instruments used to measure clinical course and treatment response may need revisiting. Here, we highlight that the 'gold-standard' symptom rating scales for hypo/mania and depression were developed in an era when abnormalities of mood were viewed as the cardinal symptom of bipolar disorder. We contend that archetypal measures fail to give proportionate weighting to activity or energy, undermining their utility in monitoring bipolar disorder and treatment response in clinical and research practice.Declarations of interestJ.S. and G.M. are members of mMARCH, (Motor Activity Research Consortium for Health), which is led by Dr Kathleen Merikangas, National Institute for Mental Health. J.S. reports being a visiting professor at Diderot University, the Norwegian University of Science and Technology, Swinburne University of Technology and The University of Sydney; receiving grant funding from the UK Medical Research Council and from the UK Research for Patient Benefit programme; and receiving a personal fee from Janssen-Cilag for a non-promotional talk on sleep problems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Professor, Psychological Medicine,Newcastle University,UKandVisiting Professor,Institute of Psychiatry, Psychology and Neuroscience,UKandDepartment of Mental Health,NTNU,Norway and Brain and Mind Centre,The University of Sydney,Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Greg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Professor, Clinical Psychology,Centre for Mental Health, Swinburne University of Technology,Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar affective disorders</Keyword><Keyword MajorTopicYN="Y">activity and energy</Keyword><Keyword MajorTopicYN="Y">diagnostic criteria</Keyword><Keyword MajorTopicYN="Y">rating scales</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30339112</ArticleId><ArticleId IdType="pii">S0007125018001897</ArticleId><ArticleId IdType="doi">10.1192/bjp.2018.189</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15819732</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>111</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Assaultive trauma and illness course in psychotic bipolar disorder: findings from the Suffolk county mental health project.</ArticleTitle><Pagination><MedlinePgn>380-3</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Little is known about the relationship of assaultive trauma to clinical and functional outcome in patients with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We assessed trauma histories in a cohort of 109 first-admission bipolar patients with psychosis using structured interviews and medical records. Assaultive trauma included rape, physical attacks, and physical threats. Outcome was assessed using standardized ratings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty percent reported a history of assaultive trauma, mostly in childhood (&lt; or =16 years). Exposed patients were more symptomatic at each follow-up than unexposed. Sixteen percent of exposed patients remitted after one episode compared with 38.5% of the non-exposed. Patients exposed as adults were the most symptomatic at 6 months, while patients exposed in childhood were the most symptomatic at 24 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings supported the salient role of trauma history as a risk factor for poor course in severe bipolar disorder. Given the high prevalence of such exposure, clinical awareness in first-admission psychotic bipolar patients is critical.</AbstractText><CopyrightInformation>Copyright Blackwell Munksgaard 2005.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neria</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University and Anxiety Disorder Clinic, New York State Psychiatric Institute, NY 10032, USA. ny126@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bromet</LastName><ForeName>E J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Naz</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002649" MajorTopicYN="N">Child Abuse</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019548" MajorTopicYN="N">Crime Victims</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="N">Violence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15819732</ArticleId><ArticleId IdType="pii">ACP530</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2005.00530.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7972603</PMID><DateCompleted><Year>1994</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-5772</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>1994</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychophysiology</Title><ISOAbbreviation>Psychophysiology</ISOAbbreviation></Journal><ArticleTitle>Resting EEG in first-episode schizophrenia patients, bipolar psychosis patients, and their first-degree relatives.</ArticleTitle><Pagination><MedlinePgn>486-94</MedlinePgn></Pagination><Abstract><AbstractText>We evaluated the resting electroencephalogram (EEG) of 50 first-episode schizophrenia patients and 55 of their relatives, 31 first-episode bipolar patients and 35 of their relatives, and 113 nonpsychiatric subjects and 42 of their relatives. The frequency characteristics of the EEG showed moderate stability for a subgroup of these subjects (n = 106) who were tested twice, approximately 9 months apart. Both the schizophrenia and bipolar patients showed a generalized pattern of increased delta and theta and decreased alpha activity. The bipolar patients demonstrated additional right hemisphere activity that was not present among the schizophrenia patients and nonpsychiatric subjects, a finding consistent with hypotheses concerning nondominant hemisphere involvement in the regulation of elated mood. The schizophrenia patients' female relatives and/or relatives with affective disorders and the bipolar patients had significantly reduced peak alpha frequencies. This finding may be related to reduced information processing capacity among these subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clementz</LastName><ForeName>B A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California-San Diego, La Jolla 92093-0109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sponheim</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Iacono</LastName><ForeName>W G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00143</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH17069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH44643</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychophysiology</MedlineTA><NlmUniqueID>0142657</NlmUniqueID><ISSNLinking>0048-5772</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011603" MajorTopicYN="N">Psychophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7972603</ArticleId><ArticleId IdType="doi">10.1111/j.1469-8986.1994.tb01052.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23590840</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-9307</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Developmental cognitive neuroscience</Title><ISOAbbreviation>Dev Cogn Neurosci</ISOAbbreviation></Journal><ArticleTitle>Fronto-limbic function in unaffected offspring at familial risk for bipolar disorder during an emotional working memory paradigm.</ArticleTitle><Pagination><MedlinePgn>185-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dcn.2013.03.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1878-9293(13)00024-8</ELocationID><Abstract><AbstractText>Evidence from neuroimaging studies indicate that individuals with bipolar disorder (BD) exhibit altered functioning of fronto-limbic systems implicated in voluntary emotion regulation. Few studies, however, have examined the extent to which unaffected youth at familial risk for BD exhibit such alterations. Using an fMRI emotional working memory paradigm, we investigated the functioning of fronto-limbic systems in fifteen healthy bipolar offspring (8-17 years old) with at least one parent diagnosed with BD (HBO), and 16 age-matched healthy control (HC) participants. Neural activity and functional connectivity analyses focused on a priori neural regions supporting emotion processing (amygdala and ventral striatum) and voluntary emotion regulation (ventrolateral prefrontal cortex (VLPFC), dorsolateral prefrontal cortex (DLPFC), and anterior cingulate cortex (ACC)). Relative to HC, HBO exhibited greater right VLPFC (BA47) activation in response to positive emotional distracters and reduced VLPFC modulation of the amygdala to both the positive and negative emotional distracters; there were no group differences in connectivity for the neutral distracters. These findings suggest that alterations in the functioning of fronto-limbic systems implicated in voluntary emotion regulation are present in unaffected bipolar offspring. Future longitudinal studies are needed to determine the extent to which such alterations represent neurodevelopmental markers of risk for future onset of BD.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ladouceur</LastName><ForeName>Cecile D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. ladouceurcd@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diwadkar</LastName><ForeName>Vaibhav A</ForeName><Initials>VA</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bass</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Mary L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH083001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060952</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH60952</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Dev Cogn Neurosci</MedlineTA><NlmUniqueID>101541838</NlmUniqueID><ISSNLinking>1878-9293</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="Y">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>02</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23590840</ArticleId><ArticleId IdType="pii">S1878-9293(13)00024-8</ArticleId><ArticleId IdType="doi">10.1016/j.dcn.2013.03.004</ArticleId><ArticleId IdType="pmc">PMC3676715</ArticleId><ArticleId IdType="mid">NIHMS461280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2006 Feb;8(1):28-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16411978</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Dec;183(3):308-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16249909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May;147(1-3):397-400</Citation><ArticleIdList><ArticleId IdType="pubmed">22980403</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2006;1(1):308-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17406250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):326-39</Citation><ArticleIdList><ArticleId IdType="pubmed">22631618</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1997 Oct;6(3):218-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9344826</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Oct 15;53(1):58-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20595014</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2009 May;33(5):613-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18948135</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2003 Jul-Aug;37(4):297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">12765852</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Dec 20;65(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">9029668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2012 Mar;51(3):294-303</Citation><ArticleIdList><ArticleId IdType="pubmed">22365465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Mar 31;201(3):196-205</Citation><ArticleIdList><ArticleId IdType="pubmed">22510433</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1736-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11818573</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jan;42(1):29-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21733287</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2004 Apr;8(4):170-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15050513</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):1105-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17064430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2000 Mar;10(3):206-19</Citation><ArticleIdList><ArticleId IdType="pubmed">10731217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Jan;43(4):432-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18586275</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1064-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20855051</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jun;60(6):601-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12796223</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Jul;19(3):1233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12880848</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Aug 15;168(3):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19564050</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2006 Oct 23;17(15):1591-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17001274</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Affect Behav Neurosci. 2010 May;10(2):159-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20498341</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Apr;36(4):545-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9100430</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Integr Neurosci. 2012 Aug 31;6:65</Citation><ArticleIdList><ArticleId IdType="pubmed">22969712</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Apr 15;162(3):244-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18294820</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jun;162(6):1211-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15930074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Feb;11(1):70-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19133968</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2004;129(2):361-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15501593</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Mar 15;55(6):578-87</Citation><ArticleIdList><ArticleId IdType="pubmed">15013826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cogn Psychol (Hove). 2011 Sep;23(6):669-694</Citation><ArticleIdList><ArticleId IdType="pubmed">22059115</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2005 Apr 29;360(1456):781-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15937012</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2000 Jun;4(6):215-222</Citation><ArticleIdList><ArticleId IdType="pubmed">10827444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2012 Jan;46(1):22-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22024484</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Sep 1;66(5):451-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19450794</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8900-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16735472</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 1971 Mar;9(1):97-113</Citation><ArticleIdList><ArticleId IdType="pubmed">5146491</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Mar;66(3):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19255378</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2011 Aug;216(4):485-99</Citation><ArticleIdList><ArticleId IdType="pubmed">21390505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2011 Apr;1224:40-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21486295</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5803-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7597032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):308-319</Citation><ArticleIdList><ArticleId IdType="pubmed">19242292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2007 May;17(5):1047-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16801377</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2011 Jan;36(1):153-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20571485</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Aug 15;37(2):623-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17570686</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Jan 15;162(1):27-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18063349</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Oct 15;28(1):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15993624</ArticleId></ArticleIdList></Reference><Reference><Citation>Emotion. 2009 Dec;9(6):855-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20001128</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25688436</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1939-1846</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of abnormal psychology</Title><ISOAbbreviation>J Abnorm Psychol</ISOAbbreviation></Journal><ArticleTitle>Threat sensitivity in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>93-101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1037/a0038065</ELocationID><Abstract><AbstractText>Life stress is a major predictor of the course of bipolar disorder. Few studies have used laboratory paradigms to examine stress reactivity in bipolar disorder, and none have assessed autonomic reactivity to laboratory stressors. In the present investigation we sought to address this gap in the literature. Participants, 27 diagnosed with bipolar I disorder and 24 controls with no history of mood disorder, were asked to complete a complex working memory task presented as "a test of general intelligence." Self-reported emotions were assessed at baseline and after participants were given task instructions; autonomic physiology was assessed at baseline and continuously during the stressor task. Compared to controls, individuals with bipolar disorder reported greater increases in pretask anxiety from baseline and showed greater cardiovascular threat reactivity during the task. Group differences in cardiovascular threat reactivity were significantly correlated with comorbid anxiety in the bipolar group. Our results suggest that a multimethod approach to assessing stress reactivity-including the use of physiological parameters that differentiate between maladaptive and adaptive profiles of stress responding-can yield valuable information regarding stress sensitivity and its associations with negative affectivity in bipolar disorder. (PsycINFO Database Record (c) 2015 APA, all rights reserved). </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muhtadie</LastName><ForeName>Luma</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sheri L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-9945-4816</Identifier><AffiliationInfo><Affiliation>Department of Psychology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 MH020006</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Abnorm Psychol</MedlineTA><NlmUniqueID>0034461</NlmUniqueID><ISSNLinking>0021-843X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001341" MajorTopicYN="N">Autonomic Nervous System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002320" MajorTopicYN="N">Cardiovascular Physiological Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25688436</ArticleId><ArticleId IdType="pii">2015-06432-010</ArticleId><ArticleId IdType="doi">10.1037/a0038065</ArticleId><ArticleId IdType="pmc">PMC4353603</ArticleId><ArticleId IdType="mid">NIHMS666961</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Sci. 2001 May;12(3):225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11437305</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1985 Feb;142(2):175-81</Citation><ArticleIdList><ArticleId IdType="pubmed">3970242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2002 Sep;83(3):678-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12219862</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 May;152(5):795-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7726323</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2003 Feb;107(2):124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12534438</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1997 Apr;48(4):491-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9090732</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2005;21(2):71-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15786484</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006;67 Suppl 1:5-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16426110</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2011 Feb;36(2):258-65</Citation><ArticleIdList><ArticleId IdType="pubmed">20732746</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Nov 15;42(10):948-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9359982</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2000 Sep-Oct;41(5):339-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11011829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Aug;65(8):1106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15323597</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2008 Feb;94(2):278-91</Citation><ArticleIdList><ArticleId IdType="pubmed">18211177</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):515-28</Citation><ArticleIdList><ArticleId IdType="pubmed">12946880</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2010 Dec;99(6):933-47</Citation><ArticleIdList><ArticleId IdType="pubmed">21114352</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Feb;113(1-2):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18684514</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2003 Apr;84(4):771-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12703648</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Psychol Gen. 2012 Aug;141(3):417-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21942377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pers Soc Psychol Bull. 2011 Jan;37(1):94-106</Citation><ArticleIdList><ArticleId IdType="pubmed">21177876</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Jan;35(1):136-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18990711</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2007 Apr;92(4):698-716</Citation><ArticleIdList><ArticleId IdType="pubmed">17469953</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2011 Feb;23(1):40-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21318195</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 May;127(5):381-93</Citation><ArticleIdList><ArticleId IdType="pubmed">22906117</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychophysiol. 2009 Sep;73(3):308-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19465066</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Aug 30;179(1):47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20478632</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Sci. 2009 Nov;20(11):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19843261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2007 Jul;55(7):1044-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17608877</ArticleId></ArticleIdList></Reference><Reference><Citation>Emotion. 2007 May;7(2):336-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17516812</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Apr;67(4):584-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16669723</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2011 Jan;28(1):5-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20734364</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychophysiology. 2010 May 1;47(3):535-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20030765</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1997 Aug;106(3):449-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9241946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley Interdiscip Rev Cogn Sci. 2012;3(3):301-313</Citation><ArticleIdList><ArticleId IdType="pubmed">23240069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2004 Aug;185:97-101</Citation><ArticleIdList><ArticleId IdType="pubmed">15286059</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2006 Aug;115(3):539-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16866593</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Dec;161(12):2222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15569893</ArticleId></ArticleIdList></Reference><Reference><Citation>Memory. 2009 Aug;17(6):635-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19536691</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Behav Med. 1998 Spring;20(2):47-58</Citation><ArticleIdList><ArticleId IdType="pubmed">9989308</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Jul;189:20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16816301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2009 Sep;65(9):925-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19459195</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Jun;38(6):771-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17922938</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rev. 2001 Jul;108(3):593-623</Citation><ArticleIdList><ArticleId IdType="pubmed">11488379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Mar;71(3):296-303</Citation><ArticleIdList><ArticleId IdType="pubmed">20331931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 2001 Sep 1;23(3):133-143</Citation><ArticleIdList><ArticleId IdType="pubmed">21765592</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 2004 May;130(3):355-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15122924</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 2005;56:393-421</Citation><ArticleIdList><ArticleId IdType="pubmed">15709941</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2007 Mar;28(3):477-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16469418</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2013 Sep 02;1:15</Citation><ArticleIdList><ArticleId IdType="pubmed">25505682</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Apr;85(3):301-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15780700</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16754406</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-1237</ISSN><JournalIssue CitedMedium="Print"><Volume>18 Suppl 1</Volume><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult patients.</ArticleTitle><Pagination><MedlinePgn>9-14</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Safety, tolerability, and efficacy of carbamazepine (CBZ) have been demonstrated in numerous studies over the last three decades. Until recently, CBZ studies largely involved immediate-release formulations, while long-term studies have been few in number. The recent development of beaded CBZ extended-release capsules (CBZ-ERC) (Shire, Wayne, PA, USA) provides a new formulation with potential advantages in safety, tolerability, and efficacy over earlier formulations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The present study assesses these parameters in patients of various bipolar subtypes (mixed/manic, bipolar I depression, and bipolar II), in a single-site private practice setting. Data were obtained from the charts of 300 patients&gt;or=18 years old who met DSM-IV criteria for bipolar disorder. Clinical response to CBZ-ERC therapy was defined as a score of &lt;or=3 on the Clinical Global Impression-Improvement (CGI-I) scale, while relapse was defined as a change in CGI-I to &gt;or=4 in those subjects who had previously achieved clinical response.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical response occurred in 73% of patients, leading to a mean CGI-I score of 2.5 (SD=1.2). Relapse was seen in 33% of responders. Most common adverse events were somnolence, dizziness, and nausea. A high level of treatment response and a low relapse rate were observed in long-term treatment with CBZ-ERC in adults with bipolar disorder. The limited number and nature of the adverse events observed during the course of this study provide evidence of the safety and tolerability of CBZ-ERC.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Carbamazepine extended-release capsules appear safe and efficacious for the treatment of bipolar disorder. Controlled studies are warranted to further establish the safety, tolerability, and efficacy of CBZ-ERC for treatment of adult bipolar patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Lawrence D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Red Oak Psychiatry Associates, Houston, TX 77090, USA. larrydg@earthlink.net</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002214">Capsules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16754406</ArticleId><ArticleId IdType="pii">X377556565V4438L</ArticleId><ArticleId IdType="doi">10.1080/10401230600653320</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18582440</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-8993</ISSN><JournalIssue CitedMedium="Print"><Volume>1235</Volume><PubDate><Year>2008</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Brain research</Title><ISOAbbreviation>Brain Res</ISOAbbreviation></Journal><ArticleTitle>Bipolar pathophysiology and development of improved treatments.</ArticleTitle><Pagination><MedlinePgn>92-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brainres.2008.05.084</ELocationID><Abstract><AbstractText>The purpose of this review is to provide strategies and their rationale which can facilitate scientifically productive investigations into genetic, neuronal, brain functional and clinical aspects of bipolar disorder. The presentation addresses both factors that have impeded and those that have facilitated landmark advances on the pathophysiology and treatment of bipolar disorders. Application of the strategies can provide a scientific platform that may be useful to basic and clinical scientists for the purposes of achieving seminal advances in understanding pathophysiology, including inherited and experience based contributors to disease expression. Current diagnostic criteria omit certain key symptoms, do not include illness course or family history and lack specification of the importance of fundamental symptomatology. Consideration of such factors in inclusion and exclusion criteria, and in assessment instruments in basic and clinical studies, serves to strengthen the capability of a research plan to test key hypotheses regarding moderating and mediating factors of this complex illness. For example, most studies of brain structure and function and of new interventions have selected subjects on the basis of traditional full syndromal criteria. Evidence indicates that additional consideration of principal behavioral domains of bipolar symptomatology, e.g., anxiety, psychosis, impulsivity, elevated psychomotor and cognitive processing speed, rather than strictly depressive or manic syndromes can provide more homogeneous samples for study, and increase the focus of experimental hypotheses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 7792, San Antonio, Texas 78229-3900, USA. bowdenc@uthscsa.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 MH068662</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH086045</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Res</MedlineTA><NlmUniqueID>0045503</NlmUniqueID><ISSNLinking>0006-8993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>34</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18582440</ArticleId><ArticleId IdType="pii">S0006-8993(08)01373-5</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2008.05.084</ArticleId><ArticleId IdType="pmc">PMC3794894</ArticleId><ArticleId IdType="mid">NIHMS74721</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Feb 28;175(3):221-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20022384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">11869757</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 1999 Dec;1(2):98-108</Citation><ArticleIdList><ArticleId IdType="pubmed">11252666</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12633125</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Oct;61(10):804-8; quiz 809</Citation><ArticleIdList><ArticleId IdType="pubmed">11078046</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Jun;100(1-3):227-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17097740</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Aug;81(2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15306137</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2003 Aug;13 Suppl 2:S43-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12957719</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Jan;158(1):125-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11136645</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2005 Sep-Oct;38(5):268-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16179813</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jun;157(6):956-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10831476</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1991;240(6):339-48</Citation><ArticleIdList><ArticleId IdType="pubmed">1831665</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jan;55(1):27-32</Citation><ArticleIdList><ArticleId IdType="pubmed">9435757</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):531-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17680925</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Apr;16(2 Suppl 1):4S-14S</Citation><ArticleIdList><ArticleId IdType="pubmed">8707999</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jul;162(7):1243-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15994704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):163-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9858076</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Sep;116(3):189-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17655560</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1991 May;37(2):195-205</Citation><ArticleIdList><ArticleId IdType="pubmed">1876629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):143-51</Citation><ArticleIdList><ArticleId IdType="pubmed">9858074</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Oct;88(2):217-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16125784</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jul;34(8):1904-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19295510</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Feb;63(2):120-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11874212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Oct;67(10):1501-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17107240</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2007 Jun;12(6):439-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17545954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002;4 Suppl 1:21-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12479671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Aug;5(4):243-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12895202</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2003 Dec;8(12):930-2, 941-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14978468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):123-32</Citation><ArticleIdList><ArticleId IdType="pubmed">11869759</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2002 Apr;26(4):530-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11927177</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Apr;67(4):584-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16669723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15383128</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Burden of general medical conditions among individuals with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>368-73</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Treatment of coexisting medical comorbidities may reduce the risk of adverse outcomes among patients with bipolar disorder. We determined the prevalence of general medical conditions in a population-based sample of patients diagnosed with bipolar disorder in the Veterans Administration (VA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a cross-sectional study of patients (n = 4310) diagnosed with bipolar disorder in fiscal year 2001 receiving care at VA facilities located within the mid-Atlantic region. General medical conditions were assessed using ICD-9 codes, and we compared the prevalence of each condition in our bipolar sample with national data on the VA patient population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age was 53 (SD = 13), 10% were women, and 12% African-American. The mean age of the VA national patient population was higher (58 years). The most prevalent conditions among patients with bipolar disorder included cardiovascular (e.g. hypertension, 35%), endocrine (e.g. hyperlipidemia, 23%; diabetes, 17%), and alcohol use disorder (25%). When compared with national data, the prevalence of diabetes was higher in the bipolar cohort than in the national cohort (17.2% versus 15.6%; p = 0.0035). Hepatitis C was more common in the bipolar group than the national cohort (5.9% versus 1.1%; p &lt; 0.001). Lower back pain (15.4% versus 10.6%; p &lt; 0.0001) and pulmonary conditions (e.g. COPD: 10.6% versus 9.4%; p = 0.005) were also more prevalent among the bipolar cohort than the VA national cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Individuals with bipolar disorder possess a substantial burden of general medical comorbidity, and are occurring at an earlier age than in the general VA patient population, suggesting the need for earlier detection and treatment for patients with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kilbourne</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA 15240, USA. amy.kilbourne@med.va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornelius</LastName><ForeName>Jack R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Pincus</LastName><ForeName>Harold A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Shad</LastName><ForeName>Mujeeb</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Salloum</LastName><ForeName>Ihsan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Conigliaro</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Gretchen L</ForeName><Initials>GL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006949" MajorTopicYN="N">Hyperlipidemias</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017116" MajorTopicYN="N">Low Back Pain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15383128</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00138.x</ArticleId><ArticleId IdType="pii">BDI138</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6888613</PMID><DateCompleted><Year>1983</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>7</Issue><PubDate><Year>1983</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Preventive lithium treatment in manic-depressive disease: experiences and progress in recent years].</ArticleTitle><Pagination><MedlinePgn>331-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schou</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prophylaktische Lithiumbehandlung bei manisch-depressiver Krankheit: Erfahrungen und Fortschritte der letzten Jahre.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="N">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014882" MajorTopicYN="N">Water-Electrolyte Balance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6888613</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19267696</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Structural abnormalities of ventrolateral and orbitofrontal cortex in patients with familial bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>135-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2009.00666.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Abnormalities of ventral prefrontal function have been widely reported in bipolar disorder, but reports of structural abnormalities in the same region are less consistent. We examined the presence and location of ventral prefrontal abnormalities in a large sample of individuals with bipolar disorder and their relationship to gender, psychotic symptoms, and age.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Structural magnetic resonance imaging brain scans were carried out on 66 individuals with bipolar disorder, type I, and 66 controls. Voxel-based morphometry was used to examine differences in grey and white matter density between the groups and their relationship with a lifetime occurrence of psychotic symptoms and age.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Reductions in grey matter density were seen in the left and right lateral orbital gyri and the right inferior frontal gyrus, while white matter density reductions were seen in the corona radiata and the left temporal stem. In contrast, hallucinations and positive symptoms were associated with grey matter reduction in the left middle temporal gyrus. Age was more strongly associated with the right inferior frontal gyrus grey matter reductions in the bipolar group than in the controls, but not with any other finding.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Abnormalities of the ventral prefrontal cortex are likely to be involved in the aetiopathology of bipolar disorder, while hallucinations appear to be more closely associated with temporal lobe abnormality, extending earlier work in schizophrenia. Further prospective studies are required to comprehensively address the trajectory of these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stanfield</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK. andrew.stanfield@ed.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moorhead</LastName><ForeName>T William J</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Job</LastName><ForeName>Dominic E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>McKirdy</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sussmann</LastName><ForeName>Jessika E D</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Giles</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Johnstone</LastName><ForeName>Eve C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Lawrie</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>McIntosh</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0600429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19267696</ArticleId><ArticleId IdType="pii">BDI666</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2009.00666.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8895945</PMID><DateCompleted><Year>1997</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0176-3679</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>1996</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pharmacopsychiatry</Title><ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation></Journal><ArticleTitle>Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>193-5</MedlinePgn></Pagination><Abstract><AbstractText>The new antiepileptic lamotrigine has been shown to be effective in the treatment of focal epilepsies with or without secondary generalization and has also been suggested to be efficacious in the treatment and prophylaxis of affective disorders. Therefore, we analyzed its possible benefit in a patient with refractory bipolar affective disorder. Lamotrigine (up to 150 mg/d) was added to valproate (2700 mg/d), substituting previously administered neuroleptics. A considerable improvement of the patient's condition was achieved several days after the beginning of lamotrigine co-administration, and lasted over the total follow-up period of more than one year. The plasma concentrations after total remission were in the range of 1.9 to 6.2 mg/l for lamotrigine and 57.1 to 95.2 mg/l for valproate. This positive action of lamotrigine is discussed in the context of the drug's elementary effects on sodium and calcium channels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Freiburg, Department of Psychiatry and Psychotherapy, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hesslinger</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>van Calker</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pharmacopsychiatry</MedlineTA><NlmUniqueID>8402938</NlmUniqueID><ISSNLinking>0176-3679</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8895945</ArticleId><ArticleId IdType="doi">10.1055/s-2007-979570</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>